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ÖSSZEFOGLALÁS 
Az  epidermolysis  bullosa  acquisita  krónikus  
subepidermális  lokalizációjú,  fizikai  beha-
tásra  manifesztálódó,  a bullosus  pemphigoid  
csoportba  tartozó  bőrbetegség.  Szerzők  egy  
klinikailag,  szövettanilag  és  immunhisztoló-
giailag  jól  dokumentált,  generalizált  tüne-
tekkel jelentkezett  epidermolysis  billiósában  
szenvedő  betegük  esetét  közlik.  A  végleges  
diagnózis  felállításában  az  anamnesztikus  
adatokon,  jellegzetes  klinikai  tüneteken kívül 
a  Fluorescence  Overlay  Antigen  Mapping  
(FOAM)  technikának  és az  imnnmoblot  vizs-
gálatoknak  nagy  jelentőséget  tulajdoníta-
nak. A  betegnél  alkalmazott  nagy  dózisú,  fél  
évig  tartó  szteroid  és  azathioprin  kezelés  je-
lentősen  mérsékelte  az  újabb  hólyagok  je-
lentkezését.  A  gyógyszer  kihagyása  után fél 
évvel  is  a  betegnél  csak  nagyobb  traumák  
hatására  alakulnak  ki a nyomásnak  kitett  te-
rületeken  kis  hólyagok.  
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Az  epidermolysis  bullosa  acquisita  (EBA)  
viszonylag  ritka  krónikus,  veleszületett,  de  
általában  csak  az  élet  későbbi  szakaszában  
(40-60  év  között)  manifesztálódó  autoim-
mun  jelenségeket  is  mutató  (9),  a  bullosus  
pemphigoid  (BP)  csoportba  tartozó  hólya-
gos bőrbetegség  (7). A kórképet  Elliot  leírá-
SUMMARY 
Epidermolysis  bullosa  acquisita  (EBA)  is  a  
chronic,  subepidermal,  mechanically-indu-
ced  blistering  disease  of  the  skin.  Not  only  
the therapy,  but also  the diagnosis  is  someti-
mes  difficult.  This  report  concerns  a  well-
documented  case  of a man who  had  genera-
lized  EBA for  2 years.  The diagnosis  of EBA 
was  established  on the basis  of the  anamnes-
tic  data,  the  clinical  picture,  the  histology,  
the  immunohistology,  and  immunoblot  and  
fluorescent  overlaying  antigen  mapping  in-
vestigations.  The  treatment  of  the  patient  
with  high  doses  of prednisolone  and  azathi-
oprine  was partially  successful.  Following  a  
6-month  period  without  any  drugs,  new  me-
chanically-induced  blisters  are  developing  
only  on the extremities,  and much less  frequ-
ently  than  earlier.  
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sa  alapján  1895  óta  ismerjük  (6).  Kablitz  
1904-ben,  Wise  és  mtsa  1915-ben  közölt  
eseteket,  azonban  az  elnevezés  Hundley  és  
Smith-tői  ered  (10).  Azóta  több  közlemény  
látott  napvilágot  és  a kritériumokat  Roenigk  
és  mtsai  fogalmazták  meg  1971-ben  (14),  
amelyek  gyakorlatilag  ma  is  helytállóak.  
Dr. Dobozy  Attila  egyetemi  tanár  tíz  éves  tanári jubileumára  írt  közlemény  
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Az  EB A  klinikai  kritériumai:  
1)  fokozott  bőr  sérülékenység,  trauma  indu-
kálta  hólyagok,  erosiók  (a  sacralis  terüle-
ten,  térden,  könyökön,  lábon,  kézen),  at-
rófiás  hegek,  miliumok,  és  körömdystro-
phia; 
2)  felnőttkori  manifesztáció;  
3)  más epidermolysis  bullosa betegség  nincs  
a  familiaris  anamnézisben;  
4)  egyéb  bullosus  kórkép  kizárható.  
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A  klinikai  diagnózis  általában  nem  nehéz,  
azonban  az immunhisztológiai,  elektronmik-
roszkópos  verifikáció  esetenként  problémás  
lehet. 
Egy  1995-től észlelt  eset  kapcsán  ismertetjük  
a modem  diagnosztikai  lehetőségeket.  
Esetismertetés 
40  éves  férfi beteget  1995  márciusában  vettük  
fel  először  klinikánkra.  Panaszai ,  hólyagos  tíine-
2. ábra 
A:  Subepidermalis  bulla.  
Szeparálódott  BM.  (PAS  
festés,  eredeti  nagyítás  
50X) 
B:  Subepidermalis  bulla  
(HE  festés,  eredeti  
nagyítás  100X)  
3.  ábra  
A:  DIF  vizsgálat  (ant ihumán  IgG/FITC-vel) .  In  
vivo  szeparálódott  BM  linearis  pozitivitása  
C:  D I F  vizsgálat  (ant ihumán  IgG/FITC-vel) .  
"Salt-split"  epidermis:  pozitív  BM  reakció  
D:  DIF  vizsgálat  (ant ihumán  IgG/FITC-vel) .  
"Salt-split" epidermis  dermalis  részén  pozitív  
BM  reakció  
B:  F O A M  technika:  az  antihumán  IgG/FITC  
zöld  színű  reakciót  ad,  a  Vll-es  típusú  
kollagént  indirekt  módszerrel  rhodaminnal  
jelölt  ant iszérummal  mutattuk  ki  (piros  
színű).  Az  FITC  zöld  és  a  rhodamin  piros  
f luoreszcencia  átfedése  adja  a  kettőzött  sárga  
színű  BM  reakciót.  
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tei  egy  évvel  korábban  jelentkeztek  főleg  a  nyo-
másnak  kitett  területeken,  de  esetenként  a  törzsön  
is.  Családban  hasonló  betegség  nem  fordult  elő.  
Gyermekkorában  agyhártya  gyulladása  volt,  
1995-ben  tonsil lectiomia  történt  a  betegnél.  Ko-
rábban  Erythromycin ,  Delagil,  Prednisolon,  Col-
chicin  és  Sand immun  kezelésben  részesült  ered-
mény  nélkül.  
Felvételekor  testszerte,  főleg  a  nyomásnak  ki-
tett  területeken  lehetett  látni  gyulladásmentes  ala-
pon  ülő,  feszes  falú, borsónyi,  babnyi,  helyenként  
nagyobb  hólyagokat ,  valamint  a  felfakadt  hólya-
gok  helyén  erosiokat  és  pörköt.  A száj nyálkahár-
tyán,  a  nyelven  is  látható  egy-két  felületes  erosio.  
A lábkörmök  hiányoznak.  A kézháton,  az  ujjakon,  
a lábháton,  a gyógyult  hólyagok  helyén  mil iumok  
alakultak  ki.  (1.  ábra)  (1.  címlap)  
Kivizsgálása  során  enyhén  emelkedett  fehér-
vérsej tszámot  és  szérum  bilirubin  értéket,  hasi  
ultrahang  vizsgálattal  hepatomegaliát  találtunk.  
Amyloidosisra ,  belszervi  malignus  daganatra,  pa-
raproteinaemiára  utaló  eltérést  nem  tudtunk  ki-
mutatni . 
Szövettan:  HE,  PAS,  PAS+D  festés  a  hám  le-
válását  igazolta.  A  basalis  membrán  (BM)  nagy-
része  a  hámon,  illetve  a  hólyagfedélen  látható.  A  
kiserek  körül  mérsékelt  fokú,  idült  lobsejtes  be-
szűrődés  van,  acantholysis  nincs.  (2.  ábra)  
Immunhisztológia:  direkt  immunofluoreszcen-
ciás  (IF)  vizsgálattal  linearis  IgG  és  C3  BM  fluo-
reszcenciát  láttunk,  helyenként  a  BM  szeparáció-
jával .  Ker ingő  autoantitestet  indirekt  IF  eljárással  
nem  tudtunk  demonstrálni .  A  "salt-split"  epider-
mis  vizsgálat  során  mind  a dermalis,  mind  az  epi-
dermalis  B M  fluoreszkált  IgG-vel  és  C3-mal .  
Ezen  IF leletek  alapján  felvetődött  az  a  lehetőség,  
hogy  E B A  és  BP  együttes  előfordulásáról  van  
szó.  Ezért  a  kórkép  besorolása  érdekében  F O A M  
(Fluorescence  Overlay  Antigen  Mapping)  vizsgá-
latot  (1,  2,  3)  végeztünk  (antigén  térképezés  fluo-
reszcenciás  anyagok  egymásra  rétegezésével).  
A  F O A M  vizsgálattal  egyértelműen  igazolni  
lehetett,  hogy  az  IgG  és  C3-mal  pozitív  (még  a  
szeparációt  mutató,  az  epidermishez  közelebb  lé-
vő)  B M  is  VII  típusú  kollagén  ellenes  antitestek-
kel  adott  pozitivitást,  ugyanakkor  laminin  poziti-
vitást  nem  lehetett  kimutatni  (3.  ábra).  
Az  immunoblot  vizsgálatokkal  az  EBA-ra  jel-
lemző  2 9 0  k D  molekulasúlyú  protein  ellenes  au-
toantitesteket  mutattunk  ki  a  beteg  szérumában,  
ant igénforrásként  dermalis  extractumot  használ-
tunk  (4.  ábra).  
A jel legzetes  klinikai  tünetek,  a  betegség  lefo-
lyása,  az  immunhisztológiai  és  immunoblot  vizs-
gálatok  alapján  betegünknél  az  EBA  diagnózist  
állítottuk  fel.  
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-<  180  
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4.  ábra:  Immunoblot  vizsgálat  
(1.2.  dermalis  extractum,  
3.  4.  keratinocita  extractum)  
1: EBA  kontroll  szérum  
2:  a vizsgált  beteg  széruma  
3:  bullosus  pemphigoid  (BP)  kontroll  szérum  
A 230  kD  és  180 kD  molekulasúlynál  lehet  
IgG  kötődést  kimutatni.  
4:  A vizsgált  beteg  széruma  
Kötődés  a BP szérumnak  megfele lő  helyen  
nem  látható.  
Terápia 
A  bevezetett  nagy  dózisú  steroid  (100  mg/die  
Prednisolon)  és  azathioprin  (150  mg/die  Imuran)  
kezelésre  állapota  sokat javult .  A spontán  hólyag-
képződés  megszűnt.  A gyógyszereket  fél  éves  ke-
zelés  után  fokozatosan  leépítettük  és  je lenleg  6  
hónapja  csak  az  erős  traumák  hatására  je lentkez-
nek  hólyagok,  bőre  egyébként  tünetmentes.  
175 
Megbeszélés 
Az EBA diagnózisa,  a jellegzetes  klinikai  
tünetek  és immunhisztológiai  leletek  alapján  
nem  nehéz.  Néha  -  mint  esetünkben  is  -
lehetnek  problémák  és  ilyenkor  a  végleges  
diagnózis felállításához modernebb  eszközö-
ket  is igénybe  kell  venni.  
Legutóbb  Dohránszky  és Hunyadi  közölték  a  
"salt-split"  epidermis  vizsgálatok  jelentősé-
gét  a  hólyagos  kórképek  diagnosztikájában  
(5).  Az  ott  közöltek,  az  irodalmi  adatok  (7)  
és  az  általunk  észlelt  lelet  alapján,  BP-ra  is  
lehetett  gondolni  (mind  az epidermisre  loka-
lizálódó,  mind  a dermisre  kötődő  BM  pozi-
tív  reakciót  adott  IgG-vel  és  C3-mal).  A  ge-
neralizált  tünetek  és  ezen  lelet  miatt  volt  
szükség  további  vizsgálatokra.  
A szövettani  és  immunhisztológiai  vizsgála-
ton  kívül  elektronmikroszkópos  és  immun-
elektronmikroszkópos  leletek  segíthetnek  a  
pontos  diagnózis  felállításában.  Kárpáti  és  
mtsai  (11)  immunogold  technikával  mutat-
ták ki  az IgG kötődést  a BM  lamina  densa  és  
sublamina  densa  területéhez.  Ezzel  lehet  el-
különíteni  a  kórképet  a  BP-tól,  ahol  a  kötő-
dés  a  lamina  lucida  területére  szorítkozik.  
Hasonlóan  differenciáldiagnosztikai  értékű  a  
holland  szerzők által bevezetett  elektronmik-
roszkópos  vizsgálatot  mellőző  FOAM  tech-
nika (1,2,  3). A módszer lényege, hogy  több-
féle konjugátummal  végzik  a szövetek  inku-
bációját.  A konjugátumokat  különböző  fluo-
rokrómokkal  jelzik.  Más-más  szűrővel  vizs-
gálva  a  preparátumot  a  specifikus  monova-
lens  konjugátumokkal  létrejött  kötődést  kü-
lönböző  színekben  látjuk.  Videó  mikrosz-
kóppal,  komputer  technikával,  fotótechniká-
val  a metszetek  egymásra  vetíthetők  és  így  a  
színek  kombinációjából  egyes  helyeken  a  
színkombinációk  hiányából  következtethe-
tünk  a  diagnózisra  (ily  módon  látható  a  FO-
AM  technikával  készített  képen  a  szeparáló-
dott  BM  sárga  fluoreszcenciája,  amely  a VII-
es  collagén  ellenes  antiszérum  piros  és  az  
IÍZG antiszérum  zöld  színének  keverékéből  
adódik).  Topográfiás  festéssel  a  BM  külön-
böző  struktúráit  lokalizálhatjuk  (3).  
Esetünkben  FOAM  technikával  egyértelmű-
en  igazolni  lehetett,  hogy  a BM  IgG  reakció  
azon  a  helyen  jelentkezik,  ahol  VII  típusú  
collagént  lehet  kimutatni  (8),  ez  pedig  a  
lamina  densa  és  a  sublamina  densa  területet  
jelzi.  Az  immunoblot  vizsgálatok  is  EBA  
mellett  szóltak  (7).  A  bevezetett  steroid  és  
azathioprin  kombinált  kezelés  meglepően  jó  
hatásfokú  volt  ebben  a  köztudottan  terápia  
rezisztens  betegségben.  Az  irodalom  tanúsá-
ga  szerint  számos  terápiás  próbálkozás  tör-
tént  ebben  a  betegségben  és  a  különféle  
kombinált  kezelések  esetenként  jó  ered-
ményhez  vezettek  (4,  9,  12,  13).  Érdekes  
módon  betegünknél  a  cyclosporin  kezelés  
nem  vált  be.  
Az esetet viszonylagos  ritkasága,  a felmerült 
diagnosztikus  problémák  és  az  újabb  diag-
nosztikus  lehetőségek,  a  bevezetett  terápia  
hatásossága  miatt  tartottuk  közlésre  érde-
mesnek. 
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In  an earlier  study,  the  circulating  autoantibodies  in patients  with  bullous  pemphigoid  
(BP)  were  demonstrated  in  higher  frequencies  by  means  of  an  immunoblot  technique  then  via  
indirect  immunofluorescence.  In  the  present  work  with  the  help  of  Peptide  Structure  software,  
two  matched  antigenic  epitopes  were  chosen  and  synthesized.  The  sera  of  34  patients  with  BP  
were  investigated  in  parallel  by  an  immunoblot  technique  using  a  human  epidermal  extract,  
and  by  an  ELISA  technique  with  synthetic  peptides.  The  sera  of  16  healthy  persons  and  10  
patients  with  other  bullous  diseases  served  as  controls.  Among  the  34  patients  with  BP,  23  
sera  proved  positive  for  at  least  one  synthetic  peptide.  Positive  reactions  with  the  major  BP  
antigen  (230  kD)  were  found  in  22  patients  by  immunoblot  technique  and  in  16  patients  by  
the  ELISA  technique  with  the synthetic  peptide,  whereas  with  the  minor  BP  antigen  (180  kD),  
positive  reactions  were  found  in  9  patients  by  the  immunoblot  technique  and  18  patients  by  
the  ELISA  technique  using  the  synthetic  antigenic  epitope  of  the  minor  BP  antigen.  
All  control  sera  were  negative  for  both  antigens  in  ELISA  investigations.  In  3  patients  with  
pemphigus  vulgaris,  characteristic  bands  against  pemphigus  vulgaris  antigen  were  identified  
by  means  of  the  immunoblot  technique,  but  all  other  cases  were  negative.  It  is  suggested  that  
the  development  of  this  technique  may  lead  to  an  opportunity  for  the  rapid  and  simple  
diagnosis  of  BP.  
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Bullous  pemphigoid  (BP)  is  a  subepidermal  blistering  disease  of  elderly  people,  
but  the  condition  can  occur  in  the  under-forties  and  occasionally  in  children,  too.  Direct  
immunofluorescence  (DIF)  studies revealed  preformed Ig  and  C3  linear  deposition  along  
the  basement  membrane  zone  (BMZ).  About  three-quarters  of  these  patients  have  a  
circulating  antibody  to  the  BMZ.  The  BP  antigen  appears  to  exhibit  molecular  
heterogeneity.  There  is  a  major 230  kD  and  a minor  180  kD peptide  antigen.  Through  a  
use of patients'  autoantibodies,  complementary  DNAs  (cDNAs)  of both BP antigens  have  
been  isolated,  and  the  amino  acid  sequences  for  the  human  230  kD  and  180  kD  
autoantigens  were deduced  [1,2].  
We  have  now  addressed  the  question  of  whether  the  demonstration  of  circulating  
antibodies  against  the  minor  (180  kD)  and  major  (230  kD)  BP  antigens  is  possible  by  
means  of  an ELISA technique with antigenic synthetic  peptides.  
Material  and methods  
With  the  help  of  Peptide  Structure  software,  several  antigenic  epitopes  were  chosen  and  
synthesized.  The  predicted  epitopic  peptides  were  synthesized  by  solid-phase  technique  utilizing  'Boc  
chemistry  [3].  The  peptide  chain  was  elongated  on  an  MBHA  (p-methyl-benzhydril-amine)  resin  and  
the  syntheses  were  carried  out  using  an  ABI  430A  automatic  machine  with  certain  minor  modifications  
on  the  standard  protocol.  The  completed  peptide  resins  were  treated  with  liquid  HF and  the  resulted  free  
peptides  were  solubilized  in  10% aqueous  acetic  acid,  filtered  and  lyophilized.  The  crude  peptides  were  
purified  by  semipreparative  reverse  phase  HPLC.  The  purified  peptides  were  characterized  by  am[no  
acid  composition  and  mass  spectrometry.  Peptide  purifies  were  above  95%  (HPLC  and  capillary  
electrophoresis).  According  to  previous  investigations,  two  of  the  peptides  gave  positive  reactions  with  
BP  patients'  sera  by  means  of  the  ELISA  technique.  We  therefore  further  investigated  these  two  
synthetic  peptides.  One  of  them  represented  the  230  kD,  and  the  other  the  180  kD  antigen.  Thirty-four  
patients  with  proved  BP  were  investigated  (17  females  and  17 males,  aged 43-89  years,  mean 72  years).  
The  diagnosis  was  established  on  the  basis  of  the  clinical  picture  and  by  histology,  as  well  as  by  DIF  
investigations.  In  all  patients,  the  sera  were  examined  by  indirect  immunofluorescence  (IIF)  and  by  
immunoblotting  too,  as  described  earlier  [4].  
The  patients'  sera  were  investigated  by  ELISA  technique  to  determine  antibodies  against  the  
antigenic  epitopes  representing  either  the  230  kD  or  the  180  kD  antigen.  For  this  technique,  0.1  pg/100  
pi  concentrations  of  antigen  and  1:100  dilutions  of  sera  were  used.  Our  earlier  studies  indicated  a  
positive  result  when  OD>X+2SD  (OD  =  optical  density,  X  =  mean  OD  of  control  subjects,  and  SD  =  
standard  deviation  of  control  OD).  
Sera  from  16 blood  bank  donors  (8  females  and  8 males,  aged 25-53  years,  mean  33  years),  and  
10 patients  (7  females  and  3  males,  aged  39-83  years,  mean  49  years)  with  other  bullous  diseases  (drug  
allergy,  porphyria  cutanea  tarda  and  3  patients  with  pemphigus  vulgaris)  served  as  controls.  
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Results 
All  control  sera  were  negative for both  antigens  in  the  ELISA  investigations.  In  3  
patients  with pemphigus vulgaris, characteristic  bands  against pemphigus  vulgaris  antigen  
(130  kD and  80  kD  )  were  identified  by  means  of  the  immunoblot  technique,  but  all  the  
other cases  were  negative.  
Among  the  34  patients  with  BP,  23  sera  proved  positive  for  at  least  one  synthetic  
peptide.  Positive  reactions  with  the  major  BP  antigen  were  found  in  22  patients  by  the  
immunoblot  technique  and  in  16 patients  by the ELISA  technique  with  synthetic  peptide,  
with the minor BP antigen,  positive reactions  were found in  9 patients by  the  immunoblot  
technique  and  in  18 patients by the ELISA technique  when the synthetic  antigenic  epitope  
of the minor antigen  was used. 
The summarized  results are to be seen in Tables I, II,  and III.  Statistical differences 
between the various positive  and negative results  were not found by the Fischer exact  test.  
Table  I  
Correlation  between  indirect  immunofluorescence  (IIF), immunoblotting  (IB)  and ELISA  investigations  of  sera  
of patients  with  bullous pemphigoid  (positive  by  direct  immunofluorescence  technique)  
Bullous pemphigoid  ELISA only 230  kD  ELISA only  180 kD  ELISA  both 230  and  ELISA  both 230  and  
(n=34)  positive  positive  180 kD positive  180 kD  negative  
*IB+,  IIF+  
(n=8) 
IB+,  IIF—  
(n=13) 
IB-,  IIF+  
(n=l) 
IB-,  IIF—  
(n=12) 
DIF-positive 
(n=34) 
0 
4 
0 
1 
1 
1 
0 
5 
7 
3 
6 
0 
2 
11 
4 
2 
1 
4 
11 
*IB+ =  immunoblot:  positive  result  
IIF- =  indirect  immunofluorescence  : negative  result  
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Discussion 
About  three  quarters  of  patients  with  BP  have  circulating  antibodies  to  the  
basement  membrane  demonstrable  by  IIF.  In  our  study,  immunoblotting  proved  to  be  
more sensitive than IIF for the identification of different antibodies. Eight out  of  34  (22%)  
sera  of  patients  with  BP  gave  positivity  by  means  of  IIF  and  21  of  34  (61%)  sera  by  
means  of  immunoblotting  assay.  Our  results  are  in  accordance  with  the  findings  of  
Bernard  et  al.  [5].  Earlier  investigations  [6,  7]  demonstrated  either  that  80%  of  patients  
with  BP  have  circulating  IgG  that  binds  to  fusion proteins  encoding  for  both  the  amino  
and  carboxyl  terminal  regions  of  the  putative  alpha  helical  coiled-coil  rod  of  the  230  kD  
cDNA  or  that  53%  of  patients  with  BP  have  circulating  IgG  by  means  of  an  ELISA  
technique  with  a segment  of  a human  cDNA  encoding  a 42-amino-acid  stretch  of  the  BP  
180 kD antigen (GST-S  1).  
Table  II  
Summarized  results  of  correlation  between  ELISA  
and immunoblotting  investigations  
ELISA  positive  ELISA  negative  
Blot  positive  15 6 
Blot  negative  8 5 
DIF positive 23 11 
Table  III  
Correlation  of  the results  of ELISA  and  immunoblotting  
investigations  according  to  different  antigens  
Bullous  pemphigoid  230  kD 180 kD 
(n=34) BP antigen BP antigen  
ELISA  positive  17 19 
Blot  positive  22 9 
In  our  investigations  with  synthetic  antigenic  epitopes,  the  ELISA  technique  
revealed  serum  positivity  in  67.6%  of  the  patients  with  BP.  Our  results  suggest  that  the  
epitope  of  the  180  kD antigen  gave much  higher  positivity  than  that  of  the 230  kD protein 
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by ELISA  technique respective  to the  immunoblotting  method. Therefore, to  increase  the  
usefulness  of  the  230  kD  antigen  as  a  diagnostic  tool,  other  epitopes  within  the  protein  
should be  learned.  
We  consider  that  this  kind  of  investigation  offers  a  new  possibility  to  determine  
antibodies  in patients  with  BP. By  using  a mixture  of these  synthetic  antigenic  epitopes  it  
is possible  to  diagnose  patients  with  BP  in  a relative  simple  way  by  means  of  an  ELISA  
technique,  which is much cheaper,  and  a highly equipped  laboratory  is not  necessary.  
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Immunoblotting  studies  with  salt-split  human  epidermis  were  performed  on  sera  from  
15  patients  with  pemphigus  vulgaris  and  20  patients  with  bullous  pemphigoid  by  using  
peroxidase-labelled  antihuman  IgG  and  IgA.  Eleven  sera  of  pemphigus  vulgaris  patients  
yielded  a  130  kD  specific  protein  band  against  the  pemphigus  vulgaris  antigen.  Most  of  the  
sera  gave  additional  specific  bands  at  210  and  80  kD,  with  lower  intensity.  The  sera  of  4  
patients,  3  of  them  were  in  clinical  remission,  did  not  yield  specific  bands.  Seventeen  sera  of  
the  20  bullous  pemphigoid  patients  yielded  a  220-230  kD  protein  band  against  the  major  
bullous  pemphigoid  antigen  and  4  of  them  gave  another  specific  band  at  160-180  kD.  Five  
sera  produced  multiple  bands  (220,  130,  100  and  75  kD).  IgA  antibodies  against  the  major  
bullous  pemphigoid  antigen  were  demonstrated  in  2  cases  with  IgA  deposits  along  their  
basement  membrane,  as  revealed  by  direct  immunofluorescence.  The  immunoblot  patterns  
correlated  only  weakly  with  the  clinical  findings  in  bullous  pemphigoid.  There  was  a  
considerable  diversity  in both clinical  findings  and immunoblot  patterns.  
The  diseases  of  the  pemphigus  group  and  bullous  pemphigoid  (BP)  are  
characterized  by  autoantibodies  to  antigens expressed  by  keratinocytes  or  constituents  of  
the  dermal-epidermal  junction,  which  can  be  demonstrated  by  direct  immuno-
fluorescence  (DIF).  
BP is a subepidermal  blistering disease characterized  by circulating  autoantibodies  
which react  with antigens  in the lamina lucida of the basement membrane  zone (BMZ)  [1,  
2].  BP  antigens,  which  are  produced  by  basal  keratinocytes,  have  been  shown  to  be  
synthesized  by mouse  and human epidermal  cells  in  vitro  [3, 4].  It  has been reported  that  
a  220-240  kD  polypeptide  is  detectable  by  immunoprecipitation  from  keratinocyte  
cultures  and  by  Western  immunoblotting  of  human  skin  extracts  [5,  6].  This  polypeptide  
is  recognized  by  the  majority  of  BP  sera  and  appears  to  be  the  major BP  antigen.  Some  
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50-70%  of  BP sera recognize  the  major BP antigen  (230  kD),  but  a minority  of  BP  sera  
recognize  other  low  molecular  weight  bands,  most  commonly  the  180  kD band,  and  less  
frequently  bands at 200, 97 and 77  kD [6-8]. 
Pemphigus  is  an  intraepidermal  blistering  disease  group  characterized  by  
autoantibodies  reactive  with  antigens  located  in  the intercellular  spaces  or  on  the  surface  
of  epidermal  cells  [9].  There  are  two  clinically  and  immunologically  distinct  forms.  In  
pemphigus  vulgaris  (PV),  autoantibodies  are directed against  a  130 kD antigen  that forms 
a  complex  with  a  protein  of  desmosomal  and  adherent junctions,  called  plakoglobin  (85  
kD)  [10].  In  pemphigus  foliaceus  (PF),  the  autoantibodies  are  specific  for  a  160  kD  
antigen, called desmoglein I, that forms a similar complex with plakoglobin  [11,12].  
The present study included the determination of the target antigen  specificity of  the 
sera  of  20 patients  with BP and  15 patients  with PV by immunoblotting  methods,  and  the  
results were correlated  with the immunofluorescence picture. In addition, the Western  blot  
patterns of the patients with BP were correlated with certain clinical  data.  
Materials  and methods 
BP  patients.  Twenty  patients  (11  males  and  9 females;  mean  age  at onset:  69  years)  with  BP,  as  
indicated  by  clinical,  histological  and  immunohistological  criteria,  were  studied.  All  BP  patients  
exhibited  the  specific  clinical  symptoms.  The  clinical  findings  were  documented  according  to  the  
following  characteristics  [13]:  1.  Lesion  morphology,  typical  (bullae  and/or  urticated  erythema)  or  
atypical  (other  lesion  morphology).  2.  Severity,  mild  disease  (less  than  10  lesions  at  one  time  or  
localized  to  a single  body  site);  severe  disease  (more  than 50  individual  lesions,  affecting  three  or  more  
body  sites);  moderate  disease  (between  the  two  extremes).  3.  The presence  of  mucosal  lesions.  
PV  patients.  Fifteen  patients  with  PV  (not  PF  and  not  pemphigus  erythematosus);  (9  males  and  
6  females;  mean  age  at  onset:  53  years)  were  studied.  Four  of  them  were  in  remission  at  the  time  of  
serum  sampling.  
Sera  were  collected  from  these  patients  and  stored  at  - 2 0  °C  for  immunoblotting  studies.  
Normal  human  sera  (negative  controls),  and  BP  and  PV  sera  known  to  be  positive  from  
immunofluorescence  studies  (a  gift  from  Dr.  M.  Meurer,  Department  of  Dermatology,  Munich)  were  
included  in each  immunoblotting  run.  
Immunofluorescence  studies.  For  direct  immunofluorescence  (DIF)  the  standard  technique  was  
used.  Each  specimen  was  sectioned  into  5  pm  sections  on  a  cryostat.  Specimens  were  stained  for  IgG,  
IgA,  IgM  and  C3  by  incubation  of  the  sections  with  monospecific  FITC-labelled  antibodies  (Human  
Ltd.,  Budapest).  For  indirect  immunofluorescence  (I1F)  all  serum  samples  were  examined  by  using  
cryostat  sections  of  rabbit  oesophagus  and/or  normal  human  skin.  Sera  were  initially  diluted  1:32  in  
phosphate-buffered  saline.  The  sections  were  incubated  with  the patient's  serum  and  then  examined  for  
the presence  of  IgG  by  using  a FITC-labelled  conjugate.  
Immunoblotting.  Immunoblotting  studies  were  performed  according  to  Hashimoto  et  al.  [14]  
with  slight  modifications.  Normal  human  skin  was  obtained  from  patients  undergoing  plastic  surgery.  
The  skin  pieces  were  incubated  in  a  mixture  of  1  M  NaCl,  1  mM  EDTA  and  10  pM  
phenylmethylsulfonyl-fluoride  (PMSF)  at  4  °C  for 72  h.  The  epidermis  was  then  easily  separated  from  
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the  dermis  and  homogenized  in  a  solution  containing  31.2  mM  Tris-HCl,  2%  SDS,  1  mM  PMSF,  
2  mM  EDTA  and  0.1  M  dithiotreitol.  After  a 24  h incubation  at  4  °C,  the  homogenizate  was  centrifuged  
at  15 000  g  and  the  supernatants  were  stored  at - 7 0  °C  until  use.  
The  constituent  proteins  of  the  epidermal  extracts  were  separated  out  by  SDS-PAGE  [15]  (with  
6%  separating  gel)  and  then  transferred  to  nitrocellulose  [161  before  probing  with  the  test  sera.  All  sera  
were  used  to  probe  immunoblots  at  a  dilution  of  1:40.  Specific  binding  by  the  sera  was  detected  by  
using  peroxidase-linked  class-specific  second  antibodies  (goat  antihuman  IgG  and  IgA;  Sigma)  and  
visualized  with  diaminobenzidine.  
Results 
The  Western  blot  patterns of  a group of  BP patients  are demonstrated  in Fig.  1.  All  
sera  (including  those  of  healthy  controls)  yielded  a  diffuse  reactivity  in  the  30-60  kD  
range.  The  strong  specific  bands  show  the  reaction  between  the  230  kD  BP  antigen  and  
the  antibodies  of  the  patients'  sera.  In  this  group  of  patients,  specific  reactivity  can  be  
demonstrated  only  against  the  major BP antigen.  
In  another  group  of  BP  patients,  multiple  specific  bands  were  seen  on  Western  
blotting  (Fig.  2).  Specific  reactions  were  demonstrated  against  the  minor  BP antigen  (180  
kD)  and some  other epidermal  components  (220,  130,  100  and 75  kD).  
A B C D E F G H 
Fig.  I.  Blots  of BP sera showing  one dominant  band  at 230  KD with  peroxidase-labelled  antihuman  IgG.  
Lane  A: blot  of  the epidermal  extract stained  with  Coomassie  brilliant  blue;  Lane  B: normal  serum;  
Lanes C-F:  positive  BP sera;  Lane  G: negative  BP serum;  Lane  H: migration  of  standard  molecular  
weight  markers  
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A B C D E F G H 
Fig.  2.  Blots  of BP  s- m showing  multiple bands  with  peroxidase-labelled  antihuman  IgG. Lane  A:  blot  
of  the epidermal  extract  stained  with Coomassie  brilliant  blue;  Lane  B: normal  serum;  Lanes  C-F:  
positive  BP sera;  Lane  G: negative  BP serum;  Lane  H: migration  of standard  molecular  weight  markers  
5 /20  2/15  
Bullous  pemphigoid  Pemphigus  vulgaris  
Fig.  3. Correlation  between  Western  immunoblotting  and  IIF results  
The  Western  blotting  pictures  were  compared  with  the  results  of  DIF  and  IIF  
investigations.  In  16  BP  patients,  DIF  revealed  IgG  and  C3,  and  in  4  cases  C3  and  IgA  
deposition  along  the  BMZ.  In  contrast,  IIF  positivity  was  found  only  in  5  patients.  It  is  
remarkable  that,  in  spite  of  the  negativity  of  the  IIF examinations,  specific  BP  reactions  
were  revealed  on  Western  blotting  in  12  patients.  Three  cases  were  negative  on  both  IIF  
and  Western  blotting  (Fig.  3).  The  sera  of  17  BP  patients  yielded  a 230  kD  protein  band  
against  the  major  BP  antigen  by  on  the  use  of  peroxidase-labelled  antihuman  IgG,  and  4  
of  them  gave  another  specific  band  at  160-180  kD.  Five  sera  produced  multiple  bands  
(220,  130,  100  and  75  kD).  IgA  antibodies  against  the  major  BP  antigen  were  
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demonstrated  in 2 cases with IgA deposits along their basement membrane,  as revealed  by  
DIF. 
The  Western  blotting  patterns  of  the  patients  with  BP  were compared  with  certain  
clinical  findings  (Table  I),  but  no  specific  correlation  was  found.  The  Western  blot  
patterns  of PV patients'  sera  are  to be seen  in Fig. 4.  Among  the PV patients,  the  sera  of  
11 yielded  a  specific  130  kD protein  band  against  the PV  antigen.  Most  of  the  sera  gave  
additional specific bands at 220 and 80-90  kD, with  lower  intensity.  
Among  the PV patients, IIF positivity  was found in only 2 cases. Specific reactions 
against  PV  antigen  (130  kD)  were  revealed  in  9  patients,  in  spite  of  the  IIF  negativity.  
Four  cases  proved  negative  by  both  methods  (Fig.  3),  and  3  of  them  were  in  clinical  
remission. 
Discussion 
IIF  techniques  are  commonly  used  to  demonstrate  the  presence  of  autoantibodies  
in the  sera  of  patients  with  BP or PV. Western  immunoblotting  with  its greater  sensitivity  
provides  a  new  possibility  for  the  detection  and  specification  of  different  antiepidermal  
antibodies in patients  with  bullous  dermatoses.  
Table I 
Correlation  between  Western  blotting  patterns  and clinical  picture  of  
patients  with  BP  
Clinical  findings  Single 230  kD Multiple  bands  Blot  negative  
(n=8) (n=9) (n=3) 
Age  at onset  (years)  60-82 48-82 60-72 
Male/female 5/3 4/5 2/1 
Lesion  morphology  3  typical  5  typical  1 typical 
3  atypical  4  atypical  1 atypical 
Severity 2  mild  6  moderate  2  moderate  
2  moderate  3 severe 
2  severe  
Mucosal  lesions  2 2 1 
No clinical  data available: 3  patients  
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Fig.  4.  Blots of  PV sera  showing  dominant  bands  at  130 kD and  85 kD with  peroxidase-labelled  antihuman  
IgG.  Lane  A: blot  of  the epidermal  extract  stained  with  Coomassie  brilliant  blue;  Lane  B: normal  serum;  Lanes  
C-F:  positive  PV  sera;  Lane G: negative  PV serum;  Lane  H: migration  of standard  molecular  weight  markers  
ABCDEFG 
Fig.  5.  Blots  of  BP sera;  DIF revealed  IgA deposition  along  the BMZ.  IgA antibodies  against  the major  BP 
antigen  (230 kD)  were demonstrated  in 2 of  them using peroxidase-linked  class-specific second  antibodies  
(goat  antihuman  IgA; Sigma)  (Lanes  D, E). Lane  A: Blot  of  the epidermal  extract  stained  with  Coomassie  
brilliant  blue;  Lane  B: normal  serum;  Lanes  C and  F: negative  BP serum;  Lane  H: migration  of  standard  
molecular  weight  markers  
In our study,  Western immunoblotting  proved  to be  a more sensitive  assay  than  IIF  
for  the  identification  of  different  antibodies.  In  60%  of  our  BP  patients  and  60%  of  our  
PV  patients  with  negative  IIF  results,  molecular  weight  specific  antigen-antibody  
reactions  were  demonstrated  by  Western  blotting  on  salt-split  epidermis  extracts.  Our  
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results  are  in  accordance  with  the  findings  of  Bernard  et  al.  [17],  but  there  are  some  
contradictionary  data  in the literature. In the study by Venning et al.  [13],  a number  of  BP  
sera  produced  negative  immunoblots,  despite  having  BMZ  antibody  detectable  on  IIF.  
Investigations  of  larger  series  of  patients  and  standardization  of  different methods  might  
yield an explanation for these discrepancies.  
For PV  patients,  the results revealed  that  11 sera yielded  a specific  130 kD protein 
band against the PV antigen. Most of the sera gave additional specific bands at 210 and  80  
kD, with  lower  intensity. The  sera  of  4 patients  did  not  give  any  specific bands,  and  it  is  
noteworthy  that  3  of  them  were  in  clinical  remission.  This  finding,  together  with  
experimental  and  clinical  evidence,  supports  the  hypothesis  that  pemphigus  
autoantibodies  play  a  direct  role  in  the  pathogenesis  of  the  disease  [18,  19].  There  was  
considerable  diversity  in  the  patients'  immunoblotting  patterns,  especially  in  BP  cases.  
The  diffuse reactivity  in  all  blots  may  correspond  to  cytokeratins  [17,  20].  All  patients  
with BP who displayed  special  reactivity  against  epidermal  extracts  yielded  a sharp  band  
at  230  kD.  This  has  been  considered  to  be  the  major  BP  antigen.  However,  9  of  them  
yielded  multiple  specific  bands  against  different  salt-split  epidermis  components  (220,  
180,  130,  100  and  75  kD).  Although  the  number  of  our  patients  is  limited,  it  seems  that  
each  patient  yields  an  individual  Western  blot  pattern  besides  the  common  reaction  
against  the 230  kD protein  component.  A similar  opinion  has  been  reported  by Shapiro  et  
al.  [21],  who  demonstrated  that  healthy  individuals  and  patients  with  autoimmune  
diseases  have  antibodies,  some  tissue-specific  and  some  not,  which  are  present  in  a  
pattern that is unique to each  individual.  
In  4  patients  with  BP,  DIF  revealed  IgA  deposition  besides  C3  along  the  BMZ.  
IgA  antibodies  against  the major BP antigen  (230  kD) were demonstrated  in  2  of them  by  
means of  immunoblotting  (Fig. 5). It  was interesting  that IgG antibodies  against  the major 
BP antigen  (230  kD) were also found on Western  blots  in these 4 patients,  in spite  of  their  
negative  IgG  DIF  results.  Western  immunoblotting  provides  a  new  possibility  for  the  
distinction  of  linear  IgA  dermatosis  (LAD)  and  BP.  LAD  is  characterized  by  circulating  
IgA  antibodies  against  a 285  kD antigen  of  dermal  extracts  [22],  but  patients  with  LAD  
lack reactivity  against the 230  kD BP epidermal  antigen.  
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M O N I T O R I N G  O F A N T I N E U T R O P H I L  C Y T O P L A S M I C  A N T I B O D I E S  ( A N C A )  IN  
P A T I E N T S  W I J H  I M M U N O L O G I C A L  W ^ O R D E R S  ,  ,  
Ka ta l in ,  N^olnár  ,  Sándor  H u s z  M á n a  Kiss  .  Gytila  P o k o m y ,  László-  Kos-ács ,  Attila  
Dobozy  »  Depar tment  of  Dermato logy  and  "1st  Department  of  Medicine,  Albert  Szent-
Györgyi  Medica l  University,  Szeged,  Hungary  
Antineutrophil  cytoplasmic  antibodies  ( A N C A )  afe  a  heterogenous  group  of  autoantibodies  
with  a  wide  and  diverse  range  of  dinicalrassociat ions.  A N C A  was  first  recognized  in  systemic  
vasculitis,  but  the  spectrum  of  subspecificit ies  and  ANCA-associated  diseases  has  subsequently  
increased  enormously.  In  vasculitis,  the  diagnostic  utility  of  proteinase  3  (PRB)-ANCA  and  
myeloperoxidase  ( M P O ) - A N C A  for  Wegener 's  granulomatosis  and  microscopic  polyangitis,  
respectively,  is  n o w  well  established.  T h e  aim'-of  this  Study  was  to -evaluate  the  diagnostic  and  
clinical  implications  of A N C A  after  testing  serum  samples  f rom  54  patients  with  different  im-
munological  disorders  (14  systemic  vasculitis,  11  systemic  lupus  erythematosus ,  12  other  
au to immune  disorders  with  vasculitis,  12  abor tus  habituaiis  and '5  chronic  inf lammatory  bowel  
disease)  for the presence  of these anubod ies '  The  A N C A  were  detected  by  means  of  an  ELISA  
technique ( E p i g n o s t ) ,  ant i -PR3  and  an t i -MPO  A N C A s  were  determined  parallel  in  all  patients.  
A m o n g  the  patients  with  systemic  vasculitis,  we  found  ani i -PR3  or  anu-MPOr A N C A  positiv-
ity  in  3  and  5  patients,  respectively.  The  results  did  not  reveal  a  close  connection  between  the  
occurrence  of  A N C A  positivity  and  the  clinical  conditions  of  t h e  patients.  In  the  SLE  group,  
both  tv-pes  of  A N C A  were  detected  in  lower  frequency.  However,  it  was  noteworthy  that  all  
patients  with  a  have  renal  involvement  were  positive  for  ant i -PR3  A N C A .  In  the  other  cases  
A N C A ,  could  be  demonstrated  rarely.  It was  concluded  that  A N C A  investigations  are  of  lim-
ited  diagnostic  and  clinical  importance,  but  in  some  cases m a y  predict  complications.  
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I M M U N O H I S T O C H E M 1 C A L  I N V E S T I G A T I O N  O F  I L - 8 -  A N D  R A N T E S - P E P T I D E  
IN  A U T O I M M U N E  B U L L O U S  D I S E A S E S .  Erika  B o r n s c h e u e r .  J e n s - M .  S c h r o d e r .  
E n n o  C h r i s t o p h e r s  and  M i c h a e l  S t i che r l ing .  D e p t .  o f  D e r m a t o l o g y ,  U n i v e r s i t y  o f  Kiel.  
Kiel ,  G e r m a n y .  
A u t o i m m u n e  b u l l o u s  d i s e a s e s  o f  t h e  skin  a r e  c h a r a c t e r i z e d  b y  loca l  d e p o s i t i o n  o f  
au to reac t ive  ant ibodies .  F u r t h e r m o r e  d e r m a l  a n d  e p i d e r m a l  inf i l t ra t ion  b y  n e u t r o p h i l s  a n d  
eosinophi ls  is  initiated  by  as yet u n k n o w n  m e d i a t o r s .  M e m b e r s  o f t h e  r e c e n t l y  e s t ab l i shed  
c h e m o k i n e  family represent  po ten t  c h e m o a t t r a c t a n t s  f o r  ind iv idua l  l e u k o c y t e  subse t s .  IL-
8 w a s  found  to  be  n e u t r o p h i l - c h e m o t a c t i c  w h e r e a s  a n o t h e r  p e p t i d e ,  R A N T E S ,  is  able  t o  
act ivate  eosinophi ls .  A c c o r d i n g l y  e x p r e s s i o n  o f b o t h ,  I L - 8  a n d  R A N T E S ,  w a s  m o n i t o r e d  
by i m m u n o h i s t o c h e m i s t r y  t o  i n v e s t i g a t e  t h e  ro le  o f b o t h  c h e m o k i n e s .  C r y o s t a t e  s e c t i o n s  
o f  b u l l o u s  p e m p h i g o i d  ( n = ! 2 ) ,  p e m p h i g u s  v u l g a r i s  ( n = 3 )  and  I g A - l i n e a r - d e r m a t o s i s  
( n = 2 )  w e r e  e x a m i n e d  wi th  a  pane l  o f  in  h o u s e  a n d  c o m m e r c i a l  m o n o c l o n a l  ( m o A b )  and  
po lyc lona l  ( p c A b )  an t ibod ie s .  W i t h  n o n e  o f  t h e  a n t i - R A N T E S  a n t i b o d i e s  ( t w o  m o A b  
a n d  t w o  p c A b )  spec i f i c  i m m u n o r eac t i v i t y  c o u l d  b e  d e t e c t e d  wi th in  e i t he r  e p i d e r m i s  o r  
d e r m i s  o f  a n y  p r o b e .  Wi th  the  a n t i - I L - 8  a n t i b o d i e s  ( o n e  m o A b  and  o n e  p c A b )  d i f f e ren t  
p a t t e r n s  o f  i m m u n o r e a c t i v i t y  w e r e  o b s e r v e d  m  d i seased  as  wel l  as  n o r m a l  skin.  All  
s u p r a b a s a l  k e r a t i n o c y t e s  in  n o r m a l  skin  w e r e  m a r k e d  wi th  the  a n t i - I L - 8  m o A b  and  n o  
s igni f icant  c h a n g e s  w e r e  d e t e c t a b l e  in  b u l l o u s  skin.  W i t h  a n t i - I L - 8  p c A b  on ly  a  slight  
stainig o f  ba sa l  k e r a t i n o c y t e s  a n d  s o m e  d e r m a l  m o n o n u c l e a r  in f i l t ra t ing  ce l l s  w a s  vis ib le  
in  d i s e a s e d  and  n o r m a l  skin.  In  c o n c l u s i o n ,  c h e m o k i n e s  c a n n o t  b e  loca l i zed  wi th in  
a f f e c t e d  t i s sue .  T h i s  is  in  c o n t r a s t  t o  b l i s te r  f lu ids  from  bu l lous  p e m p h i g o i d  w h e r e  
elevated  IL-8  levels  could  be  de tec t ed  in  t h e  pas t .  T h u s ,  the  c h e m o k i n e s  m a y  i m m e d i a t e l y  
be  released  from  diseased  t i s sue  a n d  c o n s e q u e n t l y  e v a d e  i m m u n o h i s t o c h e m i c a l  r e c o v e r y .  
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EXPRESSION  OF  PLASMINOGEN  ACTIVATOR  RECEPTOR  IS  ENHANCED  BY  PEMPHIGUS  IgG  
IN  CULTURED  KERATINOCYTES.  Shi ho  Sa t oh.  MarIko  S e i s h i m a .  Mari  N o j l r j .  
Kazuko  Osada.  and  Yasuo  K i t a j i m a .  D e p a r t m e n t  of  Derma to logy .  G i f u  Univ.  
School  of  M e d i c i n e .  G i f u .  J a p a n .  
We  have  p r e v i o u s l y  r e p o r t e d  t h a t  pemphigus  IgG(P- lgG)  c a u s e s  a  
d i s t i n c t  i n c r e a s e  in  p l a s m i n o g e n  a c t i v a t o r ( P A )  a c t i v i t y  in  c u l t u r e  medium  
f o r  DJM-1  c e l l s .  S i n c e  s e c r e t e d  PA  b i n d s  t o  i t s  r e c e p t o r  on  t h e  c e l l  
membrane,  i t  i s  l i k e l y  t h a t  t h e  e x p r e s s i o n  of  r e c e p t o r ( P A R )  on  t h e  c e l l  
s u r f a c e  i s  e n h a n c e d  by  P-IgG,  s o  t h a t  PA  bound  t o  t h e  c e l l  s u r f a c e  can  
p r o d u c e  p l a s m i n  o n l y  in  the  l i m i t e d  m i c r o e n v i r o n m e n t  a round  t h e  c e l l s .  
T h i s  p l a s m i n  a c t i v i t y  g e n e r a t e d  in  t h e  m i c r o v i c i n i t y  a round  c e l l  s u r -
f a c e  may  c a u s e  a c a n t h o l y s i s  in  t h e  l i m i t e d  upper  or  s u p r a b a s a l  l a y e r s  
c h a r a c t e r i s t i c  t o  pemphigus  f o l i a c e u s ( P F )  and  pemphigus  v u l g a r i s ( P V ) ,  
r e s p e c t i v e l y .  In  o r d e r  t o  p r o v e  t h i s  h y p o t h e s i s ,  t h e  e f f e c t s  of  IgGs  f r o m  
b u l l o u s  p e m p h i g o i d  (BP).  PV. PF  and  normal  s e r a  on  PAR  were  examined  by  
Wes te rn  b l o t  and  i m m u n o f l u o r e s c e n c e  m i c r o s c o p y  in  DJM-1  c e l l s .  PV-and  PF-
IgGs  e x t r e m e l y  i n c r e a s e d  t h e  e x p r e s s i o n  of  PAR.  w h i l e  BP-and  normal  IgGs  
d i d  n o t .  These  r e s u l t s  s u g g e s t  t h a t  t h e  enhanced  PAR  e x p r e s s i o n  and  PA  
a c t i v i t y  may  be  i n v o l v e d  in  t h e  p a t h o g e n e s i s  of  l i m i t e d  a c a n t h o l y s i s  
s p e c i f i c  t o  PV  and  PF.  
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A U T O A N T I B O D I E S  D I R E C T E D  A G A I N S T  F c t R I a :  I g G  S U B T Y P E  
C O M P O S I T I O N .  P R E V A L E N C E .  A N D  D I S E A S E  S P E C I F I C I T Y .  E d d a  F i e b i g e r ,  
Sibylle  W i c h l a s .  G e o r g  S t ing l .  a n d  D i e t e r  M a u r e r ,  D e p a r t m e n t  of  D e r m a t o l o g y ,  Division  
of  I m m u n o l o g y ,  Al l e rgy  a n d  I n f e c t i o u s  D i s e a s e s  (DIAID),  Universi ty  of V i e n n a  Medica l  
Schoo l ,  V i e n n a .  Aus t r i a .  
R e c e n t l y ,  w e  i den t i f i ed  I g G  a u t o a n t i b o d i e s  ( a u t o A b s )  d i r e c t e d  a g a i n s t  t h e  a - c h a i n  of  
FccRI  ( F c t R I a )  in  s e r a  f r o m  c h r o n i c  u r t i ca r i a  ( C U )  p a t i e n t s .  T h e  a i m  of  t h e  p r e s e n t  
s t u d y w a s  to  i n v e s t i g a t e  t h e  p r e v a l e n c e  of  t h e s e  a u t o A b s  in  a  l a rger  p a n e l  of  C U  s e r a  
a n d  in  s e r a  f r o m  i n d i v i d u a l s  s u f f e r i n g  f r o m  o t h e r  ( a u t o - )  i m m u n e - m e d i a t e d  sk in  
d i s e a s e s .  In  k e e p i n g  wi th  o u r  p r e v i o u s  r e s u l t s ,  IgG  a n t i - F c e R I a  a u t o r e a c t r v i t y  w a s  
d e t e c t e d  in 3 7 %  ( 3 6 / 9 9 )  of  C U  p a t i e n t s  bu t  in  n e i t h e r  a t o p i c  de rma t i t i s  p a t i e n t s  (0 /32)  
n o r  h e a l t h y  i n d i v i d u a l s  ( 0 / 3 5 ) .  W h e r e a s  IgG  a n t i - F c c R I a  A b s  w e r e  n o t  o r  only  ra re ly  
d e t e c t e d  in  p s o r i a s i s  ( 0 / 3 0 ,  0 % ) ,  b u l l o u s  p e m p h i g o i d  (BP;  3 / 2 2 ,  1 3 % )  o r  s y s t e m i c  
l u p u s  e r y t h e m a t o s u s  ( S L E ;  3 / 1 5 ,  2 0 % )  s e r a ,  t h e s e  a u t o A b s  w e r e  p r e s e n t  in  a  
c o n s i d e r a b l e  p r o p o r t i o n  of  s e r a  f r o m  d e r m a t o m y o s i t i s  (DM;  2 2 / 4 5 ,  4 9 % )  a n d  
p e m p h i g u s  v u l g a r i s  ( P V ;  1 2 / 2 8 ,  4 3 % )  p a t i e n t s .  T h e  c o m p a r a t i v e  a n a l y s i s  of  IgG  
s u b t y p e s  r e s p o n s i b l e  f o r  t h e  o b s e r v e d  a n t i - F c e R I a  react ivi ty  in t h e s e  d i s e a s e  s t a t e s  
r e v e a l e d  s t r ik ing  d i f f e r e n c e s . W h e r e a s  C U  s e r a  c o n t a i n e d  p r e d o m i n a n t l y  lgG1  (12 /22 ,  
5 5 % )  a n d  l g G 3  ( 1 7 / 2 2 ,  7 7 % )  a u t o A b s .  F c t R  I a - s p e c i f i c  l g G 2  (6 /22 ,  2 7 % )  a n d  l g G 4  
(6 /22 , 2 7 % )  w e r e  r a r e ly  d e t e c t e d .  In  f a c t ,  only  1 o u t  of  2 2  C U  s a m p l e s  ( 4 % )  c o n t a i n e d  
l g G 4  a u t o A b s  s o l e l y .  In  s h a r p  c o n t r a s t .  l g G 2  a n d / o r  l q G 4  r a t h e r  t h a n  lgG1  a n d / o r  
l g G 3  w e r e  t h e  d o m i n a n t  IgG  s u b t y p e s  r e s p o n s i b l e  for  F c E R I a - s p e c i f i c  a u t o r e a c t i v i t y  
in s e r a  f r o m  p a t i e n t s  wi th  D M .  P V  o r  B P .  T h e s e  d i f f e r e n c e s  in  t h e  IgG  s u b t y p e s  a n d ,  
t h u s ,  in  t h e  c o m p l e m e n t -  a n d / o r  F c  r e c e p t o r - b i n d i n g  p r o p e r t i e s  of  t h e s e  a u t o A b s  a r e  
a p p e a r a n t l y  of  f u n c t i o n a l  i m p o r t a n c e .  W h i l e  it  is  no t  ye t  c l e a r  w h e t h e r  t h e  v a r i o u s  
a u t o A b  i s o t y p e s  c a n  i n f l u e n c e  F c e R l a - d e p e n d e n t  a n t i g e n  p r e s e n t a t i o n ,  w e  m a d e  t h e  
str iking  o b s e r v a t i o n  t h a t  s i gn i f i c an t  b a s o p h i l  h i s t a m i n e  r e l e a s e w a s  el ici ted  by  a u t o A b -
c o n t a i n i n g  C U  s e r a  b u t  b y  n e i t h e r  a n t i - F c c R l a - r e a c t i v e  s e r a  f r o m  DM,  S L E .  B P .  or  PV  
p a t i e n t s  n o r  a n t i - F c e R l a - n o n - r e a c t i v e  C U  s e r a .  A s  a  c o n s e q u e n c e ,  t h e r a p e u t i c  e f fo r t s  
in  C U  p a t i e n t s  s h o u l d  a i m  t o  a l t e r  t h e  qua l i ty  of  t h e  a n t i - F c e R I a  i m m u n e  r e s p o n s e  
occu r ing  in  th is  d i s e a s e .  
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PEMPHIGUS  VULGARIS  COEXISTING  WITH  CICATRICIAL  PEMPHIGOID:  
FLUORESCENCE  OVERLAY  ANTIGEN  MAPPING  STUDY.  C.  Kowalewski.  
A.  Gorkiewicz-Petkow.  and  S.  Jablonska.  Department  of  Dermatology,  
Warsaw  School  of  Medicine,  Poland  
A  52-year-old  woman  with  oral  erosions  developed  two  types  of  blisters:  
disseminated flaccid bullae and Nikolsky  sign on the trunk and extremities  and  
tense  bullae,  mainly  in  traumatized  areas,  healing  with  milia formation.  Direct  
immunofluorescence  showed  IgG  and  IgM  intercellular  deposits  in  the  
epidermis  and  linear  IgM,  IgA  and  complement  ( C3  ) deposits  at  the  dermal-
epidermal  junction.  The  in  vivo  bound  IgM,  IgA  and  C3  were  found  mainly  at  
the  dermal  side  of  the  patient's  split  skin,  however  the  weak  reaction  in  
epidermis  was  also  observed.  Serum  studies  showed  intercellular  IgG  
antibodies,  whereas  circulating  anti-BMZ  antibodies  were  not  detectable.  
Fluorescence  Overlay  Antigen  Mapping was  performed on patient's  intact  skin  
with  the  use  of  monoclonal  antibodies  against  several  baseme  nt  membrane  
zone  antigens:  laminin,  collagen  IV  and  collagen  VII.  The  overlay  image  
showed  yellow  linear  reaction  along  the  basement  membrane  due  to  a  
complete  overlap  of  green  immunofluorescence  of  in  vivo  bound  C3  deposits  
and  red  fluorescence  of  laminin  and  collagen  IV.  The  other  overlay  showed  
distinctive  red  collagen  VII  beneath  yellow-orange  band  of  C3.  The  
immunoelectron  microscopic  studies  confirmed  the  localization  of  
immunodeposits  both  in  lamina  lucida  and  lamina  densa  suggestive  of  
cicatricial pemphigoid  coexisting with pemphigus  vulgaris.  
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U L T R A S T R U C T U R A L  L O C A L I Z A T I O N  O F C E L L  J U N C T I O N A L  
C O M P O N E N T S  IN H A I L E Y - H A I L E Y  D I S E A S E ,  D A R I E R ' S  D I S E A S E .  A N D  
P E M P H I G U S  V U L G A R I S  J . T A D A  J. A R A T A 1 *  -AND  K H A S H 1 M O T O  
l ) D c p a r t m c n t  of  D e r m a t o l o g y ,  O k a y a m a  U n i v e r s i t y  M e d i c a l  S c h o o l ,  O k a v a m a ,  
J apan ,  2 ) D c p a r t m e n t  o f  D e r m a t o l o g y ,  W a y n e  S ta te  Un ive r s i ty  S c h o o l  o f  M e d i c i n e ,  
Detroi t ,  M I .  U S A  
T h e  d i s t r i b u t i o n  of  d c s m o g l e i n ,  p l a k o g l o b i n ,  a n d  E - c a d h c r i n  in  the  pc r i - l c s iona l  
and  Icsional  s k i n  o f  H a i l c y - H a i l c y  d i s e a s e ,  Dar ie r ' s  d i s e a s e ,  and  p e m p h i g u s  vu lga r i s  
was e x a m i n e d  b y  i m m u n o e l e c t r o n  m i c r o s c o p y  u s i n g  p o s t c m b c d d i n g  m e t h o d .  
In the  p c r i - l e s i o n a l  s k i n  t h e  i m m u n o l a b c l i n g  of  t h e s e  d c s m o s o m a l  c o m p o n e n t s  
was  loca l i zed  t o  d e s m o s o m e s .  A d h e r e n s  j u n c t i o n - a s s o c i a t e d  E - c a d h c r i n  w a s  at  the  
ccll  p e r i p h e r y  e x c l u d i n g  d e s m o s o m e s .  T h e  l a b e l i n g  pa t t e rn  w a s  s imi la r  a m o n g  these  
d i seases ,  but  the  l a b e l i n g  i n t e n s i t y  p a r t i c u l a r l y  that  o f  p l a k o g l o b i n  in  H a i l c y - H a i l c y  
d i s ea se  and  D a r i e r ' s  d i s e a s e ,  w a s  l e s s  t h a n  that  in  p e m p h i g u s  v u l g a r i s  and  n o r m a l  
con t ro l s .  In  t h e  a c a n t h o l y t i c  ce l l s  o f  H a i l c y - H a i l c y  d i s e a s e  and  Da r i e r ' s  d i s e a s e  the  
i m m u n o l a b c l i n g  o f  the  d e s m o s o m a l  c o m p o n e n t s  w a s  d i f f u s e l y  d i s t r i b u t e d  in  the  
c y t o p l a s m s .  T h e  l a b e l i n g  w i t h  an  a n t i b o d y  a g a i n s t  i n t r ace l l u l a r  c o m p o n e n t  of  E -
c a d h e r i n  s h o w e d  a  s i m i l a r  pa t t e rn  to  that  of  the  d e s m o s o m a l  c o m p o n e n t s  in  these  t w o  
d i seases .  T h e  l a b e l i n g  i n t e n s i t y  of  the  d e s m o s o m a l  c o m p o n e n t s  w a s  less  in  Da r i e r ' s  
d i sease  than  tha t  o f  H a i l c y - H a i l c y  d i s e a s e .  In  c o n t r a s t ,  d e s m o s o m e s  o f  d e t a c h i n g  
ke ra t i nocy te s  in  p e m p h i g u s  v u l g a r i s  st i l l  s h o w e d  the  l a b e l i n g  o f  d c s m o g l e i n  a n d  
p l a k o g l o b i n . 
T h e s e  findings  s u g g e s t  tha t  i n h e r i t e d  a c a n t h o l y t i c  d i s ea se s  s u c h  as  H a i l c y - H a i l c y  
d i s ea se  and  D a r i e r ' s  d i s e a s e  h a v e  d i f f e r e n t  p a t h o g e n e s i s  f r o m  tha t  of  a u t o i m m u n e  
a c a n t h o l y s i s  in  p e m p h i g s u s  v u l g a r i s :  T h e  in t r ace l lu l a r  c o m p o n e n t s  o f  b o t h  
d e s m o s o m e s  a n d  a d h e r e n s  j u n c t i o n s  m a y  p r i m a r i l y  be  d i s r u p t e d  in  the  g e n e t i c  
a c a n t h o l y t i c  d i s e a s e s  in  the  in i t ia l  s t a g e s  o f  a c a n t h o l y s i s .  
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tdherin  Expression  is Down-Regulated  in  a Canine Model for  Hailey-Hailey  
Use 
Slier, A. de Bruin. B. Rohrbech. M. Wyder. P. Jensen*. M. Goldschmidt* and M. Surer 
trie of Animal  Pathology. University of Bcme. Berne, Switzerland 
niment of Dermatology. University of Pennsylvania, Philadelphia. USA 
ty-Hailey  (HH)  disease  is  an  autosomal  dominant  genodermatosis  characterized  
(prabasal  acantholysis  associated  with  epidermal  hyperplasia.  Recently,  a  canine  
Bl for HH  disease has been  described  in  an  English  Setter  and  his  offsprings. To 
Migate the  adhesion  defect, we  analyzed  the expression  of  several  components  of  
pain keratinocyte  adhesion  structures,  adherens junctions  and desmosomes,  in  cell  
ires of  lesional  skin.  Northern  blot  analysis  revealed  that  the  steady-state  mRNA  
I of  E-cadherin  but  not of  o-caienin, fl-catenin, plakoglobin, nor desmoglein  I  was  
nregulated  in cell cultures of HH lesions when compared  to those of normal canine 
.  This  decreased  E-cadherin  mRNA  expression  was  further  paralleled  by  a  
Based expression of  E-cadherin  protein, as shown  by  flow cytometiy.  Interestingly,  
expression  of  E-cadherin  appeared  heterogeneous  in  immuno-histochemical  
ysis  of  HH  cell  cultures:  small  basaloid  cells  were  devoid  of  E-cadherin  
ession. whereas  larger suprabasaloid  cells expressed comparable  levels of  protein  
i normal  keratinocytes.  To  further  substantiate  this  observation  we  analyzed  
ions of  lesional  skin  as  well  as  lip epithelium  of  the  English  Setter.  Consistently  
I  the  observations  obtained  for  cell  cultures,  reduced  levels  of  E-cadherin  
tsssion  were observed  in oral  basal cells.  Surprisingly,  E-cadherin  expression  was  
int  in  all  layers  directly  adjaeent to  the  lesion.  Expression  of  a-catenin,  fl-catenin,  
ogiobin and desmoglein  I  protein  was similar  in affected tissue and noimal  control  
le.  In  summary,  our  results  indicate  that  in  this  model  of  HH  disease  cellular  
tsion  is impaired  by the downregulation  of E-cadherin  expression.  
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IDENTIFICATION  OF  SEQUENCES  IN  THE  CYTOPLASMIC  DOMAIN  OF  
H U M A N  BULLOUS  PEMPHIGOID  ANTIGEN  180 (hBP180)  REQUIRED  FOR  
ITS RECRUITMENT INTO HEMTOESMOSOMES  (HD).  
Luca Borradori, Peter J. Koch  *, Stefan Erkeland, Manuel  van Leusden, and  Amoud  
Sonnenberg.  Division of Cell Biology, Netherlands Cancer  Institute,  Amsterdam:  
•  Department  of Dermatology, Univ. of Pennsylvania,  Philadelphia.  
B P I 8 0  is  a component  of  HD, multi-protein complexes  that  mediate  edhesion  of  
epithelial  cells to the underlying basement membrane. To define  regions  involved  in  
H D  assembly,  we  have expressed  full-length hBPI80  and  deletion  mutant  forms of  
this  protein  in  the  rat  bladder  epithelial  cell  line  804G.  hBPI80  was  correctly  
targeted  to  HD,  codisiributing  with  BP230  and  the a 6  and  [14 integrin  subunits.  
markers  of  the  hcmidesmosomal  plaque.  Chimeric  cDNA  constructs  encoding  a  
membrane  targeting  signal  (K-Ras)  and  the  entire cytoplasmic  tail  of  hBP180  or  a  
cytoplasmic  tail with  increasing  internal truncations were also correctly  incorporated  
into HD.  However,  a hBPI80 chimeric  protein  lacking  a cytoplasmic  stretch of  289  
amino  acids  including  the  four  tandemly  arranged  24  residue  repeats  remained  
diffusely distributed  on  the  cell  surface.  Finally,  a  I1BPI8O construct  lacking  the  
whole  extracellular  domain  and  the  transmembrane  region  was  recruited  into  HD,  
although  a  cytoplasmic  accumulation of this molecule  was also observed.  In  COS-7  
cells  transfected  with  human a 6 A  and  |I4A  cDNA. the hBPI80 chimeric  construct  
encoding  the  membrane  targeting signal (K-Ras)  and the entire cytoplasmic  domain  
colocalized  with  a 6 | ) 4  integrin  and  with  plectin.  In  conclusion,  in  contrast  to  
previous  studies,  our  findings  indicate  that  the  cytoplasmic  domain  of  hBP180  
harbors  functional domains  necessary  and sufficient for HD targeting.  The  further  
characterization  of  relevant  sequences  within hBP180 will  extend our  understanding  
of  mechanisms  involved  in HD formation.  
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n N C T  BASEMENT  MEMBRANE  ZONE  ANTIGENS A R E  RECOGNIZED  BY  
I CICATRICIAL PEMPHIGOID SERA. 
[a P r.hntwvmni  Patrifia Ural««.».*  lean F  Nirnlav  Alain I  flaildy.  
fartment of  Dermatology, and  'institute  of  Biology and Chemistry of  the  Proteins  
CP, CNRS),  Lyon.  France.  
iuricial  pemphigoid  (CP)  is  a chronic  subepithelial  blistering  disease  of  mucous  
libraries  in  which  lesions  often  heal  with  scar  formation.  The  180kD-bullous  
phigoid  antigen  (BPAg2)  [Bernard  et  al,  1992],  the a3-subunit  of  laminin-5  
>&!65kD)  (Kirtschig  et  al.  1995],  and  a  168kD  mucosal  antigen  (MI68)  
ahestani el al,  1995] were found to be recognized  by the CP sera, 
aim of this study was to further determine the relationship between these  basement  
fnbrane  zone  antigens  identified  by  different  groups  in  CP.  We  applied  the  
punoblot  assay  using  multiple  antigenic  sources:  human  epidermal,  dermal,  and  
¿al  mucosa  extracts  and  also  the  purified  placental  laminin-5,  for  detection  of  
Ibodies  specific  for  the  most,  if  not  all. or  the  epidermal  and  dermal  antigens  
Mcularly;  BPAg2,  laminin-5,  and  M168.  The  proteins  were  separated  under  
being conditions  in 6%  polyacrylamide  gel electrophoresis. Among  the  19 CP sera, 
en  recognized  the  epidermal  antigen  of  180  IcD co-migrated  with  the  BPAg2  
htified  by  a  polyclonal  anti-BPAg2  antibody.  Five  additional  sera  labeled  the  
¡inin-S: four reacted  with  the a 3  (200kD) and one with  the 83 (140kD) chains  that  
migrated  with  the  identical  hands  labeled  by  a  rabbit  polyclonal  antibody  raised  
Inst the laminin-5. Sera from four other patients that did not  react  with the  laminin-
jpidermal  or  dermal  protein  extracts,  did  label  a  168kD  antigen  on  the  mucosal  
tacts.  Immunonffinity purified antibodies from the M168 did not further  react  with  
; BPAg2  or  laminin-5.  This  study  demonstrates  that  there  are  different  entities  
benting as CP; accotdingly  the diagnosis of CP should  lake into account  the  nature  
Ute involved  antigen.  
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D E V E L O P M E N T O F AN  ELISA  SYSTEM  FOR T H E  RAPID  DIAGNOSIS  O F  
B U L L O U S  P E M P H I G O I D  
M&ria Kiss1,  Sándor Husz',  Ilona  Marczinovils2,  János Molnár2,  Katalin  Molnár',  Gá-
bor Tóth1,  Attila Dobozy1,  Departments of  'Dermatology.  2Microbiology and  'Medical  
Chemistry,  Albert Szent-GySrgyi  Medical  Univeraity, Szeged,  Hungary  
The  bullous  pemphigoid  (BP)  sutoantigen  structures  and  their  amino  acid  sequences  
are  well  known.  We  have  addressed  the  question  of  whether  the  demonstration  of  
circulating  antibodies  against  major (BPAGI,  230  kD)  and  minor  (BPAG2,  180  kD)  
antigens  is  possible  by  means  of  an  ELISA  technique  with  synthetic  antigenic  
peptides.  With  the  help  of  PeptideStnicture  software,  two-two  matched  antigenic  
epitopes  were  chosen  and  synthetized.  The  sera  of  33  patients  with  BP  were  
investigated  in  parallel  by  an  tmmunoblot  technique using  a  human  epidermal  extract,  
and  by  an  ELISA  technique  with  synthetic  peptides.  The  sera  of  16  healthy  persons  
and  10  patients  with  other  bullous diseases  served  as controls.  Among  the  33  patients  
with  BP,  24  sera  proved  positive  for  at  least  one  synthetic  peptide.  Positive  reactions  
with  the major BP antigen were found  in 21  patients by the immunoblot  technique  and  
in  20  patients  by  the ELfSA  technique  with  the  synthetic  peptides,  positive  reactions  
were  found  in  9  patients by  the  immunoblot  technique  and  18  patients  by  the  ELISA  
technique  using  the  synthetic  antigenic  epitopes  of  the  minor  BP  antigen.  With  the  
exception  of  one  person  all  control  sera  were  negative  for  both  antigens  in  ELISA  
investigations.  In  3  patients  with  pemphigus  vulgaris,  characteristic  bands  against  
pemphigus  vulgaris antigen were identified by means of die immunoblot  technique,  but  
all  other  eases  were  negative.  It  is  suggested  that  the  development  of  this  technique  
may  lead to an opportunity  for the rapid  and simple diagnosis of BP. 
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HPKXGOID NODULARIS.  S. Kawana1. T.  Hashimoto*. A.  I to, K. 
pava.  and  H. Aral*, *Div. of  Dermatology,  St.  Luke's  
[ternational  Hospital, Tokyo,*Dept.of  Dermatology,  Keio  
,iv. school of Medicine, Tokyo, and'Dlv. of  Dermatology,  
ks City of Yamato Hospital, Kanagawa,  Japan.  
We  report  45- and  61-year-old women  with  generalized  
ii'rigo nodularis-like eruption whose clinical and  immuno-
[thoLogic features were consistent with the diagnosis  of  
Eaphigoid nodularis.  In one case, nodular  lesions  preced-
j the onset  of generalized blistering  by  two years and  in  
it other, no definite blister nor erosion was  seen except 
(r  some appearing on the soles during the course of  the  aease.  We investigated  the antigen  profiles by  reaction  
,th  the patient  sera  in the course of  the disease  using  
pnunoblot  analysis.  Western  immunoblotting  of  EDTA-
[parated epidermal  extract  revealed  that only  the  230-kD  
lllous  pemphigoid  (BP) antigen was recognized  by  circu-
iting  autoantibodies.  The  180-kD BP antigen was  recog-
,zed  by  immunoblotting of  the recombinant  protein  of  
>180 NC16a domain which shows high detection  sensitivity,  
len the reactivity of  the sera obtained  before and  after  
le  development of bullous lesions with the NCI 6a  domain  
rs  compared,  no  particular change  was  noted.  These  
,ndings  suggest  that the onset of  bullous  lesions  in  
imphigoid  nodularis as well as  the clinical  appearance  
\  hyperkeratotic  nodules is determined  by  factors  other  
[an changes  in the serum reactivity with  the BP  antigens  
Itected by our conventional immunoblotting  technique.  
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DOES INTRAVENOUS FUROSEMIDE CAUSE BULLOUS PEMPHIGOID ? 
Christian  A.  Koch.  Emcq  [,  MlTnflTT"  A  L« r rv  T t o w i  S.  Pmium.  Department  of  
Modicum, Ohio Sato University  Hospitals, Columbus, OH. 
Bullous pemphigoid (BP) is an acquired autoimmune subepidermal  blistering disease.  Certain drugs 
are risk factors for induction of  BP. The association between  BP and intra venous furosemide is rarely 
reported and has bom challenged  by a recent study (Bamiji-Carin S et al.  Drugs sssftristrd with  BP.  
Arch Dermatol  1996;132:272-6).  We prrruut a patient with BP after the administration of  intravenous  
furoaemide and review the literature on litis topic. 
A  78 year old  man with hypertension,  type U diabetes nsellitus.  rheumatoid  arthritis,  sod coronary 
artery  disease  awoke  with  tense,  painless,  nonpruritic  blisters  on  his  arms sod  legs  24  hours after 
being  treated  with  intravenous  fvroeemide  for  congestive  heart  failure.  He  wis  also  taking  
chlorpropamide,  mecoprolol, nifedipine, sceiylsalicyclic acid, oxybutyria  and ibuprofen. ail of which 
were  immediately  discontinued.  A  punch  biopsy  of  right  aetecubiul  foass  skin  revealed  a  
subepidermal  vesicular dermatitis  with a  mixed  neutrophil  and eosinophil  infiltrate,  which  by  direct  
immunofluorescence showed C3 and IgG linear deposits at the dermal epidermal junctioa.Slun  lesions  
and biopsy were typical  of  BP, for  which our patient was treated with  prednisone and  mtthotrpxitr  
His diabetes intermittently worsened and he also becama thrombocytopenic due to methotrexate. After 
9  weeks, however, his lesions healed without superimposed infections and he was discharged. 
A review of the literature revealed only 6  previously reported cases of  BP induced  by  ftiroscmide.  
All  of  these  cases  were  elderly  patients  suffering  congestive  heart  failure.  Tbe  daily  dose  of  
furoaemide  varied  from  40  mg  to  120  og.  The  bullous  skin  lesions  were  treated  either  
symptostatically  or  with  high dose corticosteroids  which  may  be  particularly  risky  for  the  elderly.  
They are often bedridden and prone to develop deep venous thrombosis,  pulmonary embolism, and/or 
infections.  Of  the drugs our  patient was  taking,  (be only  ones  which  were  listed  as  inciters of  BP  
besides  furoaemide were ibuprofen  and aeetylsalieyclic  acid.  It  is  lesi  likely  that  BP was caused  by  
either ibuprofen. which  (be patient took only rarely, or acccylal¡cyclic acid,  which be took for  many  
yews.  Our case and  previous reports suggest a relationship between  BP and  intravenous furosemide 
which oeeds (o be confirmed by prospective caee control studies of a reasonable size. 
BŐRGYÓGYÁSZATI  ÉS VENEROLÓGIAI  SZEMLE 72.  ÉVF. 2.  49-53.  
Szent-Györgyi  Albert  Orvostudományi  Egyetem  Bőrgyógyászati  Klinika  
(Igazgató  ár. Dobozy  Attila,  egyetemi  tanár)  közleménye  
Autoantitest vizsgálatok lupus  erythematosusban  
Investigation  of autoantibodies in patients with  lupus  
erythematodes 
MOLNÁR  KATALIN DR.,  KISS MÁRIA DR., HUSZ SÁNDOR DR., 
DOBOZY  ATTILA DR. 
ÖSSZEFOGLALÁS 
Az  autocintitestek  fontos  szerepet  ját-
szanak  a  kötőszöveti  betegségek  diag-
nosztikájában  és  azok  egyes  alcsoport-
jainak  elkülönítésében.  A  szerzők  összesen  
40,  lupus  erythematosusban  szenvedő  
beteget  vizsgáltak  (IS  DLE,  6  SCLE,  16  
SLE).  A  diagnózis  felállításakor  a  klinikai  
képet,  a  hisztológiai,  az  immunhisztológiai  
leletet,  valamint  az  ARA  kritériumokat  vet-
ték  figyelembe.  Az  antinukleáris  faktort  
(ANF)  immunofluoreszcenciás  technikával,  
az  extraktibilis  nukleáris  antigént  (ENA)  
ellenáramú  immunoelektroforézissel,  a  
specifikus  autoantitesteket  (anti-SSA,  -SSB,  
-Sm,  -RNP.  -kardiolipin),  ELISA  techniká-
val  vizsgálták  (Shields  Diagnostics,  
Dundee).  Összefoglalva  megállapítható,  
hogy  a  lupus  erythematosusos  betegek  
szérum  autoantitest  vizsgálata  segítséget  
nyújthat  a  betegség  prognózisának  
megítélésében. 
Kulcsszavak: 
autoantitestek  -  SLE  - S C L E  -  CDLE  
A z  a u t o a n t i t e s t e k  v i z s g á l a t a  f o n t o s  az  
a u t o i m m u n  b e t e g s é g e k  d i a g n ó z i s á b a n ,  az  
akt iv i tás  m e g í t é l é s é b e n ,  é s  az  a lcsoportok  
m e g h a t á r o z á s á h o z  is  s z ü k s é g e s .  R é g ó t a  
f o l y i k  a -kuta tás  az  e g y - e g y  d i a g n ó z i s h o z  
r e n d e l h e t ő  a u t o a n t i t e s t  p a n e l  m e g h a t á -
rozására.  és  j e l e n l e g  e z  többé-kevésbé  ki  is  
alakult  (3) .  
SUMMARY 
Autoantibodies  have  become  important  
diagnostic  tool for  the  diagnosis  of  connec-
tive  tissue  disorders  and for  defining  certain  
subgroups  of  these  diseases.  The  autoanti-
body  profile  of  our  patients  with  different  
LE diseases  and  the  clinical  importance  of  
these  investigations  were  discussed.  We  
have  chosen  a  representative  panel  of  40  
patients  suffering from  lupus  erythematodes  
(18  DLE,  6  SCLE,  16  SLE).  The  diagnosis  
based  on  the  caracteristic  clinical  
appearence,  immunhistological  and  histo-
logical  findings.  For  the  routine  indirect  
immunofluorescence  rat  liver  specimens  
sen-e  as  antigen  substrates.  Another  screen-
ing  test  was  used  for  the  detection  of  
autoantibodies  against  extractable  nuclear  
antigens  (ENA).  Finally  specific  ELlSAs  
were  performed  for  the  differentiation  of  
antibody  types  (anti-Sm,  anti-RNP,  anti-
SSA/Ro,  anti-SSB/La  and  anti-cardiolipin).  
In  sum  the  investigations  of  autoantibody  
profile  in patients  with  LE disorders  give  a  
considerable  help  to the physician  to  predict  
the course  and  the prognosis  of the  disease.  
Key  words:  
autoantibodies  -  SLE  -  SCLE  -  CDLE  
M u n k á n k  c é l j a  az  vo l t .  h o g y  az  a n a m -
n e s z t i k u s  a d a t o k a t  é s  a  k o r s z e r ű  E L I S A  
teszteket  f e lhaszná lva  meghatározzuk  klini-
kánkon  az  utóbbi  két  é v b e n  lupus  erythe-
m a t o s u s b a n  s z e n v e d ő  b e t e g e i n k  s z é r u m á -
nak  autoantitest  összetéte lé t ,  valamint  e z e k  
v i s z o n y á t  a  kl inikai  k é p h e z  é s  a  f o l y a m a t  
aktivitásához. 
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Betegek  és  módszerek  
Vizsgálata inkba  az  1993-94-ben  kl inikánkon  
meg je l en t  4 0  beteget  vontuk  be:  8  férf i t  és  32  
nőt .  Á t l a g o s  é l e t k o r u k  47 ,  ill .  46  év  vo l t .  A  
betegek  közül  18  discoid  lupus  e ry thematosus-
ban  (DLE) ,  6  subacut  cutan  lupus  e ry themato-
susban  (SCLE),  16  systemas  lupus  erythemato-
s u s b a n  ( S L E )  s z e n v e d e t t .  A  d i a g n ó z i s  fe lá l -
l í tásakor  a  klinikai  képet,  a  hisztológiai  és  az  im-
m u n h i s z t o l ó g i a i  l e l e t eke t ,  v a l a m i n t  az  A R A  
kri tériumokat  vettük  figyelembe  (9).  
F r i s s e n  d i a g n o s z t i z á l t  é s  r é g ó t a  i s m e r t  
ese teket  egyaránt  vizsgáltunk,  így  terápia  alatt  
á l lóka t  és  keze lésben  nem  részesü lőke t  is,  de  
be tegeink  a  tesztek  elvégzésének  időpont jában  
akt ív  tüne tekke l  rendelkez tek .  Kont ro l lkén t  8  
ecészséces  véradó  szérumát  használtuk.  
Az  a n t i n u k l e á r i s  e l l e n a n y a g o k  k i m u t a t á s a  
i n d i r e k t  i m m u n o f l u o r e s z c e n c i á v a l  t ö r t é n t .  
Szubszt rá tként  pa tkánymáj  metszete i t  használ-
tuk.  A  vizsgála tokat  Leitz  Or thoplan  f luoresz-
cenciás  mikroszkóppal  végeztük.  
Az  ex t rahá lha tó  nukleár is  an t igének  ( E N A )  
elleni  ant i tes teket  e l l enáramú  immunoe lek t ro -
forézis  technikával  vizsgál tuk.  Az  ENA- t  bor-
j ú t í m u s z b ó l ,  a c e t o n o s  e x t r a k c i ó v a l  i zo l á l t uk  
(4). 
Az  SSA.  SSB,  Sm.  R N P  dsDNS,  kardiolipin  
a n t i g é n e k  e l l e n i  a u t o a n t i t e s t e k  m e g h a t á -
r o z á s á h o z  E L I S A  m ó d s z e r t  ( S h i e l d s  D i a g -
nos t i c s .  D u n d e e )  h a s z n á l t u n k .  A  s z é r u m o k a t  
1:500  arányban  hígítot tuk.  Az  SSA,  SSB,  Sm,  
RNP.  dsDNS  ellenes  antitesteknél  kvalitatív,  az  
anti-kardiolipin  el lenanyagok  esetén  kvantitatív  
méréseket  vécéztünk.  
Eredmények 
Eredményeinket  oszlopdiagramokon  és  
t áb l áza tban  fog la l tuk  össze .  SLE-ben  
szenvedő'  be tegeink  (1.  ábra)  3  kezel t  
személy  kivételével  ANF,  5  esetet  kivéve  
pedig  ENA  pozitívak  voltak.  Ant i -SSA  
ellenanyagokat  az  esetek  felénél,  SSB-t  az  
esetek  1/4-nél  találtunk.  Az  anti-dsDNS  
antitest  pozitív  betegek  közül  egy  SLE-vé  
transzformálódott  CDLE-s,  aki  korábban  
vasculitisben  is szenvedett,  egy  másik  pedig  
esetszám 
14  í —  
ANF  ENA  Sm  *  RNP  SSA  SSB  DNA  
I.  ábra  
Autoantitestek  előfordulásának  gyakor isága  systemas  lupus  erythematosusban  (n=16)  
* -  Sm  vizscálat  technikai  okok  miatt  csak  6 esetben  történt.  
50 
esetszám 
ANF  ENA  Sm  RNP  SSA  SSB  DNA  
2.  ábra  
Autoantitcstek  e lőfordulásának  gyakorisága  subacut  cutan  lupus  erythematosusban  (n=6)  
esetszám 
ANF  ENA  Sm  RNP  SSA  SSB  DNA  
j.  ab  ni  
Autoanti testek  e lőfordulásának  gyakorisága  discoid  lupus  erythematosusban  (n=18)  
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keze le t l en ,  akut  tünetekkel  j e l e n t k e z ő  beteg  
v o l t .  A z  S L E - r e  s p e c i f i k u s ,  S m  e l l e n e s  
antitestet  technikai  o k o k  miatt  csak  6  eset -
b e n  tudtuk  v i z s g á l n i  é s  e g y e t l e n  e s e t b e n  
s e m  s i k e r ü l t  k i m u t a t n i  p o z i t i v i t á s t ,  a  
gyakrabban  m e g j e l e n ő  R N P - t  5  a lka lommal  
ész le l tük . 
A  S C L E - s  b e t e g e k  eredménye i  a 2 .  ábrán  
l á t h a t ó k .  K ö z ü l ü k  3 - 3  e s e t b e n ,  v á l t o z ó  
k o m b i n á c i ó b a n  A N F - t ,  E N A - t  é s  ant i -SSB  
a n t i t e s t e t ,  n a g y  a r á n y b a n  -  5  b e t e g n é l  -
S S A  e l l e n e s  ant i t e s te t  ta lál tunk.  A n t i - S m  
ül .  - R N P  antitest  2 ,  ill.  1  betegné l  fordult  
e lő .  A n t i - d s D N S  e l l e n a n y a g  egye t l en  eset -
ben  s e m  volt  m e g f i g y e l h e t ő .  
D L E - b e n  az  autoantitestek  kisebb  száza-
lékban  fordultak  e l ő  (3.  ábra).  A  18  beteg  
k ö z ü l  8 - n á l  A N F - t ,  2 - n é l  E N A - t ,  4 - n é l  
S S A - ,  1-nél  S S B - e l l e n i  antitestet  találtunk,  
1  e s e t b e n  ped ig  a n t i - S m  antitestet  tudtunk  
kimutatni . 
B e t e g e i n k  t ö b b s é g é n é l  n e m  t a l á l t u n k  
a n t i - k a r d i o l i p i n  ant i t e s te t  (1 .  táblázat ) .  4  
D L E - s ,  1  S L E - s  é s  1  S C L E - s  b e t e g n é l  
ha tárese t ,  2  S L E - s n é l ,  1  D L E - s n é l  p e d i g  
e n y h é n  e m e l k e d e t t  s z é r u m s z i n t e t  é s z l e l -
tünk.  A z  e g y i k  S L E - b e n  s z e n v e d ő  b e t e g  
a n a m n é z i s é b e n  i s m é t l ő d ő  v e t é l é s e k  szere-
peltek. 
Megbeszélés 
V i z s g á l t u k  a z  e x t r a h á l h a t ó  n u k l e á r i s  
ant igén  ( E N A ) ,  annak  két  ö s s z e t e v ő j e ,  az  
1.  táblázat  
Ant i -ka rd io l ip in  an t i t e s t  e r e d m é n y e k  lupus  
e r v t h e m a t o s u s b a n  szenvedő  betegeknél  
(n=40) 
S m  é s  a z  R N P ,  v a l a m i n t  S S A ,  S S B ,  
d s D N A ,  kardiolipin  e l leni  antitesteket  é s  az  
antinukleáris  faktort  ( A N F ) .  
A z  S m  és  az R N P  a m e s s e n g e r  R N S  érési  
fo lyamatában  részt  v e v ő  sej tmagi  ribonuk-
l e o p r o t e i n e k .  A z  a n t i - S m  e l l e n a n y a g o k  
n a g y o n  s p e c i f i k u s a k ,  d e  k e v é s s é  s z e n z i -
t í v e k  S L E - b e n ,  m í g  a z  R N P  e l l e n e s  anti-
testek  az  L E  csoport  többi  tagjánál  is  m e g -
j e l ennek  (10) .  
A z  S S A  ce l lu lar i s  ant igén  e l s ő s o r b a n  a  
sejtmagra  lokal izá lódó,  de  időnként  a  cito-
p l a z m á b a n ,  s ő t  a  p l a z m a m e m b r á n o n  is  
m e g j e l e n ő  t e r m é s z e t e s  se j ta lkotó  r ibonuk-
leoprotein,  amely  a sejtproliferációban  játsz-
hat  s z e r e p e t .  E z e k e t  az  a n t i t e s t e k e t  l e g -
gyakrabban  S L E - b e n  é s  S C L E - b e n  detek-
tálhatjuk  (1 ) .  A z  S S B  ant i tes teket  ritkáb-
ban,  e l sősorban  S S A  poz i t ív  e se tekben  le-
het  kimutatni  (7) .  
A  k e t t ő s  s z á l ú  D N S  e l l e n i  a n t i t e s t e k  
m a g a s  s z á z a l é k b a n  t a l á l h a t ó k  m e g  a  L E  
csoportban,  érzékeny,  és  spec i f ikus  marker.  
A z  anti-kardiol ipin  antitest  a  fo sz fo l ip id  
t ípusú  ant i t e s tek  e g y i k  faj tája .  Á l t a l á b a n  
o l y a n  S L E - s  b e t e g e k  s z é r u m á b a n  j e l e n i k  
meg ,  akiknek  valamilyen  vascularis  szövőd-
ményük  van  (6).  
A z  a u t o a n t i t e s t e k  v i z s g á l a t a  s e g í t h e t  a  
d i a g n ó z i s  f e lá l l í t á sában ,  az  akt iv i tás  é s  a  
p r o g n ó z i s  m e g í t é l é s é b e n .  E h h e z  a z o n b a n  
i smernünk  kell  azt  is,  m i l y e n  kombinác ió t  
a lkotnak  az  autoant i tes tek .  A z o k  az  S L E -
ben  s z e n v e d ő  b e t e g e k ,  akiknél  csak  S S A ,  
S S B  p o z i t i v i t á s  v o l t  k i m u t a t h a t ó ,  k e d -
v e z ő b b  p r o g n ó z i s ú n a k  tűnnek,  a  b e t e g s é g  
k é s ő b b i  i d ő p o n t b a n  k e z d ő d i k ,  a  r e n á l i s  
érintettség  ritka.  H a  S S A  pozit ivitás  mellett  
S m  v a g y  d s D N A  e l l e n e s  antitesteket  is  ki  
l e h e t  m u t a t n i ,  a  b e t e g s é g  p r o g r e s s z i ó j a  
valósz ínű,  s z ö v ő d m é n y e k  léphetnek  fel  (8) .  
í g y  e g y i k  f i a t a l  l u p u s  n e p h r i t i s e s  b e t e -
günknél  erős  A N F  pozit iv i tás  mellett ,  anti-
E N A ,  - S m ,  - R N P ,  - d s D N A  e l lenanyagokat  
l e h e t e t t  k i m u t a t n i .  E g y  m á s i k  S L E - s  
betegünknél  korábban  csak A N F  volt  kimu-
tatható,  j e l e n  vizsgálatkor  a  be tegség  prog-
r e s s z i ó j á v a l  e g y ü t t  d s D N A  e l l e n e s  ant i -
testek  is  megje lentek .  A n a m n e s z t i k u s  ada-
tokból  ál lapotrosszabbodásra  (ál landó  gyen-
geségérzés ,  i smét lődő  pleuritis)  derült  fény.  
Anti-kardiolipin 
IgG units/ml  
Eredmények 
értékelése 
Betegek 
száma 
< vagy =  10  Negatív 13 SLE 
13 DLE 
5SCLE 
>10-15 Határeset 1 SLE 
4  DLE  
1 SCLE 
>15-60 Mérsékelten 
magas 
2  SLE 
1 DLE 
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Egy  korábban  ANF  pozitív  SLE-s  be-
tegünknél  nem  találtunk  autoantitesteket.  A  
vizsgálatkor  gyorsan  progrediáló  glo-
merulonephritise  miatt  citosztatikus  ke-
zelésben  részesült.  Két  esetben  találtunk  
egyértelműen  emelkedett  anti-kardiolipin  
antitestet,  ami  magyarázhatja  az  egyik  
nőbetegnél  az  ismétlődő  vetéléseket,  a  
másik  esetben  nem  volt  ilyen  anamnesz-
tikus  adat.  
Az  egyik  SCLE-ben  szenvedő  betegünk  
szérumában  SSB,  Sm,  RNP,  kardiolipin  
ellenes  antitesteket  mutattunk  ki.  A  vérvétel  
időpontjában  hőemelkedés,  gyengeség-
érzés,  fogyás  volt  a  panasz,  laborleleteiben  
leukocitopénia,  trombocitopénia  szerelt.  Az  
SSA  pozitív  SCLE-s  betegek  anamné-
zisében fény provokáló szerepe  gyakori  (a 6 
betegünkből  4-nél  mi  is ezt  tapasztaltuk),  és  
ezekben  az  esetekben  a  fényérzékenységi  
teszt  is pozitív  szokott  lenni  (5,  11).  
DLE-s  betegeink  között  1 esetben  Sm  
el lenes  antitestet  észle l tünk.  Ez  azért  
figyelemreméltó  tény,  mert  az  Sm  speci-
fikus markere  a SLE-nek.  Irodalomban  leírt  
adatok  szerint  a  DLE-ben  5%-ban  szisz-
témás  exacerbáció  alakulhat  ki,  ezért  ezen  
beteg  szoros  nyomonkövetése  szükséges  
( 2 ) . 
A  vizsgálataink  egyszeri  mintavétel,  illet-
ve  többszöri  státuszrögzítés  alapján  készül-
tek.  Ezekből  egy-egy  esetre  vonatkozóan  
lehet  következtetéseket  levonni.  A  leletek  a  
diagnózis,  az  aktivitás  és  a prognózis  meg-
ítélésében  segítségünkre  lehetnek,  de  ál-
talános  érvényű  megállapításokhoz  további  
szisztematikus  laboratóriumi  és  klinikai  
gondozó munka  szükséges.  
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PEVELQPMENT OF A SYSTEM  FOR THE DETECTION 0F  CIRCULATING  
ANTIBODIES  AGAINST  DESMOSOMXL  PROTEINS  IN  PATIENTS  WITH  
PEMPHIGUS  Katalin  Molnár'.  Man» Kiss'.  Sándor Hug'.  Ilona  Marcanovils'.  
lin"'  Molnár2.  Gábor  K.  Tóth1.  Anila  Dnbnz»'  Departments  of  'Dermatology.  
'H,)icfobiologv  and  'Medical  Chemistry.  Alhen. Szent-Gyfirnyi. Medical  University  
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The  pemphigus  vulgar» (PV)  and  pemphigus  foliagevs (PF)  autoanjjgen  structures  
are. known.  The  present  aim  was  to  develop, a  system ^for  the  demonstration  of  
circulating  antibodies  against  the  PV  antigen  (desmo$ein  3; 'D*g3)  and  the  PF  
antigen  (desmoglein  I;  dsgl)  by  means  of  an  ELISA* technique  with  synthetic  
antigenic  peptides.  With  the  help  of  Peptide  Structure  software,  two  antigenic  
epitopes  for  Dsg3  and  one  for  Dsgl  were  choserr  and  synthesized.  The  sera  of  16  
patients  with  pemphigus  were  investigated  in  parallel  by .an  immunobfot  technique  
using a human  epidermal  extract,  and  by  an ELISA technique with  synthetic  peptides.  
The  sera of  16 healthy  persons,  S patients.with  bullous pemphigoid  ind  S with  other  
bullous  diseases  served  as  controls.  Among  the  16 pemphigus  patients  ( IS  with  PV  
and  1 with  PF),  10  sera  proved  positive  for  at  least  one  synthetic  peptide.  Positive  
reactions  with  Dsg3  were  found  in  6  patients  by  immurpblot  and  in  9  patients  by  
ELISA  with the  synthetic  peptides.  With  Dsgl,  no specific reaction was detected  by  
immunobfot, but  positive reactions were  found  in  7 patients by'the ELISA  technique.  
The  examinations  of  the  control  group  were  negative.  The  use  of  an  ELISA-based  
system  with  the  antigenic,  synthetic  epitopes  might  simplify  the  diagnosis  of  the  
pemphigus group, but  it does not  appear  suitable for differentiation of PV  and  PF.  
EPIDERMOLYSIS  BULLOSA  SIMPLEX  (DOWLING-MEARA  TYPE)  
ASSOCIATED  WITH  PYLORIC  ATRESIA  AND  CONGENITAL  UROLOGIC  
ABNORMALITIES  S-C Kim,  P-K  Kim.  SN Chang,  TH  Park.  SY  Kim*.  Department  
of  Dermatology.  Yonsei  University  College of  Medicine.  Sowha Children's  Hospital*.  
Seoul.  Korea 
The  Dowling-Meara  form is  a  rare  subtype  of  epidermolysis  bullosa  simplcx(EBS)  
and  is  characterized  clinically  by  herpetifonn  clustering  of  blisters  and  palmc^plantar  
keratoderma. The concomitant occurrence of inherited  epidermolysis bullosa and  pyloric  
atresia(PA)  was  reported  mostly  in junctional  EB.  In  EBS only one  case  b  reported  in  
the literature, but its subtype was unknown.  We report  a case of (he Dowling-Meara  type  
of  EBS  associated  with  congenital  pyloric  atresia  and  urologie  abnormalities.  The  
diagnosb  was  confirmed  by  immunofluorescent  mapping  and  transmission  electron  
microscopic studies. Immunofluorescent mapping showed  that serum  from a patient  with  
bullous  pemphigoid  was  faintly  bound  to  the  floor  of  the  blister,  and  monoclonal  
antibody against  type  IV and  VII collagens were also  stained  on  the  floor  of the  blister.  
Electron  microscopy  showed  epidermolytic  cleavage  and  prominent  clumping  of  
tonofilaments  in  the  basal  and  suprabasal  keratinocytes.  An  abdominal  radiograph  and  
barium  swallow  showed  complete  obstruction  at  the  pyloric  channel  level.  Widespread  
bullous  lesions  cleared  completely  at  3  months  of  age  without  treatment.  Posterior  
urethral  valve,  type  III  and  detrusor  sphincter  dyssynergia  were  found at  12 months  of  
age.  At  I5ih  months a bulb  recurred  on  left great  toe and  nail  shedding  was  observed.  
His  father and  a  paternal  uncle  had similar  bullous eruptions at  infancy which  improved  
spontaneously  by  the age of  1. Clinical  manifestations of the present case  and  his family 
show phenotypic heterogeneity  in Dowling-Meara  ty pe of  EBS.  
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ABNORMAL KERATIN FILAMENT ASSOCIATION WITH  HEM1DESMOSOMES  
IN JUNCTIONAL EPIDERMOLYSIS  BULLOSA.  J.R. McMillan'.  J.A.  McGrath ' .  
M.J. Tidman2 .  R.A.J.  Eadv1.  'S i John's  Institute of  Dermatology. UMDS.  St  
Thomas's  Hospital.  London.  2Dept. of  Dermatology. Royal Infirmary.  Edinburgh.  
U .K . 
Juncuonal  epidermolysis  bullosa (JEB)  Is a group of genetic blistering skin  disorders  
resulting from defeats in a variety of hemidesmosome (HD)-anchoring  filament  
components including laminin S. the  180 kD bullous pemphigoid antigen (BPI80)  and  
the integrin a 634  Because  HDs are involved  not only in  kenttinovyte-extracellular  
matrix adherence, but also in normal anchorage of kcraun intermediate filaments (KIFs) 
to the basal keratinocytc membrane, we wanted to know- wrhether this  intracellular  
function of hemidesmosomes was also perturbed in JEB.  We used quantitative  electron  
microscopic methods to assess certain morphological features of HD-KIF interactions  in  
skin from normal subjects (n=l  1) and from patients  w ith different forms of JEB (n= 13). 
At least  SO HDs from each individual were scored for ihe presence of  inner plaques and 
for close association  with  KIFs.  Values were expressed as a  percentage of  the  total  
number of  HDs counted.  In normal skin 83 J  a 3.3 (SEM) HDs were associated  with  
KIFs and 9 0 . 1 1 1 . 9  had  inner plaques.  In Hertiiz JEB (laminin  S defects. n=4)  these  
values were reduced to 45.3 a  11.5 (P<0.01; analysis of  variance)  and 50.3 a  12.8  
(P<0.01)  respectively.  In JEB with pyloric atresia (u604 defects, n=3)  the values  were  
even less at 41.8 a 7.0 (P<0.01) and 44.5 a 5 . 7 (P<0.0l).  In  the non-Herlitz  group  
(laminin  S defects. n=3) the counts were 66.7 a 7.1  (P>0.05)  and  70.5  a 8.5  (P<0.05).  
and for the BPI80 defects (n=3)  they were 54.3 a  13.8 (P<0.0l)  and  57.1  a  13.9  
(P<0.OI).  These findings suggest that the molecular abnormalities underlying different 
forms of JEB appear to affect certain critical  intracellular functions of  HDs, such as the 
normal connections with  KIFs.  This may have important implications for the 
maintenance of basai keratinocytc integrity and  resilience  in JEB. 
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TEMPERATURE-DEPENDENT  DISSOCIATION  OF THE BPI80  HOMOTRIMER  
TO THE MONOMER.  Hendri  H.  Pas. Guus J.  Kloosterhuis.  Miranda  Nijenhuis.  
Marcelus C.  I.  M. de lone. Jan  B. van dcr Meer and  Marcel  F. Jonkman.  Dept.  of  
Dermatology,  Uoiversity Hospital, Groningen, The  Netherlands.  
The  180 kDa  bullous pemphigoid  antigen (BP!80),  or type XVII collagen, is a  trans-
membrane keratinocyie hemidesmosomal  protein of which  the extracellular  part  
(approximately  120 kDa) contains  13 putative collagen  domains.  The  collagenous  
character of this protein  suggests that  it has the potential of forming a collagen  triple-
helix structure  in vivo. When  BP180 was extracted  with  SDS  from  human  skin  or  
cultured human  keratinocytes,  it manifested itself m SDS-PAGE as an aggregated  form  
with  a molecular weight  suggestive of a trimer. This associated  form of BP 180 could  be  
"melted" down to the  mooomeric  180 kDa  form by incubation of the extracts  at  
elevated  temperatures.  During 40 minutes incubations at various temperatures  the  
transition  from  trimer to monomer could be completed  between  32 and 38 °C.  I£ before 
extraction, the cells were treated  with the chemical cross-linker  DTSSP, BPI80  could  
be ' locked" in the trimeric  form which  then became heat-resistant.  Two-dimensional  
SDS-PAGE,  followed by  siK erstaining  and unmunoblotting  revealed that the  associated  
form consisted  of solely BP 180 and contained no other  protein.  
This study shows that  m human  skin BPI80 is present  in a homotrimeric  form.  
Furthermore the transition  of the trimer to the monomer, l e .  the  melting of the  triple  
helix, can be visualized  by SDS-PAGE.  This ample  method  could be  a valuable tool  to  
study the stability of mutant  forms of type XVII  coUagen.  
"S 
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Ideatlflcadoa  of  oew target  antigens Involved  In subepithelial  halloas  dermatoses.  
Rezs  F.  Chohestani.  Jean  Francois  Nicolas.*  Pauicisl  Rousselle."  Alain  Claudy.  
Department  of  Dermatology  and  INSERM  U80.  E  Herriot  Hospital.  Y IBCP.  Lyon.  
France. 
Several subepithelial  bullous dermatoses of  hereditary or autoimmune origin have been 
described  to date  in  which  different components  of  the epithelial  basement  membrane  
zone  (BMZ)  are  known  as  the  targets  in  these  disorders.  Pathologic  involvement  of  
plectin.  180kD-bullous pemphigoid antigen (collagen XVII) and collagen  VII  localizing  
at the various levels of  BMZ have been shown to result in dcrmal-cpidermal  dissociation.  
We here present our data about identification of  new target antigens  recognized  by auto-
antibodies  from  patients  w-itb  various  forms  of  subepithelial  auto-immune  bullous  
dermatoses (SABD) 
Antigenic  specificity of  142 SABD sera  was determined  by immunobfot assay  using  
different  protein  lysates  derived  from: cultured  human  keratinocyies.  human  dermis,  
human buccal  and  gingival  mucosae and  purified laminin-5. Anu-BMZ  reactivity  of  the  
patients'  sera  had  been  further confirmed  by  immunofluorescence  microscopy  on  1M  
XaCl-splil skin  (SSSX SABD sera were found lo conlam auto-antibodies  mostly  directed  
against either  the  180 and/or  230 kD bullous  pemphigoid  antigens (n=l 12). or  the  145-
290kD collagen  VII (n=IO). The a 3  and 83 chain of  laminin-5 were  recognized  by  five  
sera  labelling the dermal side  of SSS.  A  !68kD mucosal  antigen.  CO-mi grating  with  the  
polypeptide  recognized  by an anri-a6 integrin  antibody, was  labelled by  five  other  sera  
binding the epidermal  side of  SSS. The clinical  features of  patients with  aoli-taminin-5  
and ami-a6  integrin  auto-antibodies  resemble  to  those  of  cicatricial  pemphigoid.  One  
more  scrum, from a patient with clinical  features suggestive of a severe  form of  bullous  
pemphigoid.  Identified exclusively  a  185kD dermal  antigen co-migrating  with  collagen  
type IV as Isbeiled by s specific rabbit polyclonal antibody. 
Identification of a6-integrio. a3-  and 83- ehaiiia of  laminin-5 and collagen  IV as newly 
described auto-antigens  in immune-mediated  bullous dermatoses further highlights  their  
important rolc(s) In eell to matrix adhesion of epithelial  BMZ 
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IMPLICATIONS  OF INTRAGENIC  MARKER  HOMOZYGOSITY  AND HAPLOTYPE SHARING 
IN GENERALIZED ATROPHIC 8ENIGN  EPIDERMOLYSIS  BULLOSA  (GABE8)  
Hans  Seheffer1,  Rain  P.  Stulp  ,  Edwin  Veftind  .  Leana  Bruckner-Tuderman  .  Tobias  
Gedde-Oahl  Jr.1,  Garard  J .  ta  Meermah  .  A/noud  Sonnenbdtg  ,  Chartas  H.C.M.  Bbys  ,  
Marcel  F.  Jonkman* 
'  Oept.  of  Medical  Genetics,  University  of  Groningen.  Groningen. Uta  Netherlands  
* Dept.  of  Dermatology,  University  of  Münster,  Münster,  Germany  
1  Dept.  of  Dermatology  and  Institute  of  Forensic  Medicine,  National  Hospital.  Oslo,  
Norway 
4  Oivision  of  Call Biology,  The Netherlands  Cancer  Institute,  Amsterdam.  The  Netherlands  
'  Oept.  of  Dermatology.  University  Hospital  Groningen.  Groningen,  The  Netherlands  
Generalized  atrophic  benign  epidermolysis  bullosa  (GABE8)  is  s  form  of  junctional  epider-
molysis  bullosa  (JEB)  with  a  recessive  mode  of  inheritance.  In  the  majority  of  GA8EB  
patients  the  product  of  the  C0L17A1  gene,  the  180  kD  bullous  pemphigoid  antigen  
IBP180),  is  undetectable  in  skin.  We  have  identified  an  intragenic  COL17A1  micro-
satellite  marker  for  which  83%  of  randomly  selected  control  individuals  are  heterozy-
gous.  We  observed  homozygosity  for  different  alleles  of  this  marker  in  five  out  of  six  
collagen  type  XVII-negative  GA8EB patients  of  different  European  descent.  Five  of  the  6  
C0L17A1  alleles  of  three  patients  originating  from  the  eastern  part  of  The  Netherlands  
were  identical,  as  were  the  haptotypss  including  flanking  markers.  The  2342delG  muta-
tion  was  identified  in  all  these  five  alleles.  This  confirms  the  expectation  that  due  to  
genetic  drift  end  hidden  inbreeding  for  en  autosomal  recessive  disorder  with  low  gene  
frequency  such  as  coilagsn  type  XVII-nsgstive  GABEB  most  disease  alleles  from  a  re-
stricted  geographical  area  wiH  be  "identical  by  descent".  Our  results  demonstrate  that  
involvement  of  a  candidate  gene  can  be  confirmed  by  looking  for  identity  by  descent  of  
highly  informative Intragenic  markers.  
CORRESPONDENCE  161  
and  sin elevated  erythrocyte sedimentation  rate  of 76 mm  in  the  
first  hour.  Examination  of  human  leucocyte  antigens  revealed  
positive  B51.  
A  skin  biopsy  specimen  was  taken  from  an  erythematous  
area  with  a central  pustule.  Histological  features  correspond-
ing  to  the  central  pustular  lesion  showed  necrosis  of  the  
epidermis,  dense  lymphocytic  infiltration,  and  considerable  
cell  debris  that  extended  through  the  mid-dermis  into  the  
subcutis.  Necrotizing  vasculitis  characterized  by  angiocentric  
lymphocytic  infiltration  with  fibrinoid  necrosis  of the  dermal  
vessels was  identified  in  the surrounding erythematous  lesion  
(Fig.  lb).  
The  clinical  and  laboratory  data  suggested  that  this  patient  
was  suffering  from  severe  BD  of  abrupt  onset.  Steroid  pulse  
therapy  (intravenous  infusion  of methylprednisolone.  1 g/day 
for  3daysl  was  followed  by  the  intravenous  infusion  of  
prednisolone.  60 mg  daily,  for  2 weeks.  Soon  after  this  
treatment  was  started,  the  lower  gastrointestinal  bleeding  
ceased  and  the patient's  general  condition  improved.  No  new  
skin  lesions  appeared  thereafter.  All  but  the  neurological  
symptoms  disappeared  within  the  first  2 weeks  of  treatment.  
Since  the  discontinuation  of  steroid  therapy  17 months  ago.  
the  patient  has  exhibited  only  recurrent  oral  ulcers  with  a  
slight  persistent  paralysis  of the  recurrent  nerve.  
The  present  case  fulfils  the  diagnostic  criteria  for  BD  
proposed  by  the  Research  Committee  of  Japan.1  namely:  
major  criteria:  recurrent  oral  aphthosis.  skin  lesions  
(erythema  nodosum,  subcutaneous  thrombophlebitis,  acnei-
form  or  folliculitis-like  lesions),  eye  lesions  (iridocyclitis,  
chorioretinitis),  genital  aphthae:  minor  criteria:  arthritis,  
epididymitis,  gastrointestinal  lesions,  vascular  lesions  and  
central  nervous system  involvement.  The International  Study  
Group  (IGSl  for  BD2  criteria  are  as  follows:  recurrent  oral  
ulceration  (i.e.  minor  aphthous,  major  aphthous  or  herpeti-
form ulceration  observed  by physician  or patient,  recurring  at  
least three  times in one  12-month  period): plus any  two  of the 
following: recurrent  genital  ulceration  (i.e.  aphthous  ulcera-
tion  or  scarring,  observed  by physician  or patient): eye  lesions  
(i.e.  anterior  uveitis,  posterior  uveitis,  cells  vitreous  on  slit-
lamp  examination,  retinal  vasculitis):  skin  lesions  (i.e.  
erythema  nodosum,  pseudofolliculitis. papulopustular  lesions,  
acneiform  nodules  observed  by  a  physician  in  postadolescent  
patients  not  on  corticosteroid  treatment):  and  a  positive  
pathergy  test  read  by a  physician  at 2 4 - 4 8  h. The  prevalence  
of  BD in Japan  is one  of the highest  in the  world.  According  to  
the  ISG criteria.2  however, the present acutely  ill patient  would  
not  have  been  diagnosed  as  having  BD  because  she  lacked  
preceding  oral  ulcerations  that  had  recurred  at  least  three  
times  in one  12-month  period. The  ISG criteria  were  intended  
to  provide  an  international  consensus  on  the diagnosis ofBD. 
In  typical  BD. certain  manifestations,  including  oral  aphthae,  
appear  transiently  for  brief  periods,  and  show  a  chronic  
course.1  However,  some  patients  exhibit  all  the  typical  
manifestations  at  once,  as  seen  in  the  present  case."1-''  
Thus,  according  to  ISG  criteria,  when  a  patient  with  BD  
without  any  preceding  recurrent  oral  ulcerations  later  
develops  them,  that  patient  cannot  initially  be  diagnosed  ¡is  
having  BD. simply because there has not been enough  time for 
the aphthae  to recur.  It was  reported  that  28  of the 914  cases  
(3%)  of  BD analysed  by the  ISG lacked  recurrent  oral  ulcers.  
Diagnostic  criteria  ideally  should  have  a  high  sensitivity  as  
well  as  tt  high  specificity.'  Patients  with  acute  onset  ofBD  as  
evidenced  by  life-threatening  systemic  illness  require  a  
definitive  diagnosis  in  order  to  initiate  prompt,  appropriate  
treatment.  We  therefore  suggest  that  the  ISG  criteria  be  
modified  to  state  that  the  recurrence  of  oral  ulcers  is not  an  
essential  diagnostic  criterion  in  those  cases  with  acute  onset.  
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Panniculitis  in  dermatomyositis:  report  of two  cases  
Sir.  Although  clinically  manifest  panniculitis  is  rarely  found  
in  dermatomyositis  (DM),  microscopic  panniculitis  has  fre-
quently  been  observed.  Janis  and  Winkelmann  described  a  
10%  occurrence  of  panniculitis  in  biopsy  specimens  of  
dermatomyositic  skin.1  Neidenbach  el  al.  considered  that  
panniculitis  may  be  an  inherent  part  of  DM  and  should  be  
included  us one of the diagnostic features.2  We report  here two 
cases (which  fulfilled the criteria  of Bohan and  Peter)  involving  
clinically  manifest  panniculitis,  and  discuss  the  diagnostic  
significance  of our  findings.  
A  54-year-old  woman  presented  with  a  6-month  history  of  
proximal  muscle  weakness,  low-grade  fever  and  a  15 kg 
weight  loss.  Examination  revealed  periorbital  oedema.  
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Figure  ] .  (a)  Patient  1.  Excoriated  erythematous  plaque  on  the  right  
arm.  (b)  Patient  2.  Erythematous  indurated  plaques  and  nodules  on  
the  buttocks.  
erythema  on  the  arms.  face, eyelids,  fingers,  knees  and  thorax  
and erythematous papules over the metacarpophalangeal  joints.  
Some  excoriated  erythematous  papules  on  an  indurated  base  
were present  on the  lower parts  of the arms  (Fig. la).  Abnormal  
laboratory results were as follows: lactate dehydrogenase  60811/  
L (normal  range.  N: 45-90)  and  creatine  kinase  414  U/L  (N:  
10-70).  No  anti-SSA.  anti-SSB.  anti-Sm  or  anti-dsDNA  
antibodies  or  other  antinuclear  antibodies  were  found.  An  
electromyogram  of  the  right  deltoid  muscle  displayed  char-
acteristic signs of myositis.  No internal  malignancy was found. 
A  histology  specimen  taken  from  the  arm  showed  an  
inflammatory  infiltrate  in  the  subcutis  and  fascia.  A  muscle  
biopsy  demonstrated  degeneration  of  the  fascist  and  muscle  
fibres  and  direct  immunofluorescence  showed  mononuclear  
cell  infiltration.  The  muscle  exhibited  immunocornplex  deposi-
tion  in  the  vessels  and  among  muscle  libres.  The  patient  was  
treated  with  prednisolone.  1  mg/kg  per  day.  and  azalhioprine.  
2 mg/kg  per  day. until  the symptoms  were controlled.  One year 
later,  an  abscess  was  incised  and  drained  in  the  left  inguinal  
region.  Mycobacterium tuberculosis  was  cultured  from  the  pus.  
The  patient  underwent  combined  antituberculosis  therapy.  At  
present  she  is symptom-  and  complaint-free.  
A  57-year-old  woman  presented  with  a  history  of  facial  
rash,  tiredness,  joint  pain,  low-grade  fever,  proximal  muscle  
weakness and  dysphagia. There were erythematous  indurated  
plaques  and  nodules  on  the  buttocks,  the  left  thigh  and  the  
sacral  region  (Fig.  lb).  Laboratory  examinations  revealed  
creatinine  phosphokinase  (2660U/Ll.  Antinuclear  antibodies  
(nucleolar  type.  1 : 32) examined  on mouse  liver substrate  were  
positive:  anti-SSA.  anti-SSB  and  anti-dsDNS  antibodies  were  
negative.  A  tumour  search  proved  negative.  Histological  
examination  of the  deltoid  muscle  revealed  degeneration  of the 
muscle  fibres,  focal  mononuclear  infiltration  and  vasculitis. A 
biopsy  of buttock  skin  indicated  subepidermal  oedema,  marked  
vasculitis  throughout  the  dermis,  and  a  marked  perivascular  
mononuclear  and  plasma  cell  infiltrate.  In  the  subcutis.  
intralobar  inflammation  could  be  seen.  Direct  immuno-
fluorescence  examination  of  the  skin  from  the  gluteal  area  
demonstrated  immune  complex  deposits  in  the  vessels,  while a 
deltoid  muscle  biopsy  showed  a  marked  vasculitis  with  
depositions  of  IgM.  IgA  and  C3.  The  treatment  was  initially  
methylprednisolone.  1 mg/kg per day. but  in consequence  of the 
poor  response this was changed  2 weeks later  to cyclosporin  A.  
3 mg/kg  per  day.  The  dysphagia  and  the  limitation  of  motion  
decreased.  The  patient  is now complaint-  and  symptom-free.  
Since  1924.  only  nine  cases  with  clinically  manifest  
panniculitis  have  been  described  in  the  literature.2-1"  
Fusade  el al.  considered  that  panniculitis  should  be  included  
in  the  cutaneous  features  of  DM.  and  that  the  discrepancy  
between  the  frequencies  of  clinical  manifestations  and  
histological  changes  suggested  variable  degrees  of severity  of  
the  same process.s  In contrast.  Winkelmann  eta I. were  of the 
opinion  that  although  changes  do occur  in  the  adipose tissue,  
they  are  focal  and  infrequent,  and  not  characteristic  enough  
to produce  a  clinical  syndrome  of  panniculitis."  
Calcium deposits may occur  in the skin and  soft tissue in the 
late  stages  of  DM.  The  histological  specimens  reported  
displayed  a  calcified  area  in  only  one  case.  Janis  and  
Winkelmann  found  the  true  incidence  of  calcinosis  in  DM to 
be  =  74%  among  children  and  20%  among  adults.  It  is  not  
delected  in  such  high  percentages,  because  skin  biopsies  are  
not  usually  performed  for the  purpose  of detecting  calcium.'  
The incidence  of malignancy  in  adult  patients  with  DM varies 
between  6%  and  60%.  according  to  different  reports.  A  
neoplasm  has  been  described  in  only  one  case.  All  patients  
responded  well  to  prednisolone  and  in  some  eases  to  
methotrexate  treatment,  except  for  one  patient  who  needed  
intravenous  immunoglobulins.  
Our data  and  the literature  review  suggest  that  panniculitis  
present  in  DM may  be a  positive  prognostic  sign,  as  nearly  all  
DM  patients  with  panniculitis  exhibited  a  good  clinical  
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response  to treatment,  and  internal  malignancy  was  detected  
in only one case. Overall,  we propose thai  DM accompanied  by  
panniculitis  may comprise  a  distinct  subset  of DM-
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Pyoderma  gangrenosum  associated  with  myelofibrosis  
SIR.  Pyoderma  gangrenosum  (PG).  a  severe  ulcerative  skin  
disease, is often associated  with an underlying systemic disorder. 
Myelofibrosis has been described  a few times in  association  with  
PG.1-  We describe another case of myelofibrosis and  PG. as well 
as providing  a  review  of the  literature.  
A 67-vear-old  man  presented  in  April  1991  with  remarkable  
paleness  and  splenomegaly.  Initial  work-up  revealed  anaemia,  
leucopenia  and  an  anisocytosis.  hypochromia,  and  nucleated  
red blood cells on peripheral  blood smear. A bone marrow biopsy  
showed  mild  hypercellularitv.  increased  megakaryocytes  and  a  
moderate  increase  in  reticulin.  while  aspiration  demonstrated  
myelodysplastic  changes  in  the  ervthroid  and  myeloid  precur-
sors  and  atypical  megakaryocytes.  Eight  months  later  the  
patient  was  diagnosed  as  having  myelofibrosis,  based  on  
repeated  trephine  bone  biopsy which  showed  severe  bypocclhi-
larity. a marked increase in reticulin and  foci of osteosclerosis. He 
became  progressively  more pancytopenia  suffering from recur-
rent  infections  and  requiring  frequent  blood  transfusions:  
splenectomy  was performed 2 months  later.  
In July  199 3 the patient  was admitted  because  of high fever  
and  chills.  On examination  he appeared  toxic and  febrile. The 
Figure  1.  A  large  ulcer  at  the  lower  right  shin,  surrounded  by  the  
residue  of haemorrhagic  bullae,  is covered  by  necrotic  debris.  
only  abnormal  physical  findings  were  two  painful,  red-purple  
indurations  on  the  skin  of both  foreams. with  no  evidence  of  
abscess  formation.  These  lesions  had  appeared  at  venepunc-
ture  sites  from  previous  hospitalization  14 days  earlier.  The  
patient  was treated  with aminoglycoside and vancomycin,  due  
to  clinical  suspicion  of an  infectious  process.  All  blood,  urine  
and  pus cultures  from skin  lesions  were  sterile.  
No  improvement  was  observed.  Haemorrhagic  bullae  
appeared  on  the  indurations,  followed  by  enlarging  ulcera-
tions  with  a  necrotic  base  and  violaceous  inflammatory  
borders,  and  a  discharge  of purulent,  haemorrhagic  exudate.  
A skin  biopsy  revealed  ¡111  uninvolved  epidermis  and  a diffuse, 
dense  inflammatory  cell  infiltrate  composed  mostly  of  neu-
trophils  throughout  the  dermis.  In  addition,  the  small  blood  
vessels  demonstrated  fibrin  deposits  in  their  walls  and  
extravasation  of  erythrocytes.  Gram  and  periodic  acid-Schiff  
stains  failed to demonstrate  bacteria  and  fungi,  respectively.  
A diagnosis  of  PG  was  made,  and  oral  prednisone.  80 nig 
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The  use  of  skin  substrates  deficient  
in  basement  membrane  molecules  
for the diagnosis  of  subepidermal  autoimmune  
bullous  disease  
A  case  is  presented  of  subepidermal,  autoimmune  bullous  disease  in  which  
the  initial  examinations  suggested  the  combination  of  epidermolysis  bullosa  
acquisita  and  bullous  pemphigoid.  The  diagnosis  of  epidermolysis  bullosa  
acquis i ta  w a s  m a d e  by  indirect  i m m u n o f l u o r e s c e n c e  microscopy:  the  
patient's  serum  bound  to  normal  skin  substrate  but  not  to  type  VII  collagen-
deficient  skin  substrate  derived  from  a  patient  with  mutilating  dystrophic  
epidermolys is  bullosa.  The  use  of  skin  substrates  deficient  in  basement  
membrane  molecules  also  excluded  the  presence  of  concomitant,  circulating  
bullous  pemphigoid  autoantibodies  in  our  patient.  The  diagnosis  of  epider-
molys i s  bullosa  acquisita  was  conf irmed  by  split  mapping,  f luorescence  
overlay  antigen  mapping  and  Western  blot.  (Key  words:  autoimmune  bullous  
disease,  basement  membrane,  bullous  pemphigoid,  epidermolysis  bullosa  
acquisita.  type  VII  collagen,  bullous  disorders,  immunofluorescence  micro-
scopy.) 
[n  some  cases  it  is  impossible  to  differentiate  between  epidermolysis  bullosa  acquisita  (EBA)  and  bullous  pemphigoid  (BP)  by  mere  clinical  presentation.  In  such  
uses  laboratory  investigations,  such  as  immunofluores-
ence  microscopy  and  Western  blot,  could  be  helpful  to  
ifferentiate  between  these  two  diseases.  But  what  if  repe-
tive  tests  suggest  an  unexpected  diagnosis  contradicting  
ne clinical  presentation?  
I!ase  repor t  
k 40-year  old  Hungarian  male  presented  with  complaints  
if  blisters,  oozing  erosions  and  excoriation  on  the  scalp,  
rank,  hands  and  feet  which  had  lasted  for  more  than  a  
'ear  11  J.  These  lesions  had  developed  spontaneously  or  
lad  evolved  following  minor  trauma.  The  family  history  
vas  negative  for  blistering  disorders.  
5n  physical  examination,  3-5  mm.  tense  blisters  with  
:rusts  and  milia  were  present  on  the  distal  portion  of  the  
imbs,  feet  and  toes.  On  the  hands  and  feet,  crusted  lesions  
tnd  milia  were  found.  The  tongue  mucosa  was  also  affec-
ed.  The  toe  nails  were  dystrophic.  
Die  initial  laboratory  tests  were  performed  in  Hungary.  
Direct  immunofluorescence  revealed  linear  depositions  of  
!gG  and  C3  along  the  epidermal  basement  membrane  zone  
EBMZ).  Direct  IF on  the  salt-split  skin  of  the  patient  sho-
wed  a  "combined"  staining  for  IgG  on  both  sides  of  the  
split  as  can  be  found  in  a  minority  (5%-IOVr)  of  patients  
with  BP [2.  3|.  The  serum  of  the  patient  was  shown  to  he  
positive  by  the  ELISA  lechnique  using  a  subslraie  of  syn-
thetic  oligopeptide  of  the  230  kDa  bullous  pemphigoid  
antigen  (BPAGi)  as  described  elsewhere  [4],  The  BPAG1  
oligopeptide  used  comprised  21  amino  acids  located  at  
position  1914-1934  according  to  the  peptide  sequence  of  
Sawamura  ei  al.  (Genbank  accession  number  M69225)  [5].  
Diagnostic  challenge  
So  the  question  arose  as  to  whether  this  patient  had  EBA  
as  suggested  by  the  clinical  presentation  [6|,  or  BP  mimic-
king  EBA  as  was  suggested  from  direct  IF  with  salt-split  
skin  and  ELISA  with  BP230  oligopeptide,  or  was  this  a  
combination  of  both.  Clinically.  BP  may  mimic  EBA  |7]  
and  vice  versa,  EBA  may  mimic  BP  [8].  Although  the  
simultaneous  presence  of  BP  and  EBA  in  one  person  
would  be  extremely  unusual,  the  coexistence  of  two  
autoimmune  subepidermal  blistering  disorders  has  been  
known  to  occur [9|.  Direct  or  indirect  IF  using  salt-split  
skin  cannot  exclude  this  possibility.  Western  blot  with  the  
patient's  serum  may  fail  to  detect  conformational  epitopes  
as  a  result  of  the  denaturing  conditions  [10],  
To  solve  the  problem,  we  used  frozen  skin  samples  lac-
king  the  EBA  antigen/type  VII  collagen  from  a  person  
with  severe,  mutilating  dystrophic  epidermolysis  bullosa,  
type  Hallopeau-Siemens.  as  the  substrate  for  indirect  IF  to  
test  for  the  presence  of  circulating  antibodies  against  non-
EBA  antigens  in  the  patient.  This  skin  substrate  is  defi-
cient  in  the  protein  because  of  a  genetic  mutation,  while  
the  other  proteins  of  the  EBMZ  are  naturally  present.  
Monoclonal  antibody  clone  II.  32  iGibco  BRL.  Gaithcrs-
burg,  MD)  and  LH7:2  against  respectively,  the  helical  and  
globular  aminoterminal  domains  [11]  did  not  bind  to  the  
type  VII  collagen-deficient  skin  substrate.  All  other  anti-
gens  of  the  EBMZ  were  normally  present,  including  120,  
180  and  230 kDa  BP-antigens,  as  investigated  with  mono-
clonal  antibodies.  
The  indirect  IF  was  performed  with  serum  from  the  patient  
and  with  positive  and  negative  control  sera  from  patients  
with  proven  EBA  or  BP  (BP180  and  BP230  positive)  or  
from  normal  human  controls.  In  addition,  we  performed  
fluorescence  overlay  antigen  mapping  (FOAM)  on  the  
patient's  skin  [12],  
Indirect  IF  on  skin  lacking  the  EBA  antigen  showed  no  bin-
ding  of  the  patient's  serum  IgG  or  IgA  {Fig.  1A).  Reference  
sera  from EBA  patients  did  not  bind  to  the  type  VII  collagen-
deficient  substrate.  BP  control  sera  bound  in  a  normal  linear  
pattern  along  the  EBMZ  (Fig.  IB).  As  was  expected,  normal  
human  sera  showed  no  binding.  FOAM  of  the  patient's  skin  
showed  overlap  of  type VII  collagen  as  detected  by  monoclo-
nal  LH7:2  and  IgG  depositions  along  the  EBMZ  (Fig.  2A).  
The  patient  thus  had  only  EBA  and  not  BP.  
Direct  IF  of  lesional  skin  showed  duplication  of  the  epi-
dermal  basement  membrane.  Antigen  mapping  of  a  blister  
revealed  a  spontaneous  split  below  the  lamina  densa:  stain-
ing  with  monoclonal  antibody  GB3  against  laminin  5  was  
seen  exclusively  in  the  blister  roof,  consistent  with  the  dia-
gnosis  of  EBA  (Fig.  2B).  Indirect  IF  on  normal  salt-split  
skin  now  showed  exclusive  binding  of  IgG  and  IgA  to  the  
dermal  site.  The  blister  level  in  salt-split  skin  was  always  
consistently  through  the  lamina  lucida  as  checked  by  elec-
tron  microscopy  and  antigen  mapping.  Western  blot  with  
the  patient's  serum  using  a  dermal  extract  showed  a  band  
of  290 kD,  corresponding  to  the  EBA-antigen  [13].  Wes-
tern  blot  using  cultured  keratinocyte  and  epidermal  extra-
cts  was  always  negative.  We  concluded  that  this  patient  
was  suffering from  EBA  and  not  BP.  Treatment  with  pred-
nisolone  100  mg  daily  and  azathioprine  150 mg  daily  gave  
a  good  clinical  response.  The  patient's  history,  the  pre-
sence  of  circulating  autoantibodies  and  the  response  to  
treatment  suggest  that  he  had  an  inflammatory  form  of  
EBA. 
C o m m e n t 
In  this  case,  it  was  possible  using  type VII  collagen-defi-
cient  skin  from  a  patient  with  mutilating  dystrophic  EB  to  
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Figure  1.  Indirect  immunofluorescence  microscopy  for  IgG  
binding  is  negative  using  the  patient's  serum  on  type  VII  col-
lagen-deficient  skin  substrate  from  a patient  with  severe,  dys-
trophic  epidermolysis  bullosa  (A),  whereas  it  is positive  when  
a  bullous  pemphigoid  serum  is  used  (B).  Bar  is  10 p.m. 
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Figure  2.  (A)  Antigen  mapping  of  lesional  skin  from  the  
patient  reveals  binding  of  monoclonal  antibody  GB3  to  lami-
nin  5  (red)  in  the  roof  of  the  blister  and  mouse  anti-human  
IgG  to  the  in  vivo  bound  patient's  IgG  in  the  floor  (green)  
and  to  some  extent  in  the  roof  (green-yellow)  of  the  blister.  
Note  that  red  laminin  5  is partly  located  above  the  IgG.  Thus,  
split  level  and  IgG  deposition  is  located  below  laminin  5,  
below  the  lamina  lucida/densa,  which  is  compatible  with  the  
diagnosis  of  EBA.  (B)  Fluorescence  overlay  antigen  mapping  
(FOAM)  of  the  patient's  skin  using  mouse-IgM  anti-ANA  tag-
ged  in  red  and  green  fluorescence  to  stain  the  nuclei  as  a  
geometric  reference  marker  (yellow  overlap).  The  topogra-
phic  reference  markers,  mouse  anti-human  IgG  to  the  
patient's  in  vivo  bound  IgG  in  green  and  polyclonal  rabbit  
antibody  to  human  type  VII collagen  in  red  show  yellow  over-
lap  in  the  vertical  plane  (no  red  type  VII  collagen  staining  
beneath  the  IgG),  fitting  the  diagnosis  of  EBA.  Note  that  the  
epidermal  basement  membrane  of  the  patient  is  duplicated  in  
both  figures.  Bar  is  10  pm.  
exclude  BP  in  a  case  of  clinical  EBA,  but  with  initial  labo-
ratory  tests  which  suggested  the  exclusive  or  concomitant  
presence  of  BP.  
The  combined  linear  staining  pattern  of  IgG  and  C3  ini-
tially  found  by  direct  IF  on  salt-split  skin  of  the  patient  
was  apparently  due  to  the  duplicate  epidermal  basement  
membrane.  The  positive  ELISA  on  BP230  substrate  was  
obviously  false  or  a  result  of  some  immunological  cross-
reaction. 
Another  method  which  could  have  been  used  to  arrive  at  
the  correct  diagnosis  in  this  patient,  would  have  been  the  
use  of  the  more  expensive  and  time-consuming  technique  
of  direct  immunoelectron  microscopy.  The  advantage  of  an  
EBMZ  molecule-deficient  skin  in  indirect  IF  for  the  detec-
tion  of  antigen-specific  autoantibodies  over  Western  blot  
or  ELISA,  is  that  in  the  former  all  other  antigens  of  the  
EBMZ  are  naturally  present  in  the  substrate.  Moreover,  the  
technique  is  more  simple  and  can  be  performed  in  any  
laboratory  with  equipment  for  immunofluorescence  micro-
scopy.  Obtaining  skin  substrates  that  are  deficient  in  an  
EBMZ  molecule  may  be  difficult  if  no  epidermolysis  bul-
losa  patients  are  available.  
The  concept  of  using  an  EBMZ  molecule-deficient  skin  
substrate  for  indirect  IF  can  also  be  applied  to differentiate 
between  other  autoimmune  subepidermal  bullous  disorders  
of  which  an  analogous  hereditary  EB  form  exists.  For  ins-
tance,  to  differentiate  between  anti-epiligrin  cicatricial  BP  
and  EBA  -  two  disorders  with  a  dermal  staining  pattern  on  
indirect  IF  of  salt-split  skin  -  laminin  5-deficient  skin  sub-
strate  from  patients  with  Herlitz  junctional  EB  (H-JEB)  
would  be  the  substrate  of  choice.  However,  skin  of  H-JEB  
patients  that  lack  laminin  5  has  reduced  binding  to  mono-
clonal  antibody  BM165  directed  to  the  a 3  chain,  even  if  
i 84 EJD n° 2, vol. 8.  March 1998 
:  H-JEB  is  caused  by  LAMA3  iruncuiion  muiaiions  114|.  
le  reduced  a3  staining  in  H-JEB  skin  can  be  explained  
the  presence  of  a3  in  laminin  6  and  laminin  7.  laminin  
)fnrms  that  are  present  in  the  EBMZ  115|.  Since  autoan-
todies  in  anti-epiligrin  cicatricial  BP  bind  to  the  oc3  
ain  in  laminin  isoforms  [16].  one  may  expect  reduced  
lining  with  anti-epiligrin  cicatricial  BP  serum  on  H-JEB  
in.  whereas  the  staining  intensity  is  not  reduced  when  
pe  Vll  collagen-deficient  skin  from  a  patient  with  mud-
ling  dystrophic  EB  is  used.  •  
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Summary  A  7-year-old  girl  with  generalized  erythematous,  scaling  plaques  and vesiculobullous  lesions on  the  
extremities  was  diagnosed  as  having  pemphigus  foliaceus.  Lesional  direct  immunofluorescence  
revealed intercellular  IgG, IgA and C3 deposition. The patient's serum gave positive reactions  against  
one  epitope  of  desmoglein  3  and  the  epitope  of  desmoglein  1  in  enzyme-linked  immunosorbent  
assays,  but  the  blood  sample  for  indirect  immunofluorescence  did  not  display  any  circulating  
antibodies.  The  patient  was  successfully  treated  systemically  with  prednisolone  and  dapsone.  
Currently,  she  is  taking  dapsone,  12-5 mg  daily.  She  has  been  free  of  lesions  for the  last  3  years.  
Pemphigus,  a  life-threatening  autoimmune  blistering  
disorder  that  involves  the skin  and mucous  membranes,  
can  be  divided  into  two  major  subgroups:  pemphigus  
vulgaris  (PV)  and  pemphigus  foliaceus  (PF).1-2  PF.  a  
superficial  variant  of  pemphigus,  is  extremely  rare  in  
children  and  mostly  occurs  in  the  middle-aged  and  
elderly.5-4  The  clinical  findings  in  childhood  PF  involve  
gradually  spreading  eczematized  scaly  plaques  starting  
on  the  face  and  upper  extremities,  with  the  possible  
development  of  bullae  and  superficial  crusts.3  Early  
diagnosis  and  prompt  treatment  are  based  on  the  
clinical,  histological  and  immunopathoiogical  changes.  
Case  report  
A  7-year-old  girl  presented  with  a  3-month  history  of  
generalized,  painful,  small  blisters  and  superinfected  
erosions  covered  with  thick,  yellowish  crusts.  For  
months,  there  had  been  a  history  of  red.  squamous  
plaques  on  the  scalp,  which  were  treated  as  psoriasis  
with  local  corticosteroids:  the  lesions  healed  slowly.  The  
patient  was  weak  and  in  a  poor  condition.  Physical  
examination  revealed  extensive,  generalized  erythema,  
with  superficial  erosions  covered  with  thick  yellow  
crusts,  mainly  on  the  face  (Fig.  la) ,  trunk  (Fig.  2)  and  
extremities.  Scattered  intact  superficial  blisters  were  
present  on  the  extremities,  with  a  positive  Nikolsky's  
sign. The oral mucosa was spared.  Bilateral  cervical  and  
axillary  lymphadenopathy  was  also  noted.  
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Laboratory  investigations  revealed  the  following  
abnormalities:  leucocytosis  with  a  white  blood  cell  
count  of 20-7  (10 9 /L  (normal  4 - 6 - 1 0 - 2 ) .  an  aspartate  
aminotransferase  level  of  74U/L  (normal  < 4 0 U / L )  and  
an  alanine  aminotransferase  level  of  8 3 U/L  (normal  
<40U/L) .  Skin  and  pharyngeal  swabs  for  bacterial  
cultures  were  positive  for  Staphylococcus  aureus  and  
Streptococcus  pyogenes.  
A  perilesional  biopsy  for  histology  demonstrated  a  
subcorneal  blister  with  acantholytic  cells  without  any  
inflammatory  cells  in  the  cleft  (Fig.  3).  Direct  immuno-
fluorescence  studies  of  frozen  skin  tissue  showed  posi-
tive intercellular staining  for IgG. IgA and C3 within  the  
epidermis. The circulating  antidesmoglein  1  (anti-Dsgl)  
and  anti-Dsg3  antibodies  were  examined  by  means  of  
enzyme-linked  immunosorbent  assays  (ELISAs).  using  
synthetic,  antigenic  peptides.  Antigenic  epitopes  for  
desmogleins  1 and  3 were chosen using  PeptideStructure  
software.  The  antigenic  epitope  for  desmoglein  1  con-
sists of 14 amino  acids.  It is part  of the extracellular  (EII)  
domain  located  between  two  Ca 2 +  binding  sequences.  
The  antigenic  epitope  for  Dsg3  consists  of  13  amino  
acids.  It is located in the extracellular  (EI) domain and  is  
part  of  the  Bosl  sequence.6  
Antigenic  peptides  were  dissolved  in  phosphate-buf-
fered saline  (PBS),  pH 7-4,  in 0 -1 p.g/100  p.L concentra-
tion.  Microplate  wells  were  filled  with  100  p.L  and  
allowed  to  coat  overnight  at  4°C.  Plates  were  washed  
twice  with  distilled  water,  and  the  remaining  binding  
sites were blocked with  1% bovine serum albumin  (BSA)  
in  PBS  for  1-5 h  at  37°C.  Plates  were  washed  again  
three  times  with  PBS-Tween  (PBS  containing  0-5%  
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Figure  1.  (a)  Seborrhoeic-Iike.  erythematous,  scaling  lesions  are  seen  
on  the  face,  (b)  Complete  recovery  with  mild  hyperpigmentation  on  
the  cheek.  
Figure  2.  Diffuse, exfoliative,  crusted,  eroded  plaques  are  evident  on  
the  trunk.  
Tween-20).  and  100  |xL of the  2 0 0  times  diluted  serum  
samples  was  added  per  well,  incubated  for  1 h  at  37°C  
and  washed  extensively  with  PBS-Tween.  Aliquots  of  
100  p.L of peroxidase-conjugated ant ihuman  IgG,  diluted 
1 : 5000  in  PBS-Tween.  were  then  added  to  each  well  
and  incubated  for  1 h  at  3 7 °C. Subsequently,  the  plates  
were washed  again with PBS-Tween  and  then  100  p,L of 
substrate  solution  [17 mg  of  ortho-phenylene  diamine  
(OPD)  dissolved  in  50 mL  of  phosphate-citric  acid  
buffer.  pH 5.  and  20  |i.L  of  H 2 0 2 ]  was  added  to  each  
well  and  the  colour  allowed  to  develop  for  lOmin  at  
room temperature  in the dark. The reaction  was  stopped  
by adding  50  p.L of 4  N H 2 S0 4  to each  well.  Plates  were  
read  on  an  ELISA reader  at  4 9 2  nm.  
In  ELISA investigations,  serum samples were tested  in  
triplicate, and  the mean  results  were taken.  Ten  healthy  
control  sera  were  used  in  each  microplate.  Autoanti-
body  positivity  was  accepted when  special  ELISA optical  
density  was  higher  than  the  mean  value  of  controls  
increased  by  two  standard  deviations.  The  patient's  
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serum  gave  positive  reactions  against  one  epitope  of  
Dsg3 and the epitope of Dsgl.  Blood samples  for indirect 
immunofluorescence  studies  demonstrated  no  circulat-
ing  antibodies.  The  patient's  circulating  anti-epidermal  
antibodies  were  also  examined  by  the  Western  blot  
technique  to  detect  Dsgl  or  Dsg3,  but  there  was  no  
positive  reaction.  
A  diagnosis  of  PF  was  made  and  treatment  was  
commenced  with  50mg/day  prednisolone.  This  treat-
ment resulted in only a slow remission,  and we therefore 
combined  the  corticosteroid  with  12-5 mg  of  dapsone  
twice  a  day.  In  a few days,  there  was  a satisfactory  fast  
resolution  of  the  blistering  and  a  rapid  improvement  in  
the  condition  occurred.  The  dose  of  prednisolone  was  
subsequently  tapered slowly to half the initial  dose.  One  
month  was  sufficient for almost  complete  recovery  (Fig.  
lb),  and  blood  investigations  returned  to  normal.  The  
patient  was  discharged  while  receiving  2 5 mg  of  pred-
nisolone  every  second  day.  and  12-5 mg  of  dapsone  
twice  daily.  This  treatment  has  been  tapered  so  that  
she  is now  receiving  12-5 mg  of dapsone  a  day.  She  has  
had  no  further  lesions  over  the  last  3  years.  
Discussion 
PF, a less  severe variant  of pemphigus,  is  a  rare  disease,  
especially  in  the  first  14  years:  it  affects  both  sexes  
equally' '"10  Despite  its  rarity,  however,  it  is  more  fre-
quent  in  Brazil11  and  India.1"  Adult  PF  has  been  
reported  to  be  associated  with  other  autoimmune  dis-
orders13'14  and drugs.1'  but  Graves' disease  is  the  only  
condition  reported  to coexist  with  childhood  PF.y  
Figure  3. Acantholysis  is present  in  the  granular  
layer,  with  basophilic  acantholytic  cells  inside  
the  cleft (haematoxylin  and  eosin.  original  
magnification,  x  100).  
The  clinical  manifestations  of  adult  and  juvenile  PF  
are  similar.  The  onset  is  often  slow,  with  crusting,  
yellowish,  scaling  lesions  starting  on  the  face  and  
scalp,  as  in  our  case,8  which  can  mimic  impetigo  and  
seborrhoeic  dermatitis;  unlike  PV,  the  oral  mucosa  is  
rarely  involved.'  '  Histologically,  PF is  characterized  by  
acantholysis  high  in  the  epidermis,  either  subcorneally  
or  in  the  stratum  granulosum.16  These  superficial  
changes  are  similar  in  PF  and  pemphigus  erythe-
matosus  (PE)  but,  clinically.  PE  may  simulate  lupus  
erythematosus.1'18  Our case  demonstrated  the  typical  
histology  of  PF,  with  acantholysis  in  the  upper  epider-
mis.  PF  in  general  gives  identical  immunofluorescence  
(IF) changes to  PV. Staining of the  PF lesions  for direct IF 
shows the intercellular deposition  of IgG,  C3 and.  rarely.  
IgA,19  as  detected  in  our  case.  Serum  from  PF patients  
for  indirect  IF studies  shows  IgG  staining  of  the  kera-
tinocyte  cell  surface  in  the  upper  epidermis.2  
The pathogenesis  of blister formation in pemphigus  is  
related  to  the  detection  of  autoantibody  formation  
against  PF antigen Dsgl  (160kDa)  and  the  PV  antigen  
Dsg3  (130kDa).20  Immunoblot  analysis  in  PF  patients  
revealed  circulating  autoantibodies  against  Dsgl  anti-
gen;  despite  its  potential  positivity,  the  reaction  was  
negative  in two-thirds  of the patients.21  These  antigenic  
determinations including Dsgl  and Dsg3  are  important  
in  differentiation  from  other  autoimmune  blistering  
diseases  such  as  PV2  or  PE,  which  are  not  usually  
determined  in  PE.18  Therefore,  detection  of  the  charac-
teristical  anti-epidermal  and  anti-Dsg  antibodies  can  
support  the  diagnosis.  In our  case,  investigation  of  the  
serum  circulating  antibodies  using  the  Western  blot  
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JUVENILE  PEMPHIGUS  FOLIACEUS  4 9 9  
technique  did  not  detect  any  positive  reaction  but,  
based  on  more  recent  studies  with  ELISA,22'23  we  also  
routinely  examined  the  circulating  anti-Dsgl  and  anti-
Dsg3  antibodies  by  means  of  ELISA  using  synthetic,  
antigenic  peptides.24  The  patient's  serum  gave  positive  
reactions  against one  epitope  of Dsg3  and the  epitope  of  
Dsg l .  We  used  these  antigenic  epitopes  in  more  than  
3 0  cases,  and  68%  of  the  sera  from  patients  with  
pemphigus  gave  a  specific  reaction  with  these  epitopes  
using  the  ELISA  technique.  
PF, the less severe  form of pemphigus,  may  be  treated  
simply with topical steroids or low-dose  corticosteroids;'  
the  more  generalized  form  of  PF  has  been  treated  with  
high-dose  corticosteroids.9,23  However,  Basset  et  al.26  
reported  satisfactory  results  with  dapsone  as  initial  
therapy.  We  also  achieved  fast  remission  when  we  
added  dapsone  to  low-dose  corticosteroids.  We  believe  
that  PF  is  rare  in  childhood  and  has  a  good  prognosis.  
As  Basset  e£  al.26  reported,  we  also  achieved  a  good  
result  with  dapsone  therapy.  In  our  case,  the  lesions  
disappeared  in  response  to  a  combination  of  dapsone  
and  low-dose  corticosteroids.  
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Antineutrophil  Cytoplasmic  Antibodies  and  
Other  Immunologic  Abnormalities  in  Patients  
with  Habitual  Abortion  
LÁSZLÓ  KOVÁCS.  JÁNOS  SZADÓ.  KATALIN  M O L N Á R .  ATTILA  KOVÁCS,  AND  G Y U L A  POK.OR.NY  
Kocács  L.  S:abà  J.  Molnár  K.  Kovács  A.  Pokornv  G.,  Antineutrophil  cytoplasmic  
antibodies  and other  immunologie abnormalities  in patients  with  habituai abortion.  AJRI  
1999: 41264-270  C  Munksgaard.  Copenhagen  
PROBLEM: The immunologic mechanisms of  pregnancy loss  in habitual aborters with 
antiphospholipid  and antinuclear antibodies  have  not  been  fully clarified. The  possible  
association  of  antineutrophil  cytoplasmic  antibodies  (ANCAs)  with  recurrent  miscar-
riage was  examined.  
METHOD OF STUDY:  In a  prospective,  controlled  trial of  59  women with  recurrent  
abortion,  the  prevalence  of  pAKCA  (antimyeloperoxidase).  cANCA  (antiproteinase-
3). and immunoserologic abnormalities of systemic lupus erythematosus  (SLE)—anti-
double-stranded  DNA.  anti-SSA. anti-SSB. anti-UlRNP.  anti-Sm,  anticardiolipin  and  
antinuclear antibodies.  LE-cell.  lupus anticoagulant,  and complement-3—were  investi-
gated. 
RESULTS:  pANCA  occurred  in 2.  and cANCA  in  6  of  59 case  patients,  but  neither  
was observed  in  the controls (P = 0.09  for cANCA).  cANCA  levels  were significantly 
higher in patients than in controls [P  =  0.028).  Six  recurrent aborters were identified as 
having  a  group of  immunoserologic  abnormalities  characteristic  of  SLE.  
CONCLUSIONS:  Immunologic  mechanisms  detectable  in  SLE  may  operate  in  a  
subgroup of habitual  aborters with  suspected  immunologic cause. ANCAs occur  more  
frequently  in  patients  with  recurrent  miscarriage  than  in  controls.  
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antibodies,  habitual  abortion,  
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I N T R O D U C T I O N 
Antiphospholipid  antibodies  have  been  reported  to  be  associated  with  idio-
pathic  habitual  abortion.1"7  and  recent  investigations  have  also  demonstrated  
their  value  for  the  prediction  of  an  adverse  outcome  in  subsequent  preg-
Submitted  June  29.  1998:  
accepted  August  24.  I99S.  
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nancy.""1  A  relationship  has  also  been  revealed  be-
iween  the  presence  of  antinuclear  antibodies  and  re-
eurrent  miscarriage,  although  data  are  far  less  
consistent."  1,1  Thyroid  and  antimitochondrial  anti-
bodies  have  also  been  investigated  in  connection  
with  recurrent  miscarriage.11  The  pathomechunism  
by  which  these  antibodies  may  cause  fetal  death  is  
by  no  means  clear.  It  is  betieved  by  some  that  the  
autoantibodies  may  be  only  an  epiphenomenon  
reflecting  a  separate  underlying  immunologic  mecha-
nism.11 
In  systemic  lupus  erythematosus  (SLE).  an  in-
creased  rate  of  spontaneous  abortions  may  be  ob-
served  even  before  the  onset  of  the  classical  
symptoms  of  the  disease.13  Therefore,  we  have  
started  a  study  of  women  with  idiopathic  recurrent  
spontaneous  abortion  with  the  aim  of  investigating  a  
wide  spectrum  of  immunoserologic  markers  occur-
ring  in  patients  with  SLE,  and  intend  to  follow  up  
these  patients  for  a  long  period.  We  wish  to  answer  
the  question  of  whether  the  underlying  immunologic  
disorder  may  be  regarded  as  a  preclinical  SLE  or  a  
related,  nonclassitied  systemic  autoimmune  disease.  
Systemic  vasculitides  constitute  another  group  of  
systemic  autoimmune  diseases.  Antineutrophil  cyto-
plasmic  antibodies  (ANCAs)  are  useful  tools  in  the  
diagnosis  of  certain  types  of  systemic  vasculitides.  
especially  Wegener's  granulomatosis,  microscopic  
polyangiitis.  and  Churg-Strauss  syndrome,  and  they  
occur  in  other  autoimmune  diseases  too,  such  as  
SLE.14-15  As  far  as  we  are  aware,  they  have  not  
been  investigated  previously  in  the  context  of  habit-
ual  abortion.  We  therefore  examined  their  preva-
lence among our  study  patients.  
MATERIALS  AND  METHODS  
The  study  involved  59  women  with  a  history  of  at  
least  two  consecutive  spontaneous  abortions  in  preg-
nancies  from the  same partner. Their  average age  was  
30.47  years  (range  19-47  years).  Genetic,  endocrine,  
anatomical,  infectious, and  internal  medical  causes  of  
habitual  abortion  were excluded.  None of  the  patients  
had  a  clinically  obvious  systemic autoimmune  disease  
or a chronic  medical  illness.  Eighteen of the 59 women 
had  a  prior  pregnane}' ending  in  a  live delivery.  Seven  
patients  had  pregnancies  with  two  partners.  Two  of  
them  had  at  least  two  consecutive  fetal  losses  with  
both  partners.  One  patient  had  two  miscarriages  with  
the first partner and one further spontaneous  abortion  
with  the  second.  The  remaining  four  women  all  had  
their  miscarriages  with  the  second  partner,  and  nor-
mal  pregnancies  with  the  first. The  patients  were  not  
receiving  any  regular  medication  at  the  time  of  the  
examinations. 
The  control  group  comprised  25  healthy  women  
with  no  history  of  fetal loss.  All  of  them  had  at  least  
two successful pregnancies  before the blood  sampling.  
Their  average  age  was  30.08  years  (range  21-37  
years). 
A  comparison  of  the  obstetric  data  on  the  women  
in the two groups is presented  in Table I.  Spontaneous,  
abortion  was  defined  as  pregnancy  loss  before  the  
twenty-eighth  completed  week  of  gestation.  Two  in-
trauterine  deaths  occurred  in  two  patients  in  the  
thirty-fifth  or  thirty-eighth  week  of  gestation.  The  
term  fetal loss  is therefore used  to cover both  sponta-
neous  abortions  and  late  intrauterine  deaths.  Three  
infants  died  after  live  births  in  the  twenty-fifth,  
twenty-sixth  or  twenty-seventh  week of gestation,  and  
TABLE I.  Age  and  Obstetric  History of  Habitual  Abortion  Patients  and  Normal  Controls"  
Habitual  abortion  
(n  =s 59) 
Control  (n =  25)  
Age  (years,  mean =  SO,  range)  
No.  of  previous  pregnancies  (mean ±  SD.  range)*  
No.  of  previous  live  deliveries  (mean ± SD,  range)  
No.  of  previous  fetal  losses  (overall)  (mean = SD,  range)  
No.  cf  previous  seccnc-trimester  spontaneous  abortions  (mean  -  SD,  
range) 
No.  cf  previous  induced  abortions  (mean  ±  SD.  range)  
30.47 ±  5.68,  19-47  30.08  ¿5 .33 ,  
21-37 
3.51 ±1.56,  2-9  
0.41 ±0.62,  0 -2  
2.76 =  1.21,  2-8  
0 .63=0.71,  0 -4  
0.31 =0.59,  0 -2  
2.44  ±0 .71 ,  
2-5 
2.16  ±0 .37 ,  
2-5 
0 
0 
v(L20<= 0'.41, 
0-1 
"Age.  number  of  precious  pregnancies,  otui  number  of  precious  induced  abortions  were  compared  statistically.  
SD.  standard  deviation.  
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one  inlhnt  born  at  term  died  I  day  after  delivery.  
Induced  abortions  were  performed  before  the  twelfth  
week  of  gestation  for reasons  other  than  medical  ones.  
Blood  was  taken  in  the  nonpregnant  state  from  per-
sons  in  both  groups.  
Laboratory  techniques  included  indirect  immu-
nofluorescence  lor  the  detection  of  antinuclear  anti-
bodies:  rotatory  method  utilizing  heparin  and  glass  
beads  for  lupus  erythematosus  (LE)  cell  investigation:  
rocket  immunoelectrophoresis  lor  the  measurement  of  
complcmcnt-3  levels: complement  consumption  test  to  
assess  circulating  immunocomplexes  (CICs):  determi-
nation of  activated  partial  thromboplastin  time  for the 
detection  of  lupus  anticoagulant  (LAC):  and  enzyme-
linked  immunosorbent  assays  (ELISAs)  to detect  anti-
cardiolipin  (aCL)  immunoglobulin  G  (IgG)  (Shield  
Diagnostics.  Dundee.  UK),  anti-double-stranded  
D N A  (anti-dsDNA).  anti-SSA.  anti-SSB.  anti-Sm.  
and  ant i -U lRNP  (Epignost.  Leonding  Linz.  Austria)  
autoantibodies.  Evaluation  of c A N C A  was  performed  
with  an  ELISA  using  proteinase-3  (PR-3)  as  antigen,  
while  the  presence  of  p A N C A  was  assessed  with  an  
anti-myeloperoxidase  (anti-MPO)  ELISA  (Shield  Di-
agnostics.  Dundee.  UK).  Precoated  ELISA  kits  were  
used  in  accordance  with  the  manufacturers  instruc-
tions.  Cases  were  considered  to  involve  LE-cell  posi-
tivity  when  typical  LE  cells  or  the  characteristic  
round,  homogenous  hematoxylin  bodies  were  ob-
served.  This  examination  was  not  performed  in  four  
of  the  study  patients.  Similarly.  LAC  was  not  exam-
ined  in  seven  of  the  study  patients.  
The Student's  /-test  was  used  in comparisons of  age  
and  of  the  numbers  o f  previous  pregnancies,  deliver-
ies.  and  induced  abortions  between  the  study  and  
control  groups.  The  test  or  Fisher's  exact  test  were  
applied  in  comparisons  o f  the  frequencies  of  various  
immunologic  variables  between  the  two  groups.  For  
the comparison  of  the c A N C A  levels,  the  Mann-Whit-
ney  L'-test  was  applied.  
RESULTS 
The  most  common  serologic  markers  used  in  the  
diagnosis  and  follow-up  of  SLE  were  examined  in  
both  groups.  The  frequencies  of  anti-dsDNA.  anti-
SSA.  anti-SSB.  anti-Sm.  anti-L'IRNP.  anti-cardiolipin  
igG  autoantibodies:  the  lupus  anticoagulant:  LE  cell:  
antinuclear  antibodies:  and  decreased  complement-3  
levels  in  women  suffering  habitual  abortion  and  in  
healthy  control  women  are  presented  in  Table  II.  For  
aCL.  the  prevalences  of  markedly  elevated  levels  
(more  than  2.5  times  higher  than  the  upper  limit  of  
the  normal  range)  are  also  presented.  Although  aCL  
and  LAC  occurred  more  frequently  in  habitual  
TABLE II.  Frequencies  of  Immunologic  Changes in  
Habitual  Abortion  Patients  and  in  Normal  Controls"  
Habitual Control  (%)  
abortion  (%)  
Antinuclear  antibodies  2  59  (3.39)  2  25  (8.0)  
Anti-dsDNA 2 59  (3.39)  2  25  (8.0)  
Anti-SSA 1 59  (1.69)  0 25 
Anti-SSB 1 59  (1.69)  0 25 
Anti-Sm 0  59  0 25 
Anti-U1RNP 0  59  ,0 25 
Anti-cardiolipin 17 59  (28.81)  4 25  (16.0)  
Anti-cardiolipin  moderate  5  59  (8.47)  0 25 
to high positive  
Lupus anticoagulant  6  52  (11.54)  1 22  (4.54)  
Lupus erythematosus 6.55  (10.91)  1 25  (4.0)  
cell 
Decreased 12 59  (20.34)  4 25  (16.0)  
complement-3 
pANCA 2 59  (3.39)  0 25 
cANCA* 6 59  (10.17)  0 25 
"  Xianbers  indicate  positieity  total  number  of  subjects examined,  with  
frequencies  in  brackets.  For  the  other  examined  cariables. no  signifi-
cant  difference  was found  between  the  two  groups.  
•P-0.09. 
aborters.  and  markedly  elevated  levels  of  aCL  were  
found  only  in  the  study  group  (in  five  patients),  no  
significant  differences  were  observed  in  the  preva-
lences of  the examined  serologic  variables between  the  
two  groups.  
pANCA  was found  in 2.59  examined  patients but  in  
none o f  the controls,  while c A N C A  was found  in  6. 59 
examined  patients  but  none of  the controls. This  latter  
difference  approaches,  but  does  not  quite  reach,  the  
level  of  statistical  significance  (P  =  0.09).  However,  
when  the  levels  o f  c A N C A  were  compared  in  the  two  
groups,  statistically  higher  values  were  revealed  in  the  
habitual  abortion  patients  than  in  the  healthy  persons  
iP  =  0.028).  The  titers  of  both  A N C A  types  were  in  
the  low  and  the  moderately  high  range (maximum  2.5  
times  higher  than  the  upper  limit of  the  normal  range)  
in  the  patient  group.  The  distribution  of  the  autoanti-
body  levels  in  the  study  group  is  to  be  seen  in  Fig.  I.  
A  comparison  o f  the  c A N C A  levels  in  the  habitual  
abortion  patients  and  the  controls  is  represented  in  
Tahie  Hi  and  Fig.  2.  A  similar  comparison  did  not  
re-en!  a  difference  in  the  pANCA  titers  (data  not  
showni.  The  serologic  characteristics  and  obstetric  
histories  of  the  eight  patients  with  either  pANCA  or  
cANCA  positivity  are  summarized  in  Table  IV.  The  
age  and  the  obstetric  history  data  do  not  differ signifi-
cantly  from  those  for  the  overall  group  of  habitual  
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a boners.  In  half  o f  these  e is lu  patients,  no  other  
immunoscrologic  abnormality  was  revealed,  while  the  
other  four  patients  were  positive  for  aCL.  Statistical  
analysis  did  not  confirm  that A N C A  positivity  is  more  
likely  in  patients  with  aCL.  
Among  the  59  patients  with  recurrent  abortion.  2S  
proved  positive  for  at  least  one  of  the  examined  
laboratory  variables.  The  majority  exhibited  only  one  
positive  value,  most  often  an  increased  aCL  antibody  
titer.  However,  six  patients  displayed  a  wide  spectrum  
o f  laboratory  abnormalities.  The  findings  on  these  six  
patients  are  presented  in Table  V.  N o n e  of  them  were  
positive  for either p A N C A  or c A N C A .  The  reproduce  
tive  performances  o f  these  6  women  were  as  follows:  
27  pregnancies  (4.5/person).  three  live  deliveries  (0.5/  
person).  21  spontaneous  abortions  (3.5/person),  and  
three  induced  abortions  (0.5/person).  N o  fetal  loss  
occurred  after  the  twenty-eighth  gestational  week.  
These  data  do  not  differ  significantly  from  those  for  
the  overall  group  o f  habitual  aborters.  It  should  be  
noted  that  patient  6  experienced  eight  consecutive  
spontaneous  abortions  after  a  normal  delivery,  six  
from  the  first  and  two  from  a  second  partner.  T w o  
other  women  had  recurrent  abortions  with  two  male  
partners: one o f  these women  had  a  decreased  comple-
m e n t s  level,  while  the other  had  no  immunoserologic  
abnormality. 
DISCUSSION 
It  is widely  accepted  that  antiphospholipid  antibodies  
(including  aCL  and  LAC),  and  possibly  antinuclear  
antibodies,  are  in  some  way  associated  with  recurrent  
abortion.  The  underlying  immunologic  mechanism  
has  been  the  subject  of  numerous  examinations  in-
volving  different approaches. 1 6""  In  the  present  study  
we  examined  a  number o f  immunologic  abnormalities  
on  which  the evaluation of  patients  with  SLE  is  based.  
Although  the  prevalence  o f  a C L  and  L A C  was  
higher  in  patients  with  recurrent  abortion  than  in  the  
controls,  and  high  titers o f  a C L  were  detected  only  in  
the  study  group,  no  difference  proved  significant.  
Antinuclear  antibodies  were  detected  in  small  num-
bers  of  patients  in  both  groups,  while  LE  cell  and  
decreased  complement-3  levels  were  not  infrequent  in  
patients  with  recurrent  miscarriage,  although  again  
without  statistical  significance.  In  31  of  the  patients,  
no  immunologic  positivity  was  found  at  all.  whereas  6  
otherwise  asymptomatic  habitual  aborters  could  be  
identified  in  whom  an  association  of  multiple  im-
munologic  abnormalities  was  revealed.  The  presence  
o f  this  spectrum  of  autoimmune  abnormalities,  de-
tectable  at  the  same  time,  is  very  uncommon  in  other-
wise  asymptomatic  persons.  This  laboratory  
constellation  warrants  further  investigations:  in  per-
sons  with  some  dinical  symptoms  it  would  be  highly  
suggestive  o f  S L E  
The  question  of  whether  recurrent  miscarriage  may  
be  the  first  clinical  sign  o f  S L E  has  been  addressed  
'previously.* and  it was concluded  that  the  answer  was  
negative.  However,  in  that  study,  fewer  immunologic  
markers  were  investigated,  and  the  follow-up  popula-
tion  (patients  with  antinuclear  antibody  positivity)  
was  somewhat  different  from  the  present  one.  On  the  
other  hand,  after  the  detection  o f  ant i -dsDNA  in  
otherwise  healthy individuals.  85% o f  them  developed  
clinically  overt  SLE  within  a  few  years.20  In  another  
study,  in  a  high  proportion  o f  anti-SSA  or  anti-SSB  
positive  mothers  of  children  with  isolated  congenital  
heart  block,  symptoms o f  primary  Sjogren's  syndrome  
developed  at  varying times  after delivery.21  Therefore,  
we  feel  that  it  is  worthwhile  t o  follow  up  these  pa-
tients,  especially  those with  multiple  autoimmune  lab-
oratory  abnormalities,  with  special  attention  to  the  
development  of  signs  and  symptoms  of  SLE  or  o f  
other  systemic  autoimmune  diseases.  The  question  we  
wish  to  answer  is  whether  immunologic  processes  
suspected  o f  being  involved  in  the  pathogenesis  o f  
SLE  may  be  underlying  factors  implicated  in  the  
elicitation  of  an  adverse  pregnancy  outcome  in  a  
specific  subgroup  of  patients  with  habitual  abortion.  
The  further  invesagation  o f  specific  T-cell  abnormali-
ties  is  essential  in this  regard.;2 '2 5  
Systemic  vascufaides constitute  a heterogenous  fam-
ily  o f  systemic  autoimmune  diseases.  A N C A  is  a  
P-ANCA C-ANCA 
Fig.  I.  Distribution  of  aniimveloper-
o.tidase  (pANCA I and  antiprou'inasc-.-
(cANCA)  antibodies  in  patients  with  
recurrent  abortion.  Values  below  the  
lines are  negative.  
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TABLE  III.  Comparison  of  cANCA  Levels  in  Patients  with  Recurrent  Abortion  (n =  59)  and  In Controls  (n = 25) 
Antibody  titers  (U  L)  
Mean  SD  SE  Median  Mln  Max  
Habitual  abortion  0.81  1.22  0.16  0.40  0.10  6.00  
Control  0.32  0.13  0.03  0.30  0.10  0.60  
P  = U.H2S 
SP.  \iamlurtl  Jet  Ultimi:  SE.  iluiularj  error:  Min.  minimum  i nitie:  Mux.  maximum  value.  
useful  diagnostic  aid  in some  types of  systemic  vasculi-
tides.  with  pANCA  being  prevalent  in  microscopic  
polyangiitis  and  Churg-Strauss  syndrome,  and  
cANCA  in  Wegener's  granulomatosis.  It  can  also  
occasionally  be  found  in  various  autoimmune  and  
inflammatory  diseases,  such  as  S LE.  drug-induced  
lupus,  inflammatory  bowel  diseases,  idiopathic  rapidly  
progressive  glomerulonephritis,  or  chronic  viral  hep-
atitis.  The  major  antigen  in  patients  with A N C A  with  
perinuclear  staining  (pANCA)  is  myeloperoxidase,  
while  in  those  with  diffuse  cytoplasmic  staining  
(cANCA)  it  is  proteinase-3.  We  detected  ANCA  in  
eight  patients  with  recurrent  miscarriage (pANCA  in  2  
and  cANCA  in  6)  and  in  none  of  the  controls.  The  
higher  prevalence  of cANCA  (though  the difference  is  
of  only  borderline  statistical  significance)  and  the  
higher  cANCA  levels  raise  the  possibility  that  this  
autoantibody  may  in  some  way  be  associated  with  
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Fig.  2.  A  comparison  of  cANCA  le\ -
els  in  patients  with  habitual  abort ion  
and  in  healthy  controls.  Bars  show  
mean  ±  SE.  P  =  0.02S.  
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TABLE  IV.  Associated  Laboratory  Abnormalities,  Obstetric  History,  and  Age of  Antineutrophil  Cytoplasmic  Antibody  
(ANCA)  Positive.  Recurrent  Abortion  Patients"  
Patient Associated  laboratory  abnormality  G P 
Fetal  loss  (trimester)  
1st  2nd  Age 
1 pANCA aCL 3 1 2 0 33 
2 pANCA - 3 0 2 0 39 
3 cANCA aCL 5 2 2 1 42 
4 cANCA - 3 0 3 0 28 
S cANCA aCL  CIC  8 0 5 1 28 
6 cANCA aCL  CIC  4 0 0 4 31 
7 cANCA - S 1 3 1 26 
8  ...  cANCA - 2 0 2 0 22 
"  Induced abortions are not included in the table. No  third-trimester fetal  losses occurred in these patterns. Age and obstetrical data do not differ 
significantly from  those in the oteratt group of  habitual ahorters.  '  
G. number af precious gestations:  P. number of  prêtions  lire deliceries. 
recurrent  abortion.  ANCA  levels  in  the study  patients  
are  lower  than  those  observed  in  patients  with  active  
systemic  vasculitis,  and  similar  to  the  levels  described  
in  studies  of  patients  with  SLE.  Patients  with  ANCA  
did  not  constitute  a  specific group  in  respect  of  age,  
the number of previous pregnancies, or  the number  or  
duration  of  gestation  of  the  previous  miscarriages  as  
compared  with  the  overall  group  of  patients.  
In  some  inflammatory  diseases.  ANCAs  may  arise  
as a result of  polyclonal immune activation,  but  in our 
patients  no  statistically  significant  association  of  
ANCA  with  any  other  autoantibodies  was  revealed.  
In  fact, except  for aCL. no other  autoantibodies  were  
found  in  ANCA  positive patients.  It  may  be  interest-
ing that none  of the six patients with  multiple  autoim-
mune laboratory changes had ANCA. and.  vice versa. 
ANCA  positive  patients  had  relatively  few  associated  
TABLE V.  Laboratory  Characteristics  of  Six  Patients  
Selected  Because of  the  Presence  of  an  Association  of  
Multiple  Autoimmune  Serologic  Abnormalities  
Patient 
1 LE cell  C-3. LAC CIC 
2 Ariti-SSA Anti-SSB C-3. CIC 
3 Anti-dsONA aCL CIC 
4 LE cell  LAC 
5 aCL LAC C-3: CIC 
6 ANA C-3. Leukopenia 
LE.  lupus  erytbematustis: C-.:..  decreased eumpiemem-è:  LAC.  
lupus amicoaguient:  CIC. circtdariug  iniiminueomp/exes: aCL.  unti-
eardiolipin:  .J.V.J. antinueleur antibotiy. 
laboratory  abnormalities.  While  this  may  be  a  coinci-
dence.  it  may  also  raise  the  question  of  whether  the  
reported  immunologic  findings  indicate  distinct  im-
munologic  pathomechanisms  of  repeated  abortion  in  
the  patients  in  these  two  subgroups.  
One  widely-accepted  theory36  is  that  the  activation  
of  neutrophil  granulocytes  and  endothelial  cells  by  
certain  cytokines  is  followed  by  the  translocation  of  
proteinase-3  to  the  cell  surface,  where  it  binds  ant i -
proteinase-3,  thereby  leading  to  endothelial  injury,  
intravascular  lysis  of  neutrophils,  and  microvascular  
damage. This process remains to be investigated  in  the  
endometrium  during  implantation  and  placentation.  
The  questions  of  whether  the  presence  of  ANCA.  
especially  of  cANCA.  has  a  specific  role  in  habitual  
abortion,  and  whether  it  is  of  clinical  importance  in  
reproductive  immunology  must  be  answered  after  the  
follow-up of  our  patients  and  further  examinations.  
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Scleromyxedema 
Zsuzsanna  Bata-Csorgo,  MD,a-b  Sandor  Husz,  MD,a  Marta Foldes,  MD,a  Irma Korom,  MD,a  
Katalin  Molnar,  MD,a  Marta  Morvay,  MD,a  and Attila Dobozy,  MDa  Szegedy,  Hungary  
Scleromyxedema  is  a sclerotic  variant of  papular  mucinosis,  in which  lichenoid  papules  and  scleroderma-
like  features  are  present.  We  describe  a  patient  with  scleromyxedema  with  IgG  type  lambda  chain  
paraprotein,  a systemic scierosis-like  illness, and myositis. The  patient's serum contained  Scl 70  antibodies,  
characteristic  of  scleroderma.  Electromyography  showed  signs  of  acute  myositis  and  the  creatine  
Phosphokinase  (CPK)  level  was  elevated.  Multiply  passaged  fibroblasts  from  the  patient's  skin  lesions  
showed  altered  growth  response  in  vitro.  The  patient  was  treated  with  cyclosporin  (4  mg/kg/day)  with  
improvement.  0  Am Acad Dermatol  1999;40:343-6.)  
In  1954  Gottron1  introduced  the  term  scle-romyxedema for  a  sclerotic  variant  of  papular  mucinosis .  Since  then,  numerous  cases  have  
b e e n  reported  in  which  l ichenoid  papules,  along  
with  scleroderma-like  features,  are  present.2-3  
Various  systemic  manifestations  have  also  b e e n  
reported,  such  as  myopathy,  eosinophilia,  arthritis,  
cerebral  symptoms,  and  arteriosclerotic  changes  in  
the  fundus  oculi,  kidney,  and  coronary  arteries.4-10  
We describe  a patient with scleromyxedema with  IgG  
type  X chain  paraprotein,  a systemic  sclerosis-like  ill-
ness,  and  myositis.  We describe,  for the  first  time  to  
our  knowledge,  the  use  of  cyclosporin  therapy  in  
this  disease.  
CASE  REPORT  
A  50-year-old  white  man  had  a  6-month  history  of  
thickening  skin.  The  process  began  on  his  face  and  
became generalized.  His face became  masklike,  the  open-
ing of his mouth constricted, and dysphagia developed. At 
the  same  time,  proximal  muscle  weakness  occurred.  He  
also  noticed  the  appearance  of  papules  and  nodules  on  
his  wrists,  neck,  and  behind  his  ears  (Fig  1, A and  B).  
Before  the  onset  of  this  condition,  bilateral  Dupuytren  
contractures  had  developed.  
A biopsy  specimen  taken  of  a  papule  revealed  in  the  
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papillary and  upper  reticular dermis  deposition  of  mucin  
and  proliferation  of  fibroblasts.  The  collagen  fibers  were  
mostly missing or degenerated  (Fig 2). A lymphocytic infil-
trate was also apparent. 
Laboratory investigations revealed the following abnor-
malities:  Westergreen  sedimentation  rate,  75  mm/h  (nor-
mal,  0-20  mm/h);  glutamate  oxalacetate  transaminase  
(GOT), 66  U/L (normal,  <37  U/L); glutamate  transaminase  
pyruvate,  55  U/L (normal  <40  U/L);  creatine  phosphoki-
nase  (CPK),  1862  U/L (normal,  195 U/L). Laboratory values 
were  normal  for  hematocrit,  hemoglobin,  white  blood  
cells count and differential, platelet count,  and serum  lev-
els  for bilirubin,  alkaline phosphatase,  A.GT, glucose,  elec-
trolytes,  urea  nitrogen,  and  creatinine.  Creatinine  clear-
ance  was  normal.  Peripheral  blood  lymphocyte  subsets  
(CD3,  CD4,  CD8,  and  CD23)  were  in  the  normal  range.  
Purified protein  derivative  (PPD)  induced  a normal  migra-
tion  and  phytohemagglutinin  showed  normal  stimulation  
of leukocytes. Serum immunoglobulin  levels were  normal.  
Serum  protein  electrophoresis  showed  an  IgG  X chain 
paraprotein.  The serum contained  Scl  70  antibodies-anti-
SSA,  anti-Sm,  anti-DNA-and  cryoproteins  were  absent.  
Chest  and  bone  radiography,  electrocardiography,  and  
echocardiography were negative. Abdominal  ultrasonogra-
phy showed  hepatomegaly.  Radiologic  examination  of  the  
esophagus  revealed  an  absence  of  peristalsis.  Electro-
myography  of  the  deltoid  muscle  showed  signs  of  acute  
myositis.  Eye  examination  revealed  arteriosclerotic  
changes  in the  fundus oculi. A sweat  test showed  hypohy-
drosis. A bone  marrow biopsy specimen  revealed  hypocel-
lular,  atrophic  marrow  with  no  sign  of  monoclonal  gam-
mopathy. We were  unable to carry out  pulmonary function 
tests  because  of  technical  difficulties  caused  by  the  
patient's constricted  mouth.  
The patient was treated with cyclosporin (4  mg/kg/day).  
After 7 weeks,  his skin was thinner and softer, his  proximal  
muscles were stronger,  and he  was able to open  and close  
his mouth. The papular eruptions on his hands, wrists, and 
neck had almost disappeared,  and there  was a decrease  in  
the size of the larger lesions behind his ears. There was no 
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Fig  1.  Shiny, closely set  papules and  tubers behind  ears  (A) and  papules on  hand  (B).  
Fig  2.  In  thickened  skin,  there  is proliferation  of  fibroblasts,  large amount  of  mucin  associat-
ed  with  irregularly arranged  bundles  of collagen.  (Hematoxylin-eosin  stain;  original  magnifica-
tion,  x25)  
significant change  in  his serum  CPK level  (1637  U/L),  and 
immunoelectrophuresis  showed  the  presence  of  IgG  A.  
chain  paraprotein.  
Two weeks later the  patient  died suddenly at  his  home.  
The autopsy revealed confluent bronchopneumonia  as the 
cause  of death.  Histopathology  confirmed  myositis  of  the  
diaphragm  and  esophagus  and  revealed  lymphocytic:  and  
fibrotic lesions  in the  myocardium.  
To see  whether  fibroblasts  from  lesioned  skin  would  
respond  similarly to normal  fibroblasts to scleromyxedema 
serum  and  to see whether  our  patient's  serum  possessed  
fibroblast growth  enhancing  properties  we derived  fibrob-
J  AM  ACAD  DERMATOL  Bata-Csorgo el al  3 4 5  
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Table  I.  In vitro growth of normal and scleromyxedema fibroblasts based on [3H] thymidine  incorporation  
Incorporation  of  [3H] thymidine (dpm/3 x 104 cells) 
Normal  fibroblasts  Scleromyxedema fibroblasts  
Without  serum  524  ± 1 7 4  2,455  ±  192  
5% normal  serum  3,074 +  319  14,587 ±2,720 
10% normal  serum 8,281  ±2,517  32,385 ±  1,332  
20% normal  serum  37,886  ±3,815  39,000 ±  1,634  
5% scleromyxedema  serum  30,280 ±  3,793  11,464 ± 9 2 8 
10% scleromyxedema  serum  46,158 ± 7 3 6 25,260 ±  1,823  
20% scleromyxedema  serum  51,176  ±3,614  32,578 ±  2,758  
Results are mean values ±  SD of measurements in triplicate wells. 
lasts from the  lesioned  skin  of our  patient.  Informed  con-
sent  was obtained  from the patient before the punch  biop-
sy  procedure.  Fibroblasts  from  normal  skin  of  a  plastic  
surgery  patient  and  from  the  scleromyxedema  patient  
were  grown  in  vitro  up  to  3 passages  then  plated  into  96  
well  plates  (3  x  104  cells/well)  in  DMEM+F12+10%  fetal  
bovine serum  (Life Technologies,  Paisley,  UK). Three  days  
later,  the  media was changed  to  DMEM+F12 without  FBS  
and  either  normal  human  serum  or  scleromyxedema  
serum  was added  to the cultures at various  concentrations  
(5%,  10%, and  20%, all  in triplicates). After a 24-hour  incu-
bation,  [3H] thymidine  (final  concentration.  40  Bq/mL,  
Chemapol,  Prague,  Czech  Republic)  was  added  to  the  
plates.  Cells  were  harvested  16  hours  later,  and  the  
radioactivity  measured  with  a  liquid  scintillation  counter.  
Compared with cells that were grown without serum,  both  
normal  and  scleromyxedema  fibroblasts  responded  with  
higher proliferation to normal serum  in a  dose-dependent  
manner  (Table  I, first and second columns,  rows 2,3,4, P  <  
.05  for  all).  Lesioned  fibroblasts,  however,  seemed  to  
respond  more  readily  to  lower concentrations  of  the  nor-
mal serum  (P  <  .05 at serum  levels of  5% and  10%) and,  in  
fact, grew  at  a  much  higher  rate  than  normal  fibroblasts  
even  without  serum  (Table  I,  first  and  second  columns,  
first  row,  P  =  0.01).  In  accordance  with  previously  pub-
lished  data,  our  patient's  serum  had  a growth  enhancing  
effect on  normal  fibroblasts  (Table  I,  first column,  P  <  .05  
at serum  levels  of  5% and  10% and  P  -  .1 at  20% serum).  
Lesioned  fibroblasts,  however,  did  not  respond  with  high-
er  proliferation  to  the  patient's  serum  than  to  normal  
serum  (Table  1, second  column).  These  data  suggest  the  
existence of an altered growth  regulation  in dermal  fibrob-
lasts of scleromyxedema. The  fact that  lesioned  fibroblasts  
exhibited  much  higher  proliferation  in  vitro  even  without  
serum  in  the  culture  compared  with  normal  fibroblasts  
after  repeated  passages  suggests  the  possibility  of  an  
inherent  change  in  these  cells  in  the  disease.  The  exis-
tence  of  an  altered  growth  regulatory  mechanism  in  the  
scleromyxedema  fibroblasts  is  further  supported  by  the  
different growth responses exhibited by these cells in com-
parison  with  normal  fibroblasts  toward  normal  and  scle-
romyxedema  serum.  These  results  are  in  line  with  data  
reported about  abnormal  cell growth,  increased c-myc and 
altered  c-myb and  B-myb expression  in dermal  fibroblasts  
of scleroderma  lesions.11-12  
DISCUSSION 
The  pathogenesis  of  sc leromyxedema  is  not  
known.  Characteristically,  there  is  a  hyperprolifera-
tion of  fibroblasts  in the dermis  and abnormal  depo-
sition  of  mucin.1 3  Many  studies  have  documented  
the  presence  of  an  abnormal  IgG-type  paraprotein,  
predominantly  X light chain,  in the serum.7-14  Serum  
from patients  with  scleromyxedema  has been  found  
to enhance  the  proliferation  of  normal  fibroblasts  in  
vitro.15  That  the  paraprotein  may  play  a  role  in  this  
effect  has  been  suggested,  but  serum  from  patients  
added  to  normal  human  cultured  fibroblasts  stimu-
lated  DNA  synthesis,  regardless  of  whether  the  
serum  contained  the  IgG  paraprotein  or  not.  
Moreover,  the  IgG fraction of the serum  itself had  n o  
influence on  fibroblast  proliferation.  
Various  treatments  have  b e e n  tried  in  scle-
romyxedema  with inconsistent  results.7-16 2 0  We tried 
cyclosporin,  based on  reports of  the beneficial  effect  
of cyclosporin  in conditions  (systemic sclerosis,  mor-
phea,  scleredema)  that  share  similarities  with  scle-
romyxedema.2 1  Cyclosporin,  through  its  immuno-
suppressive  effect,  could  influence  lymphokine  and  
growth  factor  production  and  it  could  directly  sup-
press  fibroblast  proliferation  and  glycosaminoglycan  
synthesis.22  On  the  basis  of  our  results,  we  believe  
that  further  evaluation  of  cyclosporin  treatment  in  
scleromyxedema  is  indicated.  
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Panniculitisszel járó dermatomyositis:  2 esetismertetés 
Dermatomyositis  with panniculitis: two cases 
MOLNÁR  KATALIN DR., KEMÉNY LAJOS DR., KOROM IRMA DR., DOBOZY ATTILA DR. 
ÖSSZEFOGLALÁS 
Dermatomyositisben  igen  ritkán  látható  panniculitis.  A  
szerzők  2  olyan  esetet  közölnek,  ahol  a  klinikai,  hisztoló-
giai  és  laboratóriumi  leletek  alapján  dermatomyositis  és  
panniculitis  együttesen  fordult  elő.  Egyik  betegnél  sem  
észleltek  helszervi  tumort.  Betegeik  az  alkalmazott  immu-
noszuppresszív  terápiára  jól  reagáltak.  Az  irodalmi  ada-
tok  és  a  2  saját  eset  alapján  úgy  gondolják,  hogy  a  panni-
culitisszel  együtt  járó  dermatomyositis  annak  egy  alcso-
portját  alkotja,  mely  jobb  prognózist  mutat.  
Kulcsszavak: 
dermatomyositis  - panniculitis  - prognózis 
SUMMARY 
Panniculitis  is  not  often  observed  in  dermatomyositis.  
Two  cases  are  reported  here  in  which  the  clinical,  
histological  and  laboratory  findings  demonstrated  
dermatomyositis  with  panninulitis.  The  patients  had  no  
internal  malignancy.  They  responded  well  to  systemic  
immunosuppressive  therapy.  On  the  basis  of  the  literature  
descriptions  and  the  present  two  cases,  it  is proposed  that  
dermatomyositis  occuring  together  with  panniculitis  
could  comprise  a  subgroup  of  dermatomyositis  with  a  
characteristically  better  prognosis.  
Key words:  
dermatomyositis  - panniculitis  -  prognosis 
A  dermatomysitis  (DM)  súlyos,  a  bőr,  az  izom  és  a  kötő-
szövet  gyulladásos  betegsége,  mely  különböző  szervrend-
szereket  érint  (I).  A  panniculitis  a  zsírszövet  gyulladásos  
betegsége.  A  panniculitis  egyes  típusai  az  etiológiai,  pato-
genetikai  és  klinikai,  hisztopatológiai  vonatkozásokat  te-
kintve  nagyon  hasonlóak  (2).  A kötőszöveti  betegségeknél  
a  zsírszövet  gyakran  érintett  az  immunológiai-gyulladásos  
reakciókban.  Habár  DM-ben  klinikailag  megnyilvánuló  
panniculitis  csak  ritkán  látható,  mikroszkópos  panniculitist  
gyakran  lehet  találni.  Janis és Winkelmann  vizsgálata  alap-
ján  a  DM-es  betegekből  származó  bőrbiopsziák  10%-nál  
panniculitis  is  megtalálható  (3).  Winkelmann  szerint  a  zsír-
szövetben  létrejött  eltérések  túlságosan  kis  kiterjedésűek,  
ritkán  fordulnak elő  és  nem  annyira  kifejezettek,  hogy  kli-
nikai  tünetekben  nyilvánuljanak  meg  (4).  Ezzel  ellenkező-
leg  Neidenbach  úgy  gondolja,  hogy  a  panniculitis  a  DM  
egy  része  és  annak jelenlétét  a DM  egy  diagnosztikus  jel-
lemzőjének  kellene  tekinteni  (5).  Két esetet  közlünk,  majd  
az irodalmi  áttekintés eredményeit foglaljuk  össze.  
Esetismertetések 
I.  eset:  Az 54 éves  nőbeteg  1994 februárjában kereste  fel  klinikán-
kat.  6 hónapja meglevő  panaszai:  felső végtagi  gyengeség,  hőemel-
kedés,  15 kg-os fogyás. A vizsgálat során periorbitális oedema, a ka-
rokon,  arcon,  ujjakon,  térden  mellkason,  szemhéjakon  bőrpír  (heli-
otrop  erythema)  és  élénkvörös  papulák  a  metacarpo-phalangealis  
ízületek  felett (Gottron jel). Az alkarok feszítő felszínén néhány  vö-
rös, ovális, indurált alapú ulcus volt  látható.  
A kóros  laboratóriumi  leletek: szérum  aszparát-aminotranszferáz:  
84 U/l  (normál tartomány: 8-20 U/l) szérum alanine-aminotranszfe-
ráz  83  U/l  (normál  tartomány:  8-20  U/l),  laktát  dehidrogenáz  608  
U/l  (normál  tartomány: 45-90  U/l) és kreatln  klnáz 414 U/l  (normál  
tartomány:  10-70  U/l). A vörösvérsejt  süllyedés  60  mm/óra  volt. A 
vérkép  10%-os eosínophlliát  mutatott. A szérum  protein  (67  g/l) és 
albumin  (32,6 g/l)  szint  csökkent,  míg  a gamma  globulin  (14,7  g/l)  
és IgM (2,07 g/l) szint emelkedett  volt. Anti-SSA, -SSB, -Sm, -RNP 
és  anti-dsDNA  antitesteket  nem  tudtunk  kimutatni.  A jobb  deltaiz-
mon elvégzett  elektromyogram  a myositisre jellemző  képet mutatta.  
Belszervi  tumort nem lehetett  kimutatni.  
A jobb felkarról, a panniculitis  által  érintett  területről  biopsia  tör-
tént. A fekély alapján elzáródott,  kis ereket; a subcutisban és a fasci-
ában gyulladásos  Infdtrátumot,  ill. oedemát  lehetett  látni. A zsírszö-
vetben  intralobárisan  limfocitás infiltrátum volt  látható.  Az  izombi-
opsia  fasciadegenerciót  és  mononuklearis  sejtes  beszűrődést,  vala-
mint súlyos izomrostdegeneráciőt  mutatott. A direkt immunofluores-
cens  vizsgálat  (nyúl,  antihuman  IgM  és  IgG-vel)  a  bazálmembrán  
területén granulumokat  mutatott ki. Az izombiopszián  az erekben és 
az  izomrostok  között  immunkomplex  depositumot  lehetett  látni. A 
klinikai,  hisztolőgiai  és  laboratóriumi  leletek  megfeleltek  a  Bohan  
és Peter által állított diagnosztikai  kritériumoknak,  így DM és panni-
culitis volt a diagnózis (6). 
A  beteg  1 mg/kg/nap  prednisolont  és  2  mg/kg/nap  azathioprint  
kapott  tünetei  elmúlásáig,  majd  a  prednisolont  leépítettük.  A beteg 
azóta tünet- és panaszmentes.  
Egy  évvel  később egy  csomó jelentkezett  a  bal  inguinális  régió-
ban,  amely  retroperitoneális  tályognak  bizonyult.  A  pusból  Myco-
bacterium  tuberculosis  tenyészett  ki. A Mycobacterium  tuberculosis  
DNS-ét  PCR  technikával  (7)  ki  tudtuk  mutatni. A beteg  1 éven  ke-
resztül  kombinált  antituberkulotikus  terápiában  részesült  (ethambu-
tol  chlorid,  isoniazide  és  pyrazinamide),  ami  hatására  tünet-  és  pa-
naszmentessé vált.  
2.  eset: Az  57  éves  nőbeteg  1995  novemberében  jelentkezett  
klinikánkon  panaszaival:  az  arca  időnként  kipirult,  fáradékony-
ság, gyengeség,  izületi  fájdalmak, hőemelkedés,  láz, nyelési  nehe-
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1.  ábra  
1 beteg.  Erythema  a mellkason,  heliotrop  erythema  
3.  ábra  
1 beteg.  Kivájt, vörös  ulcusok  a jobb  felkaron  
zítettség.  Az  utóbbi  2  évben  vállövi  gyengeség  alakult  ki.  A  glu-
teuson,  a  bal  combon  és  a  szakrális  régióban  vörös,  meleg,  száraz  
tapintású,  beszűrt  plakkok  és  csomók  voltak  tapinthatók,  melyek  
néhány  hete  alakultak  ki.  
2.  ábra  
1 beteg.  Erythemás  papulák  a metacarpophalangealis  ízületek  felett és 
erythema  a körmök  körül  
A laboratóriumi  vizsgálatok  gyorsult  süllyedést  (36 mm/h),  szérum  
alaninaminotranszferáz  (79  U/l),  szérum  aszpartát-aminotranszferáz  
(207  U/l),  kreatin  foszfokináz (2660  U/l)  és  szérum  amiláz  (285  U/l)  
szintet  mutatott.  Az  antinukleáris  antitest  vizsgálat  egér  máj  szubszt-
ráton  pozitív  lett  (nukleoláris  típus),  az  anti-S-
SA.  -SSB. -dsDNS,  a cANCA  és pANCA  vizs-
gálatok  negatívnak  bizonyultak.  
A tumorkutatás  negatív  eredményt  adott.  
A deltaizomból  vett  biopsiás  anyagon  izom-
rost  degeneráció,  fokális  mononukleáris  infilt-
ráció  és  vasculitis  volt  látható.  A gluteus  terü-
letéről  származó  bőrbiopszián  subepidermális  
oedemát,  a  dermisben  kifejezett  vasculitis!  és  
perivasculárisan  elhelyezkedő  mononukleáris  
és  plazmasejtes  beszűrődést  lehetett  látni.  A  
gluteális  területről  vett  bőrbiopszián  végzett  
direkt  immunofluorescenciás  vizsgálat  IgM  és  
C3  immunkomplex  depositumokat  mutatott  ki  
a  felületes  és  mély  erekben,  míg  a  musculus  
deltoideusból  vett  biopsziás  anyagon  kifejezett  
vasculitis  volt  látható  IgM.  IgA  és  C3  lerakó-
dással.  A  diagnózisunk  DM  és  panniculitis  
volt. 
A  terápia  napi  1 mg/kg  methylprednisolone  
volt.  Mivel  nem  volt  jelentős  javulás  a  beteg  
állapotában,  2  héttel  később  3  mg/kg/nap  cyc-
losporin  A  terápiát  kezdtünk.  A  mozgáskorlá-
tozottság  és  nyelési  nehezítettség  sokat  javult.  
A  beteg  tünet-  és  panaszmentessé  vált.  kétna-
ponta  12  mg  methylprednisolone  terápiával  
került  hazabocsátásra.  
2 3 0 
4.  ábra  
Az izombiopszia  izom-  és  fasciadegenerációt,  
mononukleáris  sejtes infiltrációt és  myositist  mutat  
5.  ábra  
2. beteg. Vörös,  meleg,  száraz  felszínű, beszűrt  plakkok  
és csomók  a  gluteuson  
Megbeszélés 
A szerzők  2 esetet  mutatnak  be,  ahol  a DM  és  panniculitis  
együttesen  fordult  elő.  A  klinikai  tünetekben  is  megnyil-
vánuló  panniculitis  DM-ben  ritkán  figyelhető  meg.  1924-
óta  csak  9  esetet  közöltek  (5.  8-15).  Hazai  szerzők  közül  
Marschalkó  és  mtsai  1998-ban  közöltek  egy  áttekintő  cik-
ket  a  dermatomyositisről,  melyben  irodalmi  adatok  alap-
ján  többek  között  a  legmodernebb  kritériumrendszert  is  
ismertetik  a  kórkép  diagnosztikájában.  Juvenilis  dermato-
myositisben  említik  panniculitis  előfordulását  (16).  Habár  
manifeszt  panniculitis  DM-ben  ritkán  látható,  szövettani  
vizsgálat  gyakran  leír mikroszkópos  panniculitist.  Janis  és  
Winkelmann  55  DM-es  beteg  szövettani  mintáját  vizsgál-
va  5 esetben  talált  fokális  panniculitist  (10%).  Allen  kuta-
tásai  alapján  panniculitis  -  az  enyhétől  a jelzett  formáig  -
meglehetősen  gyakran  fordul  elő  (17).  Fusade  és  mtsai  
szerint  a  panniculitist  a  DM  egyik  jellemző  bőrtünetének  
kell  tekinteni,  és  a  bőrtünetek  és  a  hisztológiai  leletek  kö-
zötti  eltérés  ugyanazon  folyamat  különböző  súlyosságú  
fokozatait  mutatják  (13).  Winkelmann  az  általa  közölt  
esetleírásban  a panniculitist  a  DM  velejáró tüneteként,  an-
nak  részeként  értékeli  (11).  Másrészről  Winkelmann  sze-
rint  bár  a  zsírszövetben  létrejövő  elváltozások  valóban  lé-
teznek,  azok  túlságosan  kis  területen  és  ritkán  alakulnak  
ki  ahhoz,  hogy  klinikailag  is  megnyilvánuló  tüneteket  
okozzanak  (4).  
Az  irodalomban  eddig  megjelent  és  a  most  közlendő  
DM  és  panniculitises  esetek  legfőbb jellegzetességeit  táb-
lázatban  foglaltuk  össze.  (1.  Táblázat)  Ezek  a  betegek  na-
gyon  különböző  életkornak  voltak  (3-tól  65  éves  korig,  a  
felnőtt betegek  átlagéletkora  49,1  év  volt),  érdekes  módon  
a  11  eset  3  gyermekkori  előfordulást  is  tartalmaz  (5,  8,  
12).  A nők csaknem  kétszer  olyan  gyakran  érintettek,  mint  
a férfiak, ami  a DM  ismert  nemi  megoszlásának  megfelel.  
A  panniculitis  az  esetek  egyharmadában  egyidőben  jelent  
meg  DM-mel,  3  alkalommal  a  panniculitis  megelőzte,  4-
nél  pedig  követte  a  DM  kialakulását.  A  leggyakrabban  
érintett  területet  a karok, combok  és fartájék volt. 
A  panniculitisszel  együtt  megjelenő  DM  egyik  legjel-
legzetesebb  tulajdonsága  a  mély  kötőszövet  és  az  izom  
kalcificációja. A táblázatban  szereplő  betegek  hisztológiai  
mintájában  csak  egy  alkalommal  lehetett  kimutatni  mész-
lerakódást.  Kalcium  a DM  késői  szakaszában  és  gyermek-
kori  DM-ben  detektálható  leggyakrabban.  Janis  és  Win-
kelmann  cikke  alapján  a  kalcinosis  valódi  incidenciája  
gyermekkori  DM-ben  kb.  74%,  míg  felnőtt  esetekben  
20%.  A  subcután  zsírszövet  más  jellegű  elváltozásai  is  
megjelennek  DM-ben.  Japán  szerzők  membranocisztás  el-
változást  találtak  DM-ben.  Eddig  csak  4,  hasonló  esetet  
közöltek,  melyből  egyben  a tünetek  atípusos  mycobactéri-
um fertőzés  után jelentkeztek  (15).  
Jól  ismert,  hogy  a felnőtt  DM-es  betegek  26%-ánál  ma-
lignoma diagnosztizálható  (18).  A  táblázatban  összefoglalt  
esetek  között  csak  1 alkalommal  szerepelt  tumor.  A  bete-
gek jól  reagáltak  a  Prednisolon  és  a  methotrexat  terápiára,  
egyet  kivéve,  aki  i.v. immunglobulin  kezelést  igényelt.  
1994-ben  Davidson  és  mtsai  közöltek  egy  esetet,  ahol  
egy  carcinomához  társult  DM  tuberculosissal  együtt  for-
dult  elő  (19).  A  M.  tuberculosis  infekció  a  DM  terápiája  
alatt  alakult  ki.  Hasonlóképpen,  első  esetünkben  a  myco-
baktérium  fertőzés valószínűleg  a  szteroid  kezelés  hatásá-
ra immunoszuppresszió  miatt jött  létre.  
A DM  pontos  oka  nem  ismert.  Néhány  adat  szerint  a  
DM  és  a  panniculitis  kialakulásában  a komplement  medi-
álta  vasculitisnek  is szerepe  lehet.  Nem  tisztázott,  hogy  az  
IgG  és  IgM  lerakódása  az  izmok  ereiben  okozhat-e  komp-
lement  aktivációt  (20).  Néhány  tanulmány  beszámolt  im-
munoglobulin  lerakódásról  az  izom  ereiben,  míg  más  
szerzők  azt  nem  tudták  megerősíteni  (21,  22).  A  patológiai  
háttértől  függően  panniculitisek  különböző  típusait  írták  
le:  enzim  panniculitis,  mint  pl.  a  hasnyálmirigy  enzim  
panniculitis;  alfa-1  antitripszin  deficienciából  származó  
panniculitis;  „immunológiai"  panniculitis,  mint  pl.  a  lupus  
panniculitis  vagy  a vasculitiszek  után  másodlagosan  kiala-
kuló  panniculitis;  hideg,  factitia jellegű,  postszetroid  pan-
niculitis,  cellularis  proliferativ  betegségekhez  társuló  pan-
niculitisek  stb.  (4).  Eseteinkben  az  immunológiai  jellegű  
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Eset/nem/ 
életkor 
Hivatkozás A DM  megjelenése  
a  panniculitishez  
képest 
A  tiinct  
elhelyezkedése 
Kalcifíkáció Belszervi 
tumor 
Terápia Terápiás 
hatékonyság 
l/N/3 5 egyidőben karok nincs nincs 1 mg/kg/nap  Prednisolon,  
methotrexate 
igen 
2/F/8 8 egyidőben fartájék, combok nincs nincs 2  mg/kg/nap  Prednisolon  igen 
3/F/5I 9 14  hónappal  
később 
fartájék, combok nincs rhabdomyo-
sarcoma 
50 mg/nap  Prednisolon  átmeneti 
4/N/58 10 2 héttel  később  combok,  has,  
fartájék 
nincs nincs 60 mg/nap  Prednisolon  igen 
5/N/24 II 3  hónappal  később  karok nincs nincs 60 mg/nap  Prednisolon  
3x2,5 mg/hét  methotrexate  
igen 
6/FIO 12 1 évvel  korábban  fartájék, combok nincs nincs 2 mg/kg/nap  Prednisolon  igen 
7/N/42 13 10 hónappal 
később 
fartájék, combok, 
has,  karok  
nincs nincs 1 mg/kg/nap  Prednisolon  igen 
8/F/42 14 5  évvel  korábban  fartájék, karok nincs nincs 2 mg/kg havonta  iv.  
immunoglobulin  (5x)  
igen 
9/N/65 15 egyidőben fartájék, combok, 
lábszár 
van nincs 60 mg/nap  Prednisolon  
1000 mg  methylprendisolon  
(1  alkalommal)  
igen 
10/N/54 jelen  eset  egyidőben karok nincs nincs 10 mg/kg/nap  Prednisolon  
2 mg/kg/nap  azathioprin  
igen 
II /N/57 jelen  eset  2 évvel  korábban  fartájék, combok nincs nincs 1 mg/kg/nap  methylprednisolon  
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/.  láblázat  
Dermatomyositises  és  panniculitises  esetek  
panniculitisek  alakulhattak  ki  a DM-hez  kapcsolódva.  Az  
immunológiai  mechanizmus,  amely  a  panniculitis  kiala-
kulásában  szerepet  játszhatott  a  komplement  aktivációt  
okozó  keringő  immunkomplexek  lerakódása  és  felhalmo-
zódása  volt.  Eseteinkben  lerakódott  irrimunkomplexeket  
lehetett  kimutatni  a bőr és  izom  felületes és  mély  ereiben,  
mutatva  hogy  közös  patogenetikai  úton  részt  vesznek  a  
DM  és  a panniculitis  kialakulásában.  
Adataink  és  az  irodalmi  közlések  áttanulmányozása  
után úgy  gondoljuk,  hogy  a DM-ben  megjelenő  panniculi-
tis jó  prognosztikai  jel,  hisz  csaknem  minden  egyes  beteg  
nagyon  jól  reagált  a  terápiára  és  tumort  is  csak  egy  eset-
ben  lehetett  kimutatni.  Mi  is úgy  véljük,  hogy  a  panniculi-
tisszel  együtt jelentkező  DM  annak egy  külön  alcsoportját  
alkothatja. 
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Carbohydrate  Moieties  Determine  the  Antigenicity of the  Pemphigus  Foliaccus  Antigen  
S. Ortiz-Urda,  Y. Marquart. U.  Mann.  E.  Kriehubcr.  K.  Wolff. and  K.  Rappenberger  
Department of Dermatology. University of Vienna. WJhringer Glirtel  18-20.  1090 Vienna.  Austria  
Pemphigus foliaceus (pi)  is an autoimmune bullous disease characterized by pathogenic  autoantibod-
ies  (aab) directed  against  the  extracellular  domain  of desmoglcin  I (dgl).  a desmosomal  cadherine  
type  adhesion  glycoprotein.  Desmosomes  are major  ceU adhesion  structures of epithelial  cells  and  
their  capacity to  mediate  cell  adhesion  requires  the  presence  of  sugar  residues.  Since  dgl  exhibits  
several  N-  and  O-glycosvlarion  sites,  and  pf-autoannbodies  (aab)  obviously  impair  the  adhesive  
(unction of dgl. we asked the question, whether  sugar residues might contribute to the  antigenicity  
of  the  pf-autoanrigen.  Processing  ctyosccrions  of  normal  human  skin  for  immunomorphologicai  
studies we demonstrate  chat certain lectins Concanavalin  A and wheat germ agglurinine  completely  
inhibited  the consecutive  binding of  pf-aab but  not  of a monoclonal  antibody.  Deglycosybrion  of  
skin  sections  with  N-glycosidascs  and  mannosidase  but  not  with  O-glycostdases  also  completely  
abolished  pf-aab binding. Our  assumption  that  N-  but  not  O-glycosybrion  of dgl  might  account  
for this phenomenon  was additionally supported by Western-blotting of epidermal protein  extracts:  
dgl  in  its native farm migrated  to  160 kDa.  as detected  by both.  mab-dg3.10 and pf-aab.  whereas 
after  deglycosybrion  dgl  migrated  to  a  molecular  weight  of  140-145  kDa  and  was  only  more  
detectable with  nub-dg.  Organ  culture  experiments displayed  identical  results,  i.e.. pf-aab binding 
inhibition by lectins and N-glycosidascs and subsequendy of blister formation. Our  findings  suggest  
that  caibohydrace  moieties  play  a  decisive  role  tn  the  aucoanrigenicicy  of  the  pf-autoanrigen  and  
indicate  that  the  pf-autoanrigen  is  localized  on  a  conformational  epitope  of  the  extracellubr  
domain  of dgl. 
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Transmembrane  Collagen  XVII  is Triple-Helical  and  Mediates  CeU  Adhesion  
K. Tasanen,* J.  Eble.t  M.  AumaiUey.t  H.  Schumann,  and  L.  Bruckner-Tuderman  
Department  of  Dermatology,  University  of  Miinscer.  Germany;  'Department  of  Dermatology,  
Univenity  of  Oulu,  Finland:  fDepartment  of  Physiological  Chemistry.  Univenity  of  Monster.  
Germany:  ^Department  of Biochemistry,  Univenity  of Cologne.  Germany  
Collagen  XVII, a transmembrane hemidesmosoma! component,  is mutated  in junctional  epidermo-
lysis buUosa and acts as an aucoanrigen in blistering skin diseases. In order to study the conformation 
and  functions of  this  unusual  collagen,  the  largest  collagenous  domain.  Col 15. of  collagen  XVII  
was  produced  in  a  recombinant  expression  system.  Amino  acid  analysis  of  recombinant  CollS  
domain  (rCollS)  showed  that  over  70% of the  eligible  proline  residues  were  hydroxylated  to  4-
hydroxyproline.  The  folding and  thermal'stability  of rCoita  were  probed  with  circular  dichroism  
and  trypsin  digestions.  Both  assays  indicated  that  rCollS  produced  in  the  presence  of  ascorbate  
had a triple-helical conformation and a melting temperature of25°C.  In contra», when synthesized  
without  ascorbate.  rCollS  showed  a  melting  temperature  of  18°C.  The  mutation  G627V  which  
lejds  to junctional  epidermolysis  buUosa  had  a  striking  effect on  the  thermal  stability  of  tColla,  
leading to  partial unfolding already at 4'C.  Interestingly. rCollS  promoted  cell adhesion of  several  
ceU  lines  by  a  fit  incegrin  mediated  mechanism.  Epitope  mapping  showed  chat  rCollS  was  
recognized  by  autoanrisera  of both  bullous  pemphigoid  and  linear  IgA dermatosis  patients.  
The  data  demonstrate  eolbgen  XVII  forms  a  triple-helix,  but  also  that  ascorbate  is  absolutely  
required  for the  correct  biosynthesis  and  folding of  this collagen. The CollS  domain  can  mediate  
cell  adhesion,  and  its functional  perturbance  through  generic  aberrations or  autoantibody  binding  
may  cause  epidermal-dermal  separation  in both  autoimmune  and  inherited  blistering  skin.  
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A Second  Type  XVII  Collagen  mRNA  Transcript  in  Human  Keracinocytes  
K. Molnar.*  G.  van der  Steege.  M.F. Jonknun,  S.  Husz.* J.B.  van der Meer.  and H.H.  Pas  
Department  of  Dermatology.  University  Hospital.  Groningen. The  Netherlands:  'Department  of  
Dermatology.  Albert  Szent-Gyorgyi  Medical  University.  Szeged.  Hungaiy  
The  mRNA  for  human  type  XVII  collagen  has  been  reported  to  be  a  6-kb  transcript  derived  
from  the  COL 17.4 /  gene.  Here  we  report  the  presence  in  normal  human  kerannocytes  of  an  
additional  COL  17.1 /  transcript  which  is approximately  0.6  kb  smaller  in  length.  Both  mRNA's  
hybndized on  Northern  blot with  probes directed to sequences coding for parts of the  intracellular  
and extracellular domains of type XVII collagen. By BLAST homology* search alignments, followed 
by cloning and  sequencing,  we  extended  the  3'  untranslated  region  (3*UTR)  of the known  type  
XVII  collagen mRNA  sequence by 877 bascpairs to completion. Three  BLAST identified cDNA's 
contained  a 610-bp  deletion  in  this  new 3 'UTR  sequence.  Northern  bloc  analysis  with  a  probe  
complementary  to  this deletion  only  identified the  larger mRNA.  The  deletion  of 610  bp  tn  the  
smaller  mRNA  was  verified  by  RT-PCR  and  sequencing.  Genomic  PCR  showed  the  new  
sequence to be  an extension of exon  56 of the COL 17.4 /  gene suggesting that the second  mRNA  
is  generated  by  differencial  splicing.  Alignment  of  the  3'UTR  sequences  of  human  and  mouse  
mRNA  showed  four  stretches  in  which  the  degree  of  homology  was  as  high  as  the  homology  
between  the  protein  coding  sequences  suggesting  that  these  noncoding  sequences  are  important  
for  proper  functioning of  the  messenger.  In  normal  keratinocytcs  (he  smaller  mRNA  was  found  
to  be  expressed  at  a  level  of  5-15%  of  that  of  the  larger  cranscnpt  whereas  in  a  squamous  ceU  
carcinoma  cell  line  this  ratio  was  inverted,  the  smaUer mRNA  being three  times  more  abundant  
than  the  larger  mRNA.  
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Decrease  in  Epidermal  CD44  Expression  as  a  Potential  Mechanism  for  Abnormal  Hyaluronace  
Accumulation  in  Superficial  Dermis  in  Lichen  Scterosus  and  Atrophicus  
G.  Kaya,  E.  Aujpburger.  I.  Scamenkovic.'  and J. -H.  Saurac  
Department  of  Dermatology  (DHURDV).  Univenity  Hospital  of Geneva.  Geneva.  Switzerland;  
'Department  of  Pathology.  Harvard  Medical  School,  and  Pathology  Research.  Massachusetts  
General  Hospital.  Boston.  MassachusetB 02129.  U.S.A.  
CD44  is a polymorphic  integral  membrane  glycoprotein  which  serves  as the  principal  ceU surface 
receptor  for  hvaluronate  (HA),  (he  major  component  of  the  extracellular  matrix.  CD44  is  
abundantly  found  in the  skin and  functions as a  ceU adhesion  molecule.  In  a recent  study  we  have  
observed  a  massive  dermal  accumulation  of  HA  as  a  result  of the  in vim  selective  suppression  of  
CD44  in  kerannocytes  of  mice  using  a  kerarin-5  (K3J-CD44  annsense  cransgene.  Since  the  
histological  features of  the  dorsal  skin  of  these  transgenic  mice  display  many  similarities  to  those  
of the  panencs with  lichen scterosus et atrophicus  (LSA) such  as accumulation of a loose connective 
tissue  in  the  superficial  dermis,  we  explored  the  epidermal  CD44  expression  in  the  skin  of  14  
LSA patients by immunohistochcmistry  and  in n m hybridization,  and the nature of this accumulated 
material  by  alcian  blue  and  human  CD44  receptor  globulin  (hCD44Rg)  trainings,  which  wc  
compared  with  chose of the  genital  skin of the  transgenic  mice which  had  not  been  examined  in  
the  previous  study  and  of  the  skin  from  four  lupus  erythematosus,  seven  scleroderma  and  one  
reticular  erythematous  mucinosis  (REM)  patients.  Here  we  show  that  the  expression  of CD44  in  
the epidermis of the involved  LSA skin from genital and extragenital  areas is significantly decreased, 
and  in  some  cases completely  lost,  and  that  the  accumulated  substance  in  the superficial dermis  is  
HA.  The  genital  skin  of  these  transgenic  mice  displays  the  same  phenocype  as  their  dorsal  skin  
and  skin  from  LSA  patients,  characterized  by  die  accumulation  of  HA  in  the  superficial  dermis.  
However,  keracinocyce  CD44  expression  was  unaltered  in  lupus  erythematosus,  scleroderma  and  
REM.  despite  the  presence  of  a  mucinous  material  in  the  dermis,  when  compared  with  the  
normal  skin.  These  results  indicate  that  the  decrease  of  CD44  in  the  keracinocytes  is the  central  
defect  in  LSA constituting  a  novel  mechanism  for abnormal  HA  accumulation  in  the  superficial  
dermis  which  is different  from the  one of other  inflammatory skin  conditions  and  mucinoses.  
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Long-Chain  Unsaturated  Fatty  Acids  Inhibit  92  kDa  Gelarinasc  B Mediated  Ebscoiysts.  "A  Novel  
Approach  to  Control  Elastic  Fibers  Alterations  During  Sltin  Photoaging"  
A.  Berton.  G.  Godeau.*  H.  Emonard.  P.  Beilon.t  W.  Homebeck.  and  G.  Bcllon  
Laboratory  of  Biochemistry.  C N R S  UPRESA  6021.  IFR-53  Biomolecules.  Reims.  France:  
'Laboratory  of  Biochemistry*.  Faculty  of  Odontology.  Paris  VI.  France:  tShiseido  International  
France  SAS  
Damage  to  skin  elastic  fibers  is the  hallmark  of long-term  exposure  to  solar  ultraviolet  irradiation  
and  is most  responsible  for wrinkle  formation.  It  was previously  reported  that  induction  of  matnx  
mecailoprotetnoses  ;MMPs),  particularly  92  kDa  gelannase  B (MMP-9),  occurred  at  UVB  doses  
well  below  those  that  cause  skin  reddening.  Among  MMP  family, gelatinases.  i.e..  MMP-2  and  
MMP-9  were  found to  display  elastinolytic  activity,  in  vim.  
In  this  study  we  tint  determined  the  ex  ti'tv  elastolytic  potential  of  both  endopepadases.  using  
human  skin  assue  sections  and computerized  morphomemc  analyses, and compared  tc with  chose  
of neutrophil  elastase.  
MMP-9  was  found  to  exhibit  elastolytic  activity  (a  maximal  50" j  hydrolysis  of  elastic  fibers  was  
attained  at  50  nM  concentration  of  enzyme)  but.  in  such  in mu  conditions  it  was  totally  devoid  
of proteoglycans or collagen* degrading activity. On the contrary. MMP-2 hydrolyzed  proteoglycans  
and  type  lil  collacen  but  did  not  display  elasrin  degrading  capacity  at  concentration  as  high  as  
2*0  nM.  '  *  
MMPs contain  a deep (SI')  hydrophobic  pocket  and our  previous  studies demonstrated  that  long  
chain  unsaturated  fifty  acids  could  inhibit  MMP-2  with  Ki  in  the  (Xmolar  range.  Similar  
investigations  were  performed  with  MMP-9.  in ttw  experiments  using  Mca-Pro-Leu-Gly-Leu-
Dpa-ALi-Arg-NH.  as  MMP-9  synthcae  substrate  showed  th.it  among  tiny  acids,  elaidic  acid  
(ClS:!A9  trans)  ar.d  crans-pannanc  acid  (C 18:4^9.  I t .  13.  15  all  trans)  were  the  most  potent  
MMP-9  inhibitors.  Similar  MMP-9  inhibitors* potency of  those  faery aeids  cowards  clastolysis  was  
found  tx iiiv  and  most  importantly,  in  keeping  with  their  ability* to  bind  to  elasan.  they  could  
protect  elastic fiber* against  degradation  by  MMP-9.  
Those fatty acids are inocuicous substances and  thus could be  used to prevent  elastic  fibers  network  
alterations  associated with  photoaging.  
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Distinct  Roles  of  Extracellular  Signal-Regulated  Kinase  and  pJ8  Mitogen  Activated  Protein  
Kinase  in  Enhancement  of  Collagenase-I  (MMP-1)  and  Scromclysin-I  (MMP-3)  Expression  in  
Dermal  Fibroblasts  
N.  Reunanen.  M.  Ahonen.  M.  Foschi. J.  Hon.  and  V-M.  Kahari  
MediCity  Research  Laboratory*  and  Departments  of  Dermatology  and  Medical  Biochemistry,  
University of Turku.  Finland: Univenity  of Firenze.  Italy: and Scripps  Research  Institute.  La Jolla. 
California.  U.S.A.  
We  have  examined  the  role  of  nutogen-acevated  protein  kinase  (MAPK)  signaling  pathways  in  
the  regulation  of  collagenase-1  (macnx  metalloproteinase-l.  MMP-1)  and  scromelysin-1  (MMP-
3) expression  in  normal human  skin  fibroblasts.'Tumor  necrosis  factor-Ot (TNF-a)  and  incerleukin-
(IL-iP)  are  inflammatory  cytokines,  which  induce  MMP-l  and  MMP-3  expression  in  these  
cells. TNF-a  and  IL-10  activate  the  extracellular  signal-regulated  kinase (ERK)l,2.  as well  as the 
stress-activated  protein  kinase/Jun-X-ccrminai  kinase (SAPK/JNK)  and piS  .\L4PK  in  these  cells.  
TNF-a  and  IL-tP-elicited  induction  of MMP-1  and  MMP-3 mRNA  was potendy  inhibited  by  
specific  p3H MAPK  inhibitor  SB203530.  whereas  blocking  the  ERKI.2  pathway  iRjt7.MEKl.2-'  
ERKI.2)  by  MEK1.2  activation  inhibitor  PDKS059  had  no  effect  under  similar  circumstances.  
Infccnon  of  the  ceils  with  recombinant  adenovirus  tor  comntunvcly  active  MEK1  resulted  in  
acnvation  of  ERKI.2  and JNK1.  and  markedly  enhanced  the  mRNA  levels  and  production  of  
MMP-1  and  MMP-3.  Infecting  cells  with  an  adenovirus  tor  constttunvely  active  MKK6b  Ip38  
kinase* specifically activated p38  MAPK and  induced  the expression of MMP-3. but  had no effect 
on  MMP-1  expression.  Adenovirus-mediated  expression  of dominant  negative  MKK6b  potently  
inhibited  activation  of  p33  MAPK  and  upreguhnon  of  MMP-1  and  MMP-3  production,  and  
collagenolytic  activity,  by TNF-a  and  IL-lJJ.  These  results  identity  two  distinct  pairs  of  MAPKs  
capable  of  inducing  MMP-l  jnd  MMP-3  expression  in  fibroblasts:  mitogen  responsive  ERX1.2  
and JXKI.  coordinate!)* activated  by MEKt.  and  stress-activated JNK1.2  and  p3S.  which  play an 
important  role  in  controlling  the  proteolytic  acavtty of  normal  fibroblasts.  
Experimental dermatology  •  Original  article  
Two type  XVII collagen  (BP 180)  mRNA transcripts  in  human  
keratinocytes:  a long  and  a short  form 
K. Molnár,*  G. van der  Steege, M.  F.  Jonkman, M.  Nijenhuis,  S. Husz,*  J. B. van der Meer and 
H.  H. Pas 
Department of Dermatology,  University Hospital,  Groningen,  the Netherlands,  and "Department of  Dermatology Albert Szent-Gyorgyi Medical University 
Szeged,  Hungary  
Summary  We have  analysed BP180  mRNA expression  in normal  human  keratinocytes.  Here we 
report the presence in normal keratinocytes of two  COL17A1  transcripts which differ by 
0.6 kb  in  length.  Both  mRNAs  hybridized  on  Northern  blot  with  probes  directed  to  
sequences  encoding  intracellular  and  extracellular  fragments  of  BP 180.  By  BLAST  
homology  search  alignments  we  extended  the  3'  untranslated  region  (3'UTR)  of  the  
known  BP180  mRNA  sequence  by  877  bases  to  completion.  Three  of  20  cDNAs  
identified  by  BLAST  searches  contained  a 610  bp deletion  in  this  new  3'UTR  sequence.  
Northern  blot  analysis  with  a  probe  complementary  to  this  deleted  sequence  showed  
binding only to the larger mRNA. The deletion of 610  nucleotides  in the smaller  mRNA 
was  verified  by  reverse  transcription-PCR  and  sequencing.  Genomic  PCR showed  the  
new sequence to be an extension  of exon 36  of the  COL17A1  gene which suggests  that  
the second mRNA is generated  by differential splicing.  In normal keratinocytes the level 
of  the  smaller  transcript  was  5-15%  of  that  of  the  larger  transcript  whereas  in  a  
squamous cell carcinoma cell line this ratio was reversed, the smaller mRNA being three 
times  more  abundant  than  the  larger  mRNA.  The  biological  significance  of this  newly  
identified transcript  in protein synthesis  and tissue expression  or in cell differentiation, 
proliferation  or adhesion  is as yet  unknown.  
Introduction 
BP180  (type  XVII  collagen,  BPAG2)  is  a  key  target  in  
subsets of skin  blistering diseases: it is an autoantigen  in  
the autoimmune-mediated  disorders bullous  pemphigoid,  
cicatricial pemphigoid and pemphigoid gestationis1-3  and  
is  deficient  due  to  mutations  in  non-Herlitz  junctional  
epidermolysis  bullosa.4,3  Structurally.  BP180  is a  trans-
membranous  component  of  hemidesmosomes.  attach-
ment  structures  within  basal  keratinocytes,  which  
stabilize  the  connection  between  the  epidermis  and  
the  dermis  by linking  the  keratin  intermediate  filament  
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network  to  the  anchoring  filaments  of  the  underlying  
basement  membrane.  
In stratified epithelia BP180 is located along the basal 
surface  of  the  basal  epithelial  cells,  consistent  with  its  
incorporation  into  hemidesmosomes.  Further.  BP 180  is  
found  along  the  lateral  surface  of  these  cells,  but  this  
protein  does  not  seem to  be  organized  into  hemidesmo-
somes  or  other  cytoskeleton  attachment  structures.6  
The  expression  of BP180  is  not  restricted  to  skin,  as  it  
has  also  been  detected  in  epithelia  of  other  tissues  
including  cornea,  ocular  conjunctiva,  buccal  mucosa,  
upper  oesophagus,  umbilical  cord,  transitional  epithe-
lium  of  the  bladder,  simple  epithelium  of the  placenta.7  
in  colon,  prostate,  testis,  thymus  and  in  mammary,  
salivary  and  thyroid  glands.8  Abnormal  distribution  of  
BP180  has  been  noted  in  cancerous  or  precancerous  
tissues,  specifically  in  solar  keratoses.  Bowen's  disease.  
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and squamous cell carcinoma from skin. lung,  oesophagus,  
and  cervix.9  
A 6-kb BP180  mRNA transcript  has  been  identified10  
of  which  4669  bases,  containing  a 4 4 9 1 nt  open  read-
ing  frame  (ORF),  have  been  sequenced.11  The  gene,  
COL17A1,  has  been  mapped  to the  long arm  of  chromo-
some  10,  in  band  10q24.3  and  the  genomic  organiza-
tion  of  the  4669 bp  sequence,  encompassing  56  exons,  
has  been  elucidated.12 '13  
A  second  protein.  LAD-1,  the  autoantigen  in  the  
lamina  lucida  type  of  linear  IgA  dermatososis11  1 '  is  
also  derived  from  the  C0L17A1  gene,  either  by  alter-
native  splicing  of  pre-mRNA  or  proteolytic  cleavage  of  
BP180.1 6  LAD-1  is probably  identical  to the  ectodomain  
of  BP180 . 1 6 - 1 8  
Because  of  the  heterogeneity  of  BP 180  in  terms  of  
tissue  distribution,  cellular  localization,  protein  product  
and  its  disreguiation  in  neoplasms  we  have  reinvesti-
gated  the  expression  of  BP 180  mRNA.  Here  we  report  
the  first  results,  which  show  that  human  keratinocytes  
contain  not  one  but  two  transcripts.  
Materials  and  methods  
Cell  culture  
Primary  human  keratinocytes  were  cultured  in  serum-
free keratinocyte  culture  medium  (BioWhittaker  Europe  
SPRL.  Belgium).  The  squamous  ceil  carcinoma  line  
UMSCC-22B, derived from a tumour of the  hypopharynx.19  
was  cultured  in  DMEM supplemented  with  5% foetal  calf  
serum.  2  mM  L-glutamine,  lOOU/mL  penicillin  and  
100 pig/rnL  streptomycin.  
In  silico  elongat ion  of  the  known  BP180  3 -untranslated 
region  (UTR)  mRNA  sequence  
Internet  BLAST-analysis  searches  against  the  EMBL/  
GenBank  human  EST  database  were  initially  carried  
out  with  the  4669 bp  human  BP180  mRNA  sequence  
(GenBank  #  M91669) . 1 1 ' 2 0  With  these  results,  and  the  
results  of  subsequent  BLAST  searches  with  identified  
expressed  sequence  tags  (ESTs),  a  hypothetical  sequence  
of 877  bases  could  be added  3'  to the M91669  sequence  
(Fig.  1).  
Isolation  of  mRNA  
Ceils were grown  to subconfluence and then  harvested  by  
extraction  with  1 mL/15 cm2  TRIZOL reagent  (Life Tech-
nologies).  The  RNA was  isolated  according  to the  manu-
facturer's  protocol  and  poly(A+)  mRNA was  purified from 
ORF 3'UTR 
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Figure  1  Overlapping  EST clones  identified  by  BLAST-searches  
which  combine  to yield  a 877 bp extension  of the  known  3'-UTR  
of  BP 180  mRNA. The  top  of the  figure  shows the  3'-end  of  
BP180  mRNA. starting  at  residue 4501  (numbering  according  to  
Giudice  et al.11).  which  was  elongated  using  sequence  information  
from the  20  overlapping  clones  depicted  underneath.  These  
clones  were  identified from the  Non-redundant  Database  of  
GenBank  Human  EST entries  using  the  advanced  BLAST  research  
facility at  the  National  Centre  for Biotechnology  Information  at  
Bethesda.  MD (release  version  2.0.)20  The  GenBank  accession  
numbers  of these  clones  are:  1, AA602441;  2.  AA036676:  3.  
W79203:  4. C00407;  5. AA128560:  6. AA044571;  7.  
AA033913:  8. N58654:  9.  AA568429;  10. AA044893:  11.  
AA641352;  12. AA128561:  13,  AA640586:  14,  AA034033:  
15. H87536:  16. AA658228:  17. AA718952:  18.  AA926883:  
19. W73469  and  20.  W73349.  Three  clones,  numbers  18-20.  
were  found to contain  a  610bp  deletion  (spanning  n t 4 6 3 1 -
5240)  if aligned  with  the  new  sequence.  Grey shading,  end  of  
M91669  sequence:  blue  shading,  new  hypothetical  3'UTR.  The  
switch  from the  ORF to  the  start  of the  untranslated  region  
(3'UTR)  is indicated  by the  vertical  bar  on  top  of the  constructed  
sequence. 
total  RNA  using  an  mRNA  Isolation  Kit  (Boehringer.  
Mannheim). 
RNA  probes  
Four  digoxigenin  (DIG)-labelled  RNA probes  were  synthe-
sized  using  the  SP6/T7  RNA  Labelling  kit  according  to  
the  manufacturer's  protocol  (Boehringer  Mannheiml.  
DNA  fragments  were  generated  by  PCR  (for  primers  
see  Table  1)  on  partial  cDNA  clones  encoding  the  
cytoplasmic  domain  of  BP 180  (probe  1),  the  extracellu-
lar domain  of BP 180  (probe  3) or human  genomic  DNA  
(probe  4). The  PCR products  were  subcloned  into  vector  
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Table  1  PGR primers  used  for construction  of probes.  PGR verifica-
tion  of the  610  bp deletion,  and  sequencing.  
Primer Strand 5'position* 5'-3'sequence 
F0304 + 304 tcaactggaagcacacgagg 
R0741 - 741 caggatcgttgcatcgtagg 
F3679 + 3679 gtgtggtccagcatcagcgt 
R4131 - 4131 gccgatgtcagtgccatagg 
F4542 + 4542 aggtgaccaagtctatgctg 
R5101 - 5101 gccaactgactagagaatgc 
F4649 + 4649 cacttaggtccaaggtctcc 
R5388 - 5388 gtcttgagctgatgctgtgt 
FIN55-90 + - 9 0 ' cagtagtcacggttgccata 
M13-24T - polyA ctagtaaaacgacggccagt(t)2. 
*The  nucleotide  position  numbers  refer  to  the  type  XVII  mRNA  
sequence  M91669  elongated  with  new  sequence  from  GenBank  
accession  number  AF136185.  
^Located  in  intron  55.  90  bases  upstream  of  the  first  exon  56  
nucleotide. 
pCRH (TOPO™ TA Cloning kit, Invitrogen). For probe 2. a 
cDNA  fragment  containing  bp  1771-2553  was  sub-
cloned  from  plasmid  p213  into  vector  pSPT19.4  DIG-
labelled  antisense  RNA probes  were  then  generated  by  in  
vitro  run-off  transcription  on  linearized  plasmid  DNA  
using  either  T7  or  SP6  polymerase.  The  final  probes  
were  complementary  to  BP 180  mRNA  sequences  at  
the  following  positions:  probe  1,  nt 304-741:  probe  2,  
nt 1771-2553:  probe  3,  nt 3679-4131;  probe  4.  
nt  4649-5101 .  
Nor thern  b l o t t i n g  
RNA  samples  were  separated  electrophoretically  on  a  
18% formaldehyde-1%  agarose  gel and  transferred  to  a  
positively  charged  Nylon  Membrane  filter  (Boehringer.  
Mannheim).  The  RNA was covalently  immobilized  to  the  
filter  by  a  5-min  254 nm  UV exposure.  The  filters  were  
then  hybridized  with  the  DIG-labelled  probes  and  all  
incubation  and  washing  procedures  were  performed  
according  to  the  protocol  for  DIG-labelled  Northern  
blotting  (Boehringer  Mannheim).  Chemiluminescence  
was  detected  by  exposing  the  filters  to  Kodak  Safety  
Film  ARD for 60 min.  
Results 
Human  kerat inocytes  express t w o  BP180  mRNAs  
Northern  blot  analysis  showed  human  keratinocytes  to  
express  two  different  BP 180  mRNA  transcripts  with  
molecular  sizes  of  5.8  and  5.2 kb  (Fig.  2b.  lanes  4 -6) .  
While the smaller  5.2 kb trancript  was the minor  form in 
Figure  2  Northern  blot  analysis  shows  two  transcripts  detected  
by  a  BP 180  specific  RNA  probe.  mRNA was  prepared  from  three  
different sources  of cultured  cells  and  subjected  to  Northern  
blotting.  BP 180  specific sequences  were  detected  using  probe  2.  
(a)  Lane  1. mRNA  from adult  donor  keratinocytes;  lane  2.  mRNA  
from juvenile  donor  keratinocytes:  lane  3,  mRNA  from  squamous  
cell carcinoma  cell  line  UMSGC-22B.  (b) Calibration  of  mRNA  
size:  lane  4.  mRNA:  lane  5.  DIG-labelled  RNA  molecular  weight  
markers:  lane  6.  mRNA  mixed  with  molecular  weight  markers.  
The  molecular  weights  of  the  markers  are  depicted  to  the  right  of  
lane  6  in  base  units.  
normal  keratinocytes.  with  an  expression  level  of  only  
5-15%  of the larger  transcript  (Fig. 2a. lanes  1 and  2),  it  
was  the  major  form  in  squamous  carcinoma  cells  
(Fig. 2a.  lane  3). The  observed  ratio  differences between 
these  cell  types  did  not  depend  on  culture  conditions  as  
switching  media  did  not  invert  the  ratios  (not  shown).  
The  5.2 kb  mRNA  conta ins  a de le t ion  in  the  3 -UTR 
sequence 
For  further  characterization,  the  Northern  blot  was  
repeated  but  with  three  probes complementary  to  intra-
cellular  and  extracellular  protein  coding  sequences  
(probes  1 - 3 )  and  one  probe  complementary  to  a  part  
of  the  hypothetical  3'-UTR  sequence  (probe  4).  Fig.  3  
summarizes  this  information  and  shows  that  both  
mRNAs  hybridize  on  Northern  blot  with  the  three  
probes  for  BP 180  ORF  sequences  but  that  only  the  
larger  transcript  hybridizes  with  probe  4.  
Because  the  BLAST  analysis  had  also  identified  three  
EST clones  with  a  610 bp  deletion  in  the  novel  3'-UTR  
sequence  (Fig.  1), the 0.6 kb size difference between  both  
bands  in combination  with  the  negative  hybridization  of  
probe  4  to  the  smaller  transcript  suggested  that  the  
5.2 kb  transcript  might  be  deleted  for  this  610  bp  
sequence.  We  therefore  performed  reverse  transcription  
(RT)-PCR  with  primer  sets  flanking  the  610 nt  target  
sequence.  Fig. 4(a)  shows that  indeed  two  amplification  
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Figure 3  Northern  blot  analysis  shows  the  smaller  mRNA  species  
to  be  deleted  in  the  3'UTR sequence.  mRNA  from  UMSCC-22B  
cells was  analysed  by Northern  blot  using  four different  BP 180 
specific  RNA probes,  (a)  Schematic  representation  of the  BP 180 
protein  with  the  cytoplasmic  part  to  the  left, the  transmembrane  
region  in  green,  and  the  extracellular  part  to  the  right.  Putative  
collagen  sequences11  are  indicated  in  dark  blue,  (b)  BP 180 
mRNA. Alternating  shades  of grey  indicate  the  sequences  derived  
from exons  1 -56 . 1 3  To the  right  in  light  blue  is the  additional  
877 nt  3'-UTR fragment  (see Figure  1).  (c) The  four  RNA probes  
used  for detection  of  mRNA with  their  target  sequences  indicated  
below,  (d). Northern  blot  signals  with,  from left to  right,  probes  
1 - 4 . 
1  2  3  4  5  6  7  8  9  10  11  12  13  
Figure 4  RT-PCR  and  genomic  PCR  of the  3 -UTR region,  (a)  
RT-PCR  on  purified  mRNA from keratinocytes  (lanes  2.  4  and  6)  
and  UMSCC-22B mRNA  (lanes  3.  5 and  7). The  following  primer  
sets  were  used:  lanes  2  and  3. F4542  to R5388:  lanes  4  and  5,  
F4542  to  R5101:  lanes  6 and  7, F3679  to R5388.  Lane  1  con-
tained  a  100 bp calibration  ladder.  The bands  observed  in  lanes  2.  
3.  6 and  7 in  between  the  expected  amplification  products  are  
heteroduplex  bands,  (b) Genomic  PCR on  DNA from a  healthy  
individual  using  the  following primer  sets: lane  9.  F4649  to  
R5101:  lane  10,  FIN55-90  to R5388;  lane  11.  F4542  to  R5388:  
lane  12.  FIN55-90  to R5101:  lane  13. F4542  to  R5101.  Lane  8  
contained  a  100 bp calibration  ladder.  The  primers  are  as  
described  in  Table  1.  
products  are  generated  with  sizes in  line with  a  deletion  
of  approximately  0.6 kb  (Fig.  4a,  lanes  2,  3,  6  and  7).  
Moreover,  reverse  priming  within  the  hypothetical  
610 bp  deletion  generated  only  one  product  (Fig.  4a,  
lanes  4  and  5).  
Sequencing  confirms  the  in  silico-generated  3 UTR 
sequence  as the  BP180  mRNA  3 -end 
To  generate  fragments  for  sequencing,  RT-PCR  was  
performed  on  normal  keratinocyte  mRNA  with  F4542  
as  forward  primer  and  M13-24T  (Table  1)  as  reverse  
primer. The resulting two products were cloned  in  appro-
priate  vectors  and  processed  for  sequencing.  The  
sequence  of  the  larger  fragment  started  with  the  last  
128 bp  of the  M91669  sequence,  followed by 875 bp  of  
new  sequence  and  ended  with  the  polyA  tail  fragment  
(Fig.  5). A potential  polyadenylation  signal  ATTAAA was 
found 21 nt  upstream  of the  polyA  tail.  The sequence  of  
the  smaller  fragment  was  identical  to  that  of the  larger  
fragment  except  that  it  indeed  had  a  deletion  of  610  
residues  (nt  4631-5240) .  
Genomic  PCR shows  the  610 bp  deletion  fragment  to  be  
an extension  of  exon  56  
For  genomic  analysis.  PCRs  were  carried  out  with  for-
ward priming  in either  intron  55 or exon  56 and  reverse  
priming  in  the  new  3'-UTR  sequence.  Fig.  4(b)  shows  
that  all pairs  gave PCR-amplification  products  of  lengths  
which  agree  with  a  genomic  sequence  running  unin-
terrupted  from  exon  56  to  at  least  bp  5388  of  the  
corresponding  cDNA.  
Discussion 
The BP180  3'UTR-sequence  reported  here completes  the  
3'end  of  the  BP 180  mRNA  and  together  with  the  
M91669  sequence11  5546 nt  are  now  identified.  When  
the  3'UTR  BP180  sequences  of  mouse21  and  human  
were  compared  four  stretches  of  high  homology  were  
found  (Fig.  5).  The  sequence  identity  of  these  four  
stretches  is 78-87%  which  is substantially  higher  than  
the  mean  69%  identity  of  3'  untranslated  regions  
between  human  and  mouse  and  close  to  the  85%  
identity  for protein  coding  regions.22  
A  second,  unexpected,  finding  is  that  human  kerati-
nocytes contain  not one but  two transcripts  and that  the  
smaller  transcript  lacks  a  610  base  fragment  in  the  
3'UTR.  PCR  analysis  of  genomic  DNA  showed  that  at  
least the  first  720 bp of the novel sequence are present  as  
an  uninterrupted  3'-extension  of  exon  56.13  As  this  
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Figure 5  3'UTR nucleotide sequence of 
BP180 mRNA. A total  of 877 nt could be 
added 3' to the known BP180 mRNA 
sequence (GenBank M91669).  Upper  
case: 3'-end 49 nt  of the M91669 
sequence starting at nt4621:  lower case: 
elongated sequence numbered  through  
from the M91669  sequence and starting 
at residue 4670. The polyA tail starts at 
residue 5545. The 610 nt deletion 
sequence is in italics and  its border 
nucleotides.  5'gt and  3'ag, are indicated 
in bold. The  3'UTR sequence was 
compared with the mouse BP180 mRNA 
sequence  (GenBank L08407)21  using the 
BLAST  facility at  NCBI.  Stretches of 
homology are underlined: human  4727-
4886/mouse 4685-4849.  78% identity 
over  168 residues with  11 gaps: human 
4911-4992/mouse  4880-4961.  83%  
identity over 83 residues with  two gaps: 
human  5055-5095/mouse  5007-5046.  
87% identity over 41  residues with one 
gap; human  5446-5530/mouse  5375-
5459,  83% identity over 85  residues and 
no gaps. The potential  polyadenylation  
signal  ATTAAA is double underlined. The 
nucleotide sequences of both  UTRs have 
been deposited  in the GenBank data base 
under  GenBank accession  numbers  
AF136185 (5.8kb  mRNA) and 
AF136186  (5.2 kb mRNA). 
4621 CCTGGACCAG GTCTCATAATGCATGTGGCACTTAGGTCCAAGGTCTCCAg 
4671  agggtgaaagctggagtctgtcaa  tgtcctactgagacagcacagccaac  
4721  ctagctagcaacatttgttttagtctgaacaatatatacttatagaattc  
4771  aqtcaaagatacacaatctqaaacaqcttcatggggtggactctaacagt  
4821  agttqcaatgttttagaatqaqacttacttctctgctatctaqatctqaa  
4871  ctccttqqcttctttacttagttcaagccçcaqcctaqgaaaqccaqtta  
4921  cataaaagttggctcaggagtcttagagctttacctaaatatgagcccag  
4 971  aaaacgqaggatgggggtggggcgccttcctggaggtgacacttgatggq  
5021  qqtgtgttctggttactgttctaaggctgtgccatcagctccttcctccc  
5071  ctgttcattctgcattctctaqtcagttggctaagaagtgactcttgcaa  
5121  ctaaaaaaattaagaaattcacttcccctctaggaggtgatgatagggtt  
5171  tctaatggtta  tatgta  tatcacattccca11tgcttagaaagtctga11  
5221  gtagctatgattgtccgtaggcccatactagagttcatggatatgttata  
5271  ctgaaccaggccagagcaaacagaaaaagaaggttgagggcaatggacaa  
5321  ggaaggaataaagggagaagagggaaaacagaaaacctgatgctggggac  
5371  acagcatcagctcaagacgtcaccctccattctgcactcagaaaatggca  
5421  cttqqqcrqactgggcgcaqttqqtctttaaccacttttcaatqtctaaaa  
5471  acatttqtttqtqqtctataaqatqaaacatcatttcaatcgtaaaattt  
5521  cccattaaaqaaqtttttttttcta-polvA  
sequence  also  contains  the  610 bp  deletion  fragment,  
both  mRNA  species  are  probably  generated  from  the  
COL17A1  gene  by  differential  splicing.  The  border  
nucleotides  of  the  610 bp  deleted  sequence.  5'gt  and  
3'ag  (Fig.  5)  indicate  putative  splice  sites  at  these  posi-
tions.  As  all  three  cell  lines  investigated  expressed  the  
second  mRNA  transcript  the  synthesis  of  two  messen-
gers.  either  intentional  or  unintentional,  seems  to  be  
common  in  human  keratinocytes:  its  biological  signifi-
cance.  however,  remains  unclear  at  present  and  there-
fore open to speculation.  Because the transcripts differ in 
their  3'UTR  sequence,  future  research  will  be  aimed  at  
revealing  a  possible  function  for  this  sequence  which  
may  be  connected  to  mRNA  regulation,  stability,  trans-
lational  initiation,  localization,  or  a  presently  unrecog-
nized function.2 3 - 2 s  Solving  this question may also  shed  
light on  the intriguing observation  that the  ratio  of both 
messengers  is  inverted  in  the  UMSCC-22B  carcinoma  
cells. 
In summary,  we have described the coexistence  of two 
BP180 mRNAs in human keratinocytes. This observation 
is  interesting  as  the  expression  of  BP180  shows  varia-
bility  fn cellular localization  and under circumstances  of  
cell  dedifferentiation.  Further  studies  will  reveal  if  
these  observations  are  related  to  the  expression  of  two  
messengers. 
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Abstract  Specific  ant ibodies  directed  against  special  
hemidesmosomal  proteins  are  involved  in  the  patho-
genesis  of  bullous  pemphigoid  (BP),  and  detection  of  
these  ant ibodies  is  crucial  for  a  correct  diagnosis.  As  
the  BP au toant igen  p r i m a r y  s t ruc tu res  a re  known,  the  
quest ion  was  addressed  as  to  whe ther  it  is  possible  to  
demons t r a t e  c i rculat ing  ant ibodies  against  BP  auto-
ant igens  (BPAG1  and  BPAG2)  by  means  of  an  ELISA  
system,  using  antigenic  epitopes.  With  the  help  of  the  
p r o g r a m s  Pep t ides t ruc tu re  and  Plo ts t ruc ture ,  anti-
genic  epitopes  of  BP  antigens  were  predicted,  chemi-
cally  synthesized  and  screened  using  s e r u m  f r o m  
43 proven  BP  patients. The  coding sequences  of the  best  
ant igenic  epitopes  were  then  chemically  synthesized  
and  inserted  as  m o n o m e r  and  homo-  or  hetero-oli-
gomer  forms  into  fusion-expression  plasmids  (PGEX-4T,  
Pha rmac i a )  i n - f r ame  to the  C- te rminus  of  glutathione-
S- t rans fe rase .  Fusion  products  were expressed  and  pu-
rified  f r o m  Escherichia  coli  cells  by  aff ini ty  chro-
ma tography .  The  recombinant  proteins  were  used  for  
the  detection  of  ant ibodies  in  the  se rum  of  43  BP  pa-
tients  and  of  60 controls  (including  30  healthy  persons,  
22  pat ients  with  pemphigus  vulgaris  and  8  pat ients  
with  o ther  bullous  dermatoses) .  Use  of  the  homo-  and  
hetero-ol igomers  of  the  recombinant  fusion  pept ides  
increased  the  sensitivity  of  the  disease-specific  anti-
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body  detection.  W h e n  a  mix ture  of  the  best  recombi-
nant  fusion  prote ins  was  used,  the  sensitivity  of  the  
ELISA  assays  in  the  case  of  the  BP  pat ients '  s e rum  
was  0.90.  This  system  could  fo rm  the  basis  of  a  rap id  
and  simple  system  for  the  diagnosis  of  BP.  
Key  words  Bullous  pemphigoid  antigen  1 and  2 • 
Antigenic  epitopes  • Recombinant  bacterial  proteins  •  
Diagnostic  ELISA  system  
Introduction 
Bullous  pemphigoid  (BP)  is an autoimmune  subepidermal  
blistering  disorder  which  occurs  most  frequently  in  el-
derly  people.  The  disease  is  characterized  immunologi-
cally  by  circulating  antibodies  which  react  with  autoanti-
gens  in  the  lamina  lucida  of  the  basement  membrane.  Im-
munofluorescence  studies  on  lesional  skin  of  BP  patients  
have  revealed  preformed  immunoglobulins  and  C3  linear  
deposition  along  the  basement  membrane  zone  [12].  
Previous  studies  have  demonstrated  that  BP  autoanti-
bodies  react  predominantly  with  two  distinct  proteins  of  
hemidesmosomes,  BP230  and  BP180,  now  termed  BPAG1  
and  BPAG2  [15,  21].  Specifically.  BPAG1,  a  cytoplasmic  
plaque  constituent  of  the  hemidesmosome  complexes,  be-
longs  to  a  family  of  intermediate  filament  binding  pro-
teins  [23].  In  contrast,  BPAG2  is  a  type  II  transmembrane  
protein  with  a  long,  carboxyl-terminal  collagenous  do-
main  [6].  Major  antigenic  epitopes  of  BPAG1  map  within  
the  C-terminal  end  of  the  protein  [4]  and  those  of  BPAG2  
are  located  within  the  NC16A  domain,  the  major  noncol-
lagenous  stretch  of  the extracellular  part  of  this  protein  [6,  
16].  cDNAs  of  both  BP  autoantigens  have  been  isolated  
and  amino  acid  sequences  for  these  antigens  have  been  
deduced  [20.  22].  Epitope  mapping  studies  of  human  
BPAG2  have  shown  that  the  NC16A  domain  harbours  
four major antigenic  sites  recognized  by  BP serum  [7,  26].  
The  pathogenetic  relevance  of  BP  autoantibodies  has  
been  established  using  a  passive  transfer  mouse  model  
[17].  Recent  studies  have  shown  that  rabbit  antibodies  
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raised  against  a  major  immunodominant  site  of  the  extra-
cellular  domain  are  able  to  induce  subepidermal  blisters  
via  complement  activation  when  injected  into  neonatal  
mice.  These  observations  suggest  that  BPAG2  autoanti-
bodies  are  responsible  for  dermoepidermal  separation  in  
BP. 
Besides  the  conventional  diagnostic  procedures,  direct  
immunofluorescence  (DIF),  indirect  immunofluorescence  
(IIF)  and immunoblotting,  new diagnostic  tools have  been  
described  [9,  11, 27].  In these  assays,  the  target  antigen  is  
either  a  recombinant  BPAG2  NC16A  domain  [11]  or  the  
whole  extracellular  region  of  BPAG2  devoid  of  68  amino  
acids  at  the C-terminus  [9].  
Here  we  report  that  the  detection  of  circulating  anti-
bodies  against  the BP  antigens  is  possible  by means  of  an  
ELISA  with  recombinant  antigens  containing  only  short  
antigenic  epitopes  of the two BP  antigens fused to  a gluta-
thione-S-transferase  (GST)  partner.  
Materials and methods 
Patients 
Serum from 43 BP patients (23 males  and 20 females, mean age at  
onset  69 years,  range 45  to 90  years),  proven  to  have  BP by  clini-
cal,  histological  and  immunohistological  criteria,  was  studied.  
Serum  from  30  healthy  blood  bank  donors  and  from 30  patients  
with  other  bullous  dermatoses  (including  22  with  pemphigus  and  
8  with  disorders  such  as  a  drug  allergy,  erythema  exsudativum  
multiforme, porphyria  cutanea  tarda)  served  as  controls.  
All  BP  patients  exhibited  the  specific  clinical  symptoms  and  
histological  picture.  DIF  demonstrated  that  all  patients  had  de-
posits  of  IgG and/or  C3 along  the  basement  membrane  zone.  
Peptide  synthesis  
The  sequences  of  the  BP  antigens  were  from  Swiss-Prot  and  
TrEMBL  databanks  and  were  analysed  with  the  WISCONSIN  
Package,  Version  8 (Genetic  Computer  Group,  Madison,  Wis.)  by  
means  of the programs Peptidestructure and Plotstructure. Three of 
the  fragments were  chosen  according  to their  reactivities  with  pa-
tients'  serum  in  an  ELISA  system  for further  investigations.  The  
chosen  epitopic fragments were as follows: 
-  BP1: WTQEPQPQPLEEKWQHRVVEQIP  (BPAG1, AC Q03001 
1814-1834) 
-  BP2:  RSILPYGDSMDRIEKDRLQMAP  (BPAG2,  AC Q02802 
507-528) 
- B P 3 :  GELSSRNTGHLHPTPRSPLLR  (BPAG1,  AC  Q03001  
1793-1813) 
Peptide  sequences  were  synthesized  by  a  solid-phase  technique,  
utilizing  Boc chemistry  [19]. Side-chain protecting  groups were as 
follows:  Arg(Tos),  Asp(OcHex),  Glu(OcHex),  His(Z),  Ser(Bzl),  
Thr(Bzl),  Tyr(2BrZ)  and  Lys(2CIZ).  The  peptide  chains  were  
elongated  on  a p-methylbenzhydrylamine  resin  (0.48 mmol/g)  and  
the  syntheses  were  carried  out  with  an  ABI  430A  automatic  ma-
chine,  with  certain  minor  modifications  to  the  standard  protocol.  
Couplings  were  performed  with  dicyclohexylcarbodiimide,  with  
the  exceptions  of  Asn  and  Gin,  which  were  incorporated  as  their  
9-hydroxybenzotriazole  esters.  Amino  acid  incorporation  was  
monitored  with  the  ninhydrin  test  [13].  The  completed  peptide  
resins  were  treated  with  liquid  hydrogen  fluoride/dimethyl  sul-
fide/p-cresol/p-thiocresol  (86:6:4:2,  by  volume)  at 0°C  for  1 h. 
The  hydrogen  fluoride  was  then  removed  and  the  resulting  free  
peptides  were  solubilized  in  10% aqueous  acetic  acid, filtered and 
lyophilized.  The  crude  peptides  were  purified  by  reverse-phase  
HPLC on  a Lichrosorb RP-18  10 Jim column  (16 x  250 mm).  The  
solvent  system  used  was  as  follows:  0.1%  trifluoroacetic  acid  
(TFA)  in water (A), 0.1% TFA, 80% acetonitrile  in water (B). The 
gradient was 0%  B for  15 min, then 0%  —»  15% B over 60 min,  the  
flow was 3.5 ml/min,  and detection  was at 226  nm.  
The appropriate fractions were pooled and lyophilized. The  pu-
rified peptides  were  characterized  with  a Finnigan TSQ  7000  tan-
Fig. 1  Schematic  diagrams  of  
the  recombinant  products  con-
taining antigenic  peptide  epi-
topes  of  BPAG1  and  BPAG2  
autoantigens.  Each  of  the  eight  
recombinant  fusion products  is  
composed  of GST at  the -NH 2 
end, followed by the  antigenic  
epitope(s)  at  the -COOH  ter-
minal.  Synthetic  DNA  se-
quences  were  inserted  through  
the BamHl  site  to the  GST  
gene  of  the fusion  expression  
piasmid pGEX-4T  in-frame. A 
dipeptide  of GS (one  letter  
code)  was  inserted  between  
GST and the particular  epitope 
sequence.  In  the  homologous  
and  heterologous dimer  and  
multimer constructs,  DNA  
blocks encoding  the  peptides  
without  stop codons are  linked  
to one another  by BamHl  and  
¿¿'HI  restriction  sites in-frame 
through  a sequence coding  for  
a  PPRS tetrapeptide  sequence.  
The numbers  and sequence  of  
numbers  k. 2 or 3 represent  the  
antigenic  peptide  epitope(s)  
and the order of  the  peptides  in  
the constructs,  respectively  
BP1 
BP22 
GST 
BP32 
BP11I 
BP1112 
BP221 
¿43 BP2 GST I - ~ l 
GST  ksirj-PPRS-ITI  BP31 I  CST  k?4"Ti-PPRS-|Tl  
I 
CST  krS-ill-PPRS-fTI  
i 
GST  l-G4"Tl-PPRS-i~l""l-PPRS-f~l~l  
i 
c s t  k 4 n - P P R s - r T T - P P R s - i 7 y p p R s - f n  
GST  k?S-fTl-PPRS-jT|-PPRS-fl1  
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dem  quadrupole  mass  spectrometer  equipped  with  an  electrospray  
ion  source.  Peptide  purities  were  above  97%  (HPLC)  and  the  mea-
sured  molecular  weight  values  were  in  all  cases  in good  agreement  
with  the  calculated  values.  
Plasmid  constructs  
Nucleotide  sequences  coding  for  the  synthetic  peptide  epitopes  
which  exhibited  high  reactivity  with  patients '  serum  were  chemi-
cally  synthesized  in  vitro.  Taking  into  account  codon  usage  in  
E.  coli,  the  degrees  of  substitution  in  the  DNA  sequences  of  BP1,  
BP2  and  BP3  were  16%,  29%  and  35%,  respectively.  These  syn-
thetic  DNA  sequences  were  inserted  through  the  Bam  HI  site  to  the  
G S T  gene  of  the  fusion-expression  plasmid  pGEX-4T-2  (Pharma-
cia)  in-frame. As  a  result  of  the  cloning  strategy,  a dipeptide  of  GS  
(one  letter  code)  was  inserted  between  G S T  and  the  particular  epi-
tope  sequence.  Besides  the  G S T - m o n o m e r  epitope  fusion  con-
structs. fusion variants  carrying  tandem  dimer  and  mult imer  blocks  
of  homologous  and  heterologous  epitope  units  were  constructed.  
In  the  case  of  monomer  fusion expression  constructs,  a  stop  codon  
is  at  the  end  of  the  inserted  epitopes,  fol lowed  by  Sal I  for  BP 180 
and  the  £ c o R I  restriction  enzyme  site  for  the  other  constructs.  In  
the  homologous  or  heterologous  d imer  and  mult imer  constructs,  
D N A  blocks  encoding  the  peptides  without  stop codons  are  linked  
to  one  another  by  Sam HI  and  Sg i l l  restriction  sites  in-frame  
through  a  sequence  coding  for  a PPRS  tetrapeptide  sequence.  The  
identity  of  the  inserted  DNA  blocks  and  the  flanking  plasmid  re-
gions  was  controlled  by  sequencing.  
For  a  better  understanding,  the  outline  of  the  different  mono-
mer  and  mult imer  recombinant  fusion  products  is shown  in  Fig.  1.  
Expression,  isolation  and  characterization  of  recombinant  
fus ion  products  
Recombinant  plasmids  were  expressed  and  purified  according  to  
the  method  of  Marczinovits  et  al.  [18]  as  described  briefly  as  fol-
lows.  E.  coli  D H 5 a  cells  harbouring  the  different  fusion-expres-
sion  plasmid  constructs  were  grown  in  LB  medium  and  induced  
with  0.5  m M  isopropyl  |3-D-thiogalactopyranoside  for  3  h.  Bacte-
ria  were  harvested  by  centrifugation,  then  treated  with  lysozyme  
and  disrupted  by  sonication.  Fol lowing  the  above  method,  more  
than  90%  of  the  recombinant  fusion  products  were  in  the  soluble  
fraction  of  the  cell  lysate  and  were  isolated  directly  from  this  frac-
tion  with  the  help  of  a  Glutathione  Sepharose  4B  affinity  gel  
(Pharmacia)  in  the  presence  of  1%  Triton  X-100.  The  fusion  pro-
teins  were  eluted  with  reduced  glutathione  according  to  the  in-
struction  manual  (Pharmacia).  The  recombinant  fusion  products  
were  analysed  by  electrophoresis  in  12.5%  sodium  dodecyl  sul-
fate-polyacrylamide  gels  (SDS-PAGE)  under  reducing  conditions.  
Recombinant  fusion  products  were  denoted  and  are  illustrated  in  
Fig.  1.  
Immunoblot  analysis  
Immunoblot t ing  studies  were  performed  according  to  the  method  
of  Hashimoto  et  al.  [10]  with  slight  modification.  Normal  human  
skin  was  obtained  f rom  patients  undergoing  plastic  surgery.  The  
skin  pieces were  incubated  in  a mixture  of  1 M  NaCl,  1 mM  EDTA  
and  lOpAf  phenylmethylsulfonyl  fluoride  (PMSF) a t 4 ° C  for 72  h.  
The  epidermis  was  then  easily  separated  f rom  the  dermis  and  ho-
mogenized  in  a  solution  compris ing  31.2  mM  Tris-HCl,  2%  SDS.  
1 mM  PMSF,  2  mM  E D T A  and  0.1  M  dithiothreitol.  After  incuba-
tion  for  24  h  at  4 ° C ,  the  homogenate  was  centr ifuged  at  15.000  g  
and  the  supematants  were  stored  at - 7 0 °C  until  use.  The  proteins  
of  the  epidermal  extracts  were  separated  by  S D S - P A G E  (with  6%  
separating  gel)  and  then  electrotransferred  to  a nitrocellulose  filter  
before  probing  with  test  serum.  All  serum  samples  were  used  to  
probe  immunoblots  at  a  dilution  of  1  :40.  Specif ic  binding  by  a  
serum  was  detected  using  peroxidase-linked  class-specific  second  
antibodies  (goat  ant ihuman  IgG;  Sigma)  and  visualized  with  di-
aminobenzidine. 
ELISA  techniques  
Chemical ly  synthesized  peptides  and  fusion  products  were  dis-
solved  and  diluted  in  phosphate-buffered  saline  (PBS),  pH  7.4.  
The  optimal  concentration  was  0.1  ug/well  for chemically  synthe-
sized  peptides,  and  1 pg/wel l  of  monomer  fusion  peptides  as  anti-
gens  was  used.  In  the  case  of  dimer  and  multimer  fusion  products,  
antigen  concentrations  were  equalized  to  the  peptide  components  
of  complexes .  
Antigen  solutions  were  transferred  into  wells  (100  jil/well)  of  a  
microplate  (Biohit,  high  binding  capacity)  and  allowed  to  coat  
Fig. 2  Electrophoresis  of  the  
purif ied  recombinant  products.  
The  affinity-purif ied  recombi-
nant  fusion  products  were  
analysed  by  electrophoresis  in  
12.5%  SDS-polyacrylamide  
gels  under  reducing  conditions  
and  stained  with  Coomassie  
Brilliant  Blue.  Each  lane  con-
tains  5 p g  of  the  relevant  fu-
sion  product  (lanes  1 and  8  
GST.  lane  2  GST-BP  1,  lane  3  
GST-BP2 ,  lane  4  G S T  BP22.  
lane  5  GST-B P 111,  lane  6  
GST-BP221 .  lane  7  GST-
BP1112;  A/  low  molecular  
weight  markers  in  kilodaltons).  
The  fusion  products  were  ob-
served  as  sharp  bands  in  the  
gel  and  only  in  the  case  of  
mult imers  with  higher  molecu-
lar  masses  was  slight  decompo-
sition  found. The  relative  mol-
ecular  masses  of  the  individual  
fusion  products  correlated  well  
with  the  calculated  values  
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overnight  at  4 ° C .  Plates  were  washed  twice  with  distilled  water  
and  the  remaining  binding  sites  were  blocked  with  1%  bovine  
serum  albumin  in  PBS  for  1.5  h  at  37°C .  Plates  were  washed  with  
PBS-Tween  (PBS  containing  0.05%  Tween-20) ,  and  100  |il  of  
200  x  diluted  patient  and  control  serum  was  added  per  well,  fol-
lowed  by  incubation  for  1 h  at  37 °C  and  extensive  washing  with  
PBS-Tween.  Peroxidase-conjugated  antihuman  IgG  (Sigma),  di-
luted  1 : 5000  in  PBS-Tween .  was  then  added  to  each  well  (100  pi /  
well),  fol lowed  by  incubation  for  1 h  at  37 °C. The  plates  were  then  
again  washed  with  PBS-Tween.  and  100  pi  substrate  solution  (17  
mg  o-phenylenediamine  dissolved  in  50  ml  phosphate-citr ic  acid  
buffer . pH  5.0, containing  20  pi H : 0 2 )  was  then  added  to each  well  
and  the  colour  was  allowed  to develop  for  10 min  at  room  temper-
ature  in  the  dark.  The  reaction  was  stopped  by  adding  50  pi  
4  N  H , S 0 4  to each  well. The  optical  density  (OD)  was  measured  at  
492  nm.  
The  optimal  cut-off  value  was  carefully  est imated.  Our  earlier  
studies  had  indicated  that  an  O D  cut-off  of  x  + 2SD  (where  x  is  the  
mean  O D  of  the  control  subjects,  and  SD  the  standard  deviation  of  
the  control  O D )  is  the  most  sensitive  limit  for the  establishment  of  
a  screening  procedure.  We  always  used  at  least  18 healthy  control  
samples  per  microplate  and  a cut-off  value  was  calculated  for  each  
microplate. 
Results 
from  E.  coli  cells  by  affinity  chromatography.  The  affin-
ity-purified  recombinant  products  were  analysed  by  
SDS-PAGE  and  visualized  with  Coomassie  Brilliant  Blue  
staining  (Fig. 2).  The  fusion  products  were  apparent  as  
sharp, homogeneous  bands  in  the  gel.  and  only  in  the  case  
of  multimers  with  higher  molecular  masses  was  slight  de-
composition  found.  Since  the  bands  were  in  regular  posi-
tions,  it  might  be  suggested  that  this  phenomenon  was  a  
result  of  host  cell  proteases  which  cleaved  the  linkers  be-
tween  the  peptide  blocks.  The  relative  molecular  masses  
of  the  individual  fusion  products  correlated  well  with  the  
calculated  values.  
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Immunoreactivity  of  BP1,  BP2  and  BP3  synthetic  
antigenic  peptides  
A  group  of 43  patients  with  proven  BP  were  investigated.  
The  disease-specific  autoantibodies  in  the  patients'  serum  
were  investigated  in  parallel  by  the  immunoblotting  tech-
nique  using  human  epidermal  extracts  and  by  an  ELISA  
with  BP1,  BP2  and  BP3  synthetic  peptides.  When  tested  
by  immunoblotting  against  a  human  epidermal  extract,  
serum  from  63%  of  the  patients  displayed  specific  reac-
tivity  with  BPAG1  (230  kDa)  and  29%  did  so  with  
BPAG2  (180  kDa).  Anti-BPAG2  antibodies  alone  could  
not  be demonstrated  in  our  system.  In  contrast,  the  ELISA  
investigation  with  BP1.  BP2  and  BP3  led  to  positive  re-
sults  with  serum  from 53%,  57%  and  49%  of  the  patients,  
respectively.  As  BP1  and  BP3  peptides  represent  different  
antigenic  epitopes  for  BPAG1,  altogether  serum  from  
50%  of  the  patients  reacted  with  BPAG1  (either  BP1  or  
BP3,  or  both)  and  serum  from  57%  with  BPAG2.  The  
positive  results  overlapped.  Serum  from  30  of  the  43  pa-
tients  (70%)  proved  positive  to  at  least  one  of  the  syn-
thetic  antigenic  peptides.  
All  control  serum  samples  (including  those  from  
healthy  controls  and  patients  with  other  bullous  derma-
toses)  were  negative  in  the  ELISA  with  the  synthetic  pep-
tides  as  antigen.  
Purification  and  quality  control  of  recombinant  
fusion  products  
The  coding  sequences  of  the  antigenic  epitopes  were  then  
chemically  synthesized  and  inserted  as  monomeric  and  
homo-  or  hetero-oligomeric  forms  into  fusion-expression  
plasmids  (PGEX-4T,  Pharmacia)  in-frame to  the  C-termi-
nus  of  GST.  Fusion  products  were  expressed  and  purified  
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F i g . 3 A ,  B  Western  blot  analysis  of  recombinant  fusion  products  
with  the  serum  of patients  with  BP.  A  Incubation  with  the  serum  of  
one  patient  led  to  reaction  only  with  BPAG2.  B  Incubation  with  
the  serum  of  another  patient  led  to  reaction  only  with  BPAG1.  The  
condit ions  of  SDS-PAGE  were  as  described  for Fig. 2  (lanes  1  and  
8  GST.  lane  2 GST-BP1,  lane  3 GST-BP2 ,  lane  4  G S T  BP22,  lane  
5  GST-BP111,  lane  6  GST-BP221 ,  lane  7  GST-BP1112;  M  low  
molecular  weight  markers  in  kilodaltons).  Electroblotted  proteins  
were  incubated  with  200-fold  dilutions  of  patients '  serum  for  4  h,  
and  with  peroxidase-labelled  antihuman  IgG  for  1 h.  Staining  was  
performed  with  diaminobenzidine.  Immunological  reactivity  was  
found  for  serum  with  both  BP221  and  BP1112  recombinant  prod-
ucts  because  they  involved  antigenic  peptides  from  both  autoanti-
gens  (lanes  6  and  7)  
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Table  I  Summary  of  the results  of  the  ELISA  using the  recombi-
nant fusion products  tested  in the scrum  of 43 patients  with  BP  
Fusion  proteins  Positive  cases  
No. % 
GST 3 7 
BPl 17 40 
BP2 21 49 
BPl  11 16 37 
BP22 26 60 
BPl  112  24 56 
BP221 22 51 
BP31 20 47 
BP32 27 63 
BP22 + BP32  + BPl 112 39 91 
Following  SDS-PAGE,  the  separated  fusion  products  
were  electroblotted  and  analysed  with  patients'  serum  
(Fig. 3 a,  b).  The  individual  bands  reacted  with  serum  that  
was  specific  only  for  the  autoantigen  of  BPAG2  (Fig. 3 a) 
or BPAG1  (Fig. 3 b). 
The  immunoreactivity  of  recombinant  fusion  products  
was  higher  than  that of  chemically  synthesized  
antigenic  peptides  
The  results  of  detailed  analyses  of  the  efficiency  of  each  
recombinant  fusion product  in the ELISA  system  are  sum-
marized  in Table  1. The  results  of  the  ELISA  with  the  fu-
sion  products  were  comparable  with  those  obtained  by  
immunoblotting  or  the  ELISA  with  synthetic  peptides.  
The  use  of  homo-  or  hetero-oligomers  as  substrates  in-
creased  the sensitivity  of  the procedure. To summarize  our  
sensitivity  data  for  different  fusion  products,  72%  of  the  
BP  patients  had  autoantibodies  against  at  least  one  of  the  
monomer fusion proteins  (BP1  and/or BP2),  77% had  them  
against  at  least  one  of  the  homo-oligomer  products  
(BP111  and/or BP/222),  and 79%  had  them  against  at  least  
one  of  the  hetero-oligomers  ( B P U 1 2  and/or  BP221  
and/or BP31  and/or BP32). BP22,  BP32  and BP1112  were  
found  to  be  the  most  "successful"  fusion  constructs.  The  
sensitivities  of  BP22,  BP32  and  BP1112  ELISAs  were  
0.59,  0.63  and 0.55,  respectively.  The  specificity  was  much  
better  in  all  cases  (>  0.90).  
In  order  to improve  the sensitivity  of  the ELISA  assay,  
a  mixture  of  BP22,  BP32  and  BP1112  fusion  constructs  
( 1 : 1 : 1 )  was  used  as  antigen  (1  pg  protein/well).  Use  of  
the  mixture  of  the best  antigenic  products  dramatically  in-
creased  the sensitivity  (0.90),  but the specificity  decreased  
slightly  (0.88).  
Scatter  blot  diagrams  of  the  reactivities  of  the  serum  
from  patients  with  BP  and  healthy  controls  in  different  
ELISA  systems  are  shown  in Fig. 4. 
Discussion 
In the present  study, recombinant fusion proteins  in  E.  coli  
were  expressed  by  using  recombinant  plasmids  carrying  
synthetic  antigenic  sequences  for  BPAGI  and  BPAG2.  
These  fusion  proteins  were  used  to  develop  an ELISA  to  
quantify the level of  autoantibodies  in the serum of BP  pa-
tients.  The  aim  of  the  study  was  to  develop  a  relatively  
rapid,  reliable  and  reproducible  objective  method  for  
identifying and characterizing  autoantibodies  in the  serum  
of  BP  patients  using  recombinant  fusion  proteins  as  anti-
gens.  Previous  studies  have  demonstrated  that  immuno-
blotting  is  superior  to  IIF  [14],  In  agreement  with  Chang  
et  al.  [2],  we  consider  that  the  most  important  investiga-
tion from the aspect of  the diagnosis  is  DIF.  Ghohestani  et  
al.  [5] concluded  that  IIF on  salt-split  skin  is  a reliable  as-
say  for  screening  BP  and  is  more  sensitive  than  im-
munoblotting.  In the study  reported here we  demonstrated  
that  an ELISA  with  recombinant  fusion proteins  is  similar  
or  superior  to  immunoblotting.  Giudice  et  al.  [8]  devel-
oped  an  ELISA  for  the  detection  of  autoantibodies  in  BP  
and  herpes  gestationis  using  a 42  amino  acid  ectodomain  
of BPAG2  recombinant  protein,  and found  a good  correla-
tion between  the ELISA  and  immunoblotting  assays.  
Epitope  mapping  studies  of.  human  BPAG2  have  
shown  that the NC16A  domain  of  this  protein  harbours  all  
of  the  major  extracellular  antigenic  sites  recognized  by  
the  serum  of  BP  patients.  The  immunoreactivity  of  BP  
serum  to  the  BPAG2  ectodomain  can  be  abolished  by  the  
depletion of  autoantibodies  to  the BPAG2 NC16A  domain  
[7,  26].  NC16A  contains  four  distinct  antigenic  sites  rec-
ognized  by B P  autoantibodies  [26].  Our antigenic  epitope  
(BP2)  of  BPAG2  is  a small  part  of  this  domain,  and  with  
this  synthetic  peptide  as  antigen,  the  serum  from  57%  of  
the BP patients  was  positive  by  the ELISA  technique.  Ide  
et  al.  [11]  have  developed  an  ELISA  using  recombinant  
forms of  the C-terminal  domain  of  murine  BPAG1.  Serum  
from  approximately  50%  of  BP  patients  reacted  with  
these  recombinant  proteins  on  immunoblotting,  and  most  
of  the  immunoblot-positive  serum  samples  also  recog-
nized  the  proteins  by  ELISA.  Two  epitopes  (BPl  and  
BP3)  of  BPAGI  have  been  found  and  both  are  located  
within  the  published  55-kDa  fragment  that  is  recognized  
by  serum  from  most  BP  patients  [4],  They  reacted  with  
the  serum  from  50%  of  the  BP  patients  when  synthetic  
peptides  were  used  as  antigen.  
In  immunoblot  studies  carried  out  under  denatured  
conditions,  antibodies  against  BPAGI  can  generally  be  
detected  more  frequently  than  antibodies  against  BPAG2  
[3,  14,  15],  Otherwise,  the  use  of  antigenic  epitopes  with  
the  ELISA  technique  did  not  reveal  large  differences  be-
tween  the  synthetic  peptides.  However,  it  seems  that  the  
antigenic  epitope  of  BPAG2  is  the  more  immunoreactive  
with  the  BP  patient  serum.  In  spite  of  a  faint  immunore-
activity  of  native  BPAG2  protein  being  demonstrated  by  
the  immunoblotting  technique  in  earlier  investigations,  
when  only  one  of  its  distinct  antigenic  peptide  epitopes  
was  used,  the  BPAG2  molecule  proved  to be  the  main  au-
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F i g . 4 A - D  Scatter  blot  of  reactivities  of  serum  from  patients  with  BP  and  healthy  con-
trols  in  different  ELISAs.  A  GST-BP22  fusion  construct  as  antigen  (I  pg/well);  B  GST-
BP1112  fusion construct  as antigen  (1  pg/well);  C  GST-BP32  fusion construct  as  antigen  
(1 pg/well);  I)  mixture  of  the  fusion constructs  (1 : I : I)  as  antigen  (altogether  1 pg/well). 
Immobilized  fusion constructs  were  incubated  with  serum  (diluted  1  :200).  Binding  of  au-
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toantibodies  lo immobilized  antigen  was visualized  by  o-phenylenediamine  and  H 2 0 2 ,  af-
ter  incubation  with  a  peroxidase-labelled  antihuman  IgG  (1 :5000)  The  cut-off  of  the  
ELISA  was  set  at  an  OD  value  that  was  equal  to  the  mean  value  of  the  negative  control  
serum+2SD.  The  cut-off  is  indicated  by  the dashed  line  
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toantigen.  Tanaka  et  al.  [24]  and  Bernard  et  al.  [I]  have  
also  suggested  that  BPAG2  antibodies  may  be  more  
closely  related  to  the  disease  severity  than  anti-BPAGl  
antibodies. These  results  are very similar to those  reported  
by  Zillikens  et  al.  [27],  where  the  NC16A  domain  was  
used. 
The  results  of  ELISA  investigations  with  the  fusion  
products  for  the  detection  of  circulating  autoantibodies  
against  BPAG1  and BPAG2  were  very  similar to those  for  
the chemically  synthesized  peptides.  Moreover,  the use  of  
homo-  or  hetero-oligomers  as  substrates  increased  the  
sensitivity  of  the  procedure.  In  this  way,  serum  from  79%  
of  the  BP  patients  reacted  with  these  recombinant  pro-
teins.  The  use  of  a  mixture  of  these  synthetic  epitopes  as  
antigen  greatly  increased  (90%)  the  sensitivity  of  the  pro-
cedure.  The  results  are  very  close  to  those  of  Zillikens  et  
al.  [27].  
We  followed  a  unique  approach:  the  whole  autoanti-
gens  were  substituted  with  the  authentic  short  antigenic  
epitopes  2 0 - 2 5  amino  acids  in  length.  First,  we  chemi-
cally  synthesized  three  antigenic  epitopes  of  BPAG1  
(BP1,  BP3)  and  BPAG2  (BP2)  predicted  by  computer  
programs,  and  their  usefulness  as  diagnostic  tools  was  
tested  with  serum  from  BP  patients.  The  nucleotides  of  
the  above  epitopes  deduced  from  their  amino  acid  se-
quences  were  then chemically  synthesized,  taking  into  ac-
count  codon  usage  in  E.  coli.  Finally,  we  fused  the  epi-
topes  as  monomer,  homologous  and/or  heterologous  dimer  
or  multimer  D N A  blocks  to  GST.  GST  really  does  give  
rise  to  a measurable  beneficial  conformation  of  the  fused  
peptides.  The  high  efficiency  and  fidelity  of  the  GST/ho-
momer  or  GST/heteromer  fusion  products  can  be  ex-
plained  by  the  avidity  effect of GST  dimer formation  [25]  
and  the  high  ligand  affinity  due  to  the  tandem  repetitions  
of  different antigenic  epitopes.  
Following  the  introduction  of  circular  dichroism  (CD)  
and  Fourier-transform  infrared  (FTIR)  measurements  to  
reveal  the conformational  consequences  of  peptides  as  fu-
sion  proteins,  we  observed  that GST-fusion forms  with  the  
antigenic  epitopes  show  an  increasing  contribution  of  al-
pha-helix  conformation  in the monomer  and even  more  in  
the multimer form.  However,  the C D  and  FTIR  spectra  in-
dicated  that  the  free  monomer,  dimer  and  trimer  epitopic  
peptides  were  present  as  a mixture  of  unordered  and  beta-
sheet  (extended)  conformation  (Laczko  I  et  al.,  manu-
script  in  preparation).  
We  consider  that  this  kind  of  investigation  offers  the  
possibility  of  determining  the  antibodies  in  patients  with  
BP.  Using  a  mixture  of  these  synthetic  epitopes,  it  is  pos-
sible  to  diagnose  BP  in  a relatively  simple  way  by  means  
of  an ELISA  system,  and  a highly  equipped  laboratory  is  
not  necessary.  It  is  also  important  that  each  autoantigen  
molecule  (BPAG1  and  BPAG2)  could  be  successfully  
. substituted  for  the  respective  two  or  three  antigenic  pep-
tide  epitopes  in  an  immunological  diagnostic  system.  In  
the  present  study,  the  use  of  homo-  and  hetero-oligomers  
as  substrate^  increased  the sensitivity  of  the  procedure.  
In  many  patients  with  localized  or  atypical  clinical  
symptoms  of  BP,  the autoantibody  cannot  be  measured  by  
IIF and the diagnosis  is missed  or delayed.  An  early  diag-
nosis  is  associated  with  a  better  prognosis  and  a  need  
for  lower  therapeutic  dosages  of  corticosteroid.  Retro-
spective  and  prospective  studies  might  help  in  determin-
ing  whether  recombinant  fusion  proteins  are  better  sub-
strates  for  such  correlations  than  the  monkey  oesophagus  
used  in  conventional  IIP  assays.  A  rapid  assay,  using  a  
standard,  readily  available  substrate,  which  can  be  per-
formed  with  minimal  technological  facilities,  would  sig-
nificantly  benefit  the  diagnosis  and  management  of  this  
not  rare,  and sometimes  serious  disease.  
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Abstract 
Objective.  To determine the prevalence of anti-neutrophil  cytoplasmic  antibodies  
(ANCAs)  in  patients  with  systemic  lupus  erythematosus  (SLE)  and to  evaluate  
the correlation between the ANCA positivity, the disease  activity  and the clinical 
characteristics of the disease. 
Methods.  Forty-one  patients  with  SLE  and two  control  groups  were  examined.  
One of  the  control  groups  comprised  15 patients with  systemic  vasculitis,  while  
the  other consisted of  12 healthy blood  donors.  A  quantitative ELISA technique 
was  used  to  measure  the  serum  cytoplasmic  ANCA  (cANCA)  and  perinuclear  
ANCA (pANCA) levels. 
Results: cANCA positivity was found in 3 (3/41= 7.3%) and pANCA positivity in 
10 SLE patients (10/41= 24.4%).  The mean concentration of cANCA in the SLE 
patients  was  1.0  U/l  and  that  of  pANCA  was  5.1  U/l.  In  the  vasculitis  group,  
cANCA positivity was detected in 7 cases (7/15= 47%, mean concentration:  10.5  
U/l)  and  pANCA  posotivity  in  5  cases  (5/15=33%,  mean  concentration:  15.5  
U/l).  In the healthy  control  group,  1 positivite  case  was  found for  each ANCA 
type (1/12=8%) In this group the mean concentration of cANCA was 0.7 U/l  and 
that  of  pANCA  was  3.7  U/l.  As  concerns  the  clinical  and  serological  
characteristics of SLE, there were no significant differences between the ANCA-
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positive and ANCA-negative  SLE patients. 
Conclusions.  The occurrence and mean concentration of cANCAs were similar in 
the  SLE patients  and the  healthy  controls.  The frequency of pANCA  positivity  
was higher in the SLE patients than in the healthy controls, but the concentrations 
of  the  antibodies  did not  differ. ANCA positivity  was  less frequent in  the  SLE  
patients  and  the  ANCA  concentration  was  essentially  lower  than  in  systemic  
vascuhtides;  these  differences  were  found  to  be  statistically  significant.  The  
clinical picture  and antibody profile were  similar in ANCA-positive  and negative 
SLE patients. 
Key  words:  anti-neutrophil  cytoplasmic  antibody,  vasculitis,  systemic  lupus  
erythematosus 
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Introduction 
The  anti-neutrophil  cytoplasmic  antibodies  (ANCAs)  constitute  a  family  of  
antibodies  directed against various components of the cytoplasm of the neutrophil 
granulocyte  [1,2].  In  the  classical  cytoplasmic  staining,  the  antigen is  a  29  kD  
single  chain-protein,  a  serin  proteinase-3  (PR3)  located  in  the  neutrophil  and  
monocyte  lysosomal  granules  [3].  The  perinuclear  ANCAs  (pANCAs)  bind  
predominantly to myeloperoxidase  (MPO) and occasionally to elastase, lysozyme, 
cathepsin G,  and lactoferrin localized in the  neutrophil  primary  granules.  ANCA  
positivity is often associated with certain types of systemic vasculitides.  Anti-PR3  
antibodies  occur  in  a  high  percentage  of  patients  with  active  generalized  
Wegener's  granulomatosis,  while  anti-MPO  antibodies  are  commonly  found  in  
patients  with  microscopic  polyangiitis  or  Churg-Strauss  syndrome  and  
occasionally  in  idiopathic  crescentic  glomerulonephritis  [4].  ANCAs  have  been  
searched  for  and  detected  in  other  diseases  too  (chronic  inflammatory  bowel  
diseases,  systemic  autoimmune  connective  tissue  diseases,  etc.).  On the basis  of  
the  data obtained from these  examinations,  the  term "ANCA-associated  disease"  
has been introduced.  The presence of ANCA is  intensively  examined not  only in 
vasculitides,  but  also  in  other  systemic  diseases,  such  as  systemic  lupus  
erythematosus (SLE). 
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In the present  study, we  examined the prevalence of pANCA  and cANCA 
among  SLE patients.  We  additionally  wished  to  evaluate  how ANCA  positivity  
correlates with the activity and clinical characteristics of SLE. 
Patients and methods 
Forty-one  patients  with  SLE (38  females  and 3  males)  were  examined.  The  age  
range of the patients  at the time of diagnosis was  13-70  (mean: 30.8) years, while 
at the time of sampling it was  19-70  (mean: 42.3) years.  The patients fulfilled the 
1982 revised American Rheumatism Association (ARA) criteria for the  diagnosis  
of  SLE  [5].  Patients  with  drug-induced  SLE  were  excluded.  Clinical  and  
laboratory  data  were  obtained from the  follow-up  records.  In  10  patients,  renal  
biopsy was performed: focal proliferative nephritis (type m)  was found in 1 case, 
diffuse  proliferative  nephritis  (type  IV)  in  6  cases  and  membranous  (type  V)  
nephritis  in  3  patients.  Nine  patients  had  clinical  signs  of  SLE-associated  
vasculitis: panniculitis (2 patients)  and skin vasculitis  (7 patients).  Vasculitis  was 
confirmed by histological examinations in 5 of these patients.  Thirty-two of the 41 
patients were given glucocorticoid  therapy at the time of the  sampling,  7 of them 
combined with azathioprin, 6 with cyclophosphamide  and 5 with chloroquine. The 
remaining  9  patients  needed  no  medication  or  only  non-steroidal  anti-
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inflammatory  treatment  at the  time  of  blood  sampling.  The  SLE disease  activity  
index  (SLEDAI)  was  calculated  for  every  patient;  this  index  indicated  that  31  
patients had active SLE. 
One  of  the  control  groups  contained  15  patients  with  various  types  of  
systemic  vasculitides  (mean  age:  49.4  years,  range:  22-78  years,  female:male  
ratio: 7:8). This group consisted of patients with Wegener's granulomatosis  (n=l),  
periarteritis  nodosa  (n=2),  microscopic  polyangiitis  (n=7),  Takayasu  arteritis  
(n=l), rheumatoid vasculitis (n=l)  or non-classified systemic vasculitis (n=3).  The 
other  control  group  comprised  12  healthy  blood  donors  (mean  age:  33  years,  
range: 23-46 years,  12 females). All serum samples were stored at -20 °C. 
ANCAs were measured with enzyme linked immunosorbent assay (ELISA) 
technique (Shield Diagnostics; Dundee, UK).  The antigens were PR3 for cANCA 
and MPO for pANCA.  The normal level were <2 U/l for cANCA  and <7 U/l for 
pANCA. 
Of the  other antibody examinations,  antinuclear  antibody (ANA)  detection  
was performed by means of indirect immunofluorescence,  rat liver being used as  
substrate.  ELISA was used for the detection of and- double-stranded DNA (anti-
dsDNA),  anti-SSA,  anti-SSB,  anti-Sm,  anti-Ul-RNP  (all  from  Epignost;  
Leonding/Linz,  Austria)  and anti-cardiolipin  (aCL)  (Shield Diagnostics;  Dundee,  
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UK).  Lupus  anticoagulant  (LAC)  was  investigated  via  measurement  of  the  
activated partial thromboplastin time. ANA examinations were performed in all 41 
cases,  anti-dsDNA,  anti-SSA,  anti-SSB,  anti-Sm and anti-Ul-RNP  examinations  
in  40  cases,  LAC  examinations  in  26  cases  and  aCL  examinations  in  34  SLE  
patients. 
The  chi-square  test  (p<  0.05)  was  used  for  the  statistical  analysis  of  the  
differences  in  the  prevalences  of  pANCA  and  cANCA  in  the  various  study  
groups,,  and the Dunnett t-test (p<0.05) for the differences between means. 
Results 
As  demonstrated in Table  1,  arthritis was  the most  common manifestation in our 
SLE  patients.  Skin  vasculitis  and  panniculitis  occurred  in  9  patients.  Elevated  
levels  of cANCA were  detected in 3  (7.3%)  and of pANCA in  10  SLE patients 
(24.4%)  (Fig.  la,b).  In  one  patient,  both  the  cANCA  and  the  pANCA  
concentrations  were  higher  than  normal.  The  cANCA  levels  were  in  the  low  
positive range (2-6 U/l) in all these 3  SLE patients.  Similarly,  the  antibody levels 
were only mildly elevated (7-25 U/l) in all  10 pANCA-positive  SLE patients. 
Of the  15 control patients with systemic vasculitis, 7 cANCA-positives  and  
5  pANCA-positives  were  found  (Fig.  la,b).  In  this  group,  elevated  levels  of  
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cANCAs  were  significantly more  frequent  than in the  SLE group (7/15  vs  3/41;  
p=0.0021),  while  the  prevalence  of  pANCAs  did  not  differ in  the  two  groups  
(5/15  versus  10/41;  p=0.51).  The  average  ANCA  levels  were  higher  in  the  
vasculitis  group  than  in  the  SLE  group  and  the  difference  between  them  was  
significant (cANCA:  10.5 U/l vs  1.0 U/l, p=0.035; pANCA:  15.5 U/l vs  5.1 U/l,  
p=0.035).  The  pANCA  levels  were  also  significantly  higher  than  those  in  the  
healthy controls  (pANCA:  15.5 U/l vs 3.7 U/l, p=0.044; cANCA:  10.5 U/l vs  0.7  
U/l,  p=0.07).  One  healthy  control  exhibited  positivity  against  the  PR3  and  a  
further  one  did  so  against  the  MPO  (8.3%)  (Fig.  la,b).  Although  the  mean  
antibody titers  (cANCA:  0.7  U/l,  pANCA:  3.7  U/l)  of  both ANCA types  in the 
healthy  control  group were  similar to those  in the  SLE group,  the  prevalence  of  
pANCA  positivity  was  much  higher  in  the  SLE  group  than  in  the  normal  
individuals (24.4% vs 8.3%, p=0.42). 
We examined the frequencies of the various organ involvements manifested 
at the time of sampling among ANCA-positive  and ANCA-negative  SLE patients. 
The frequencies of  occurrence  of  the  organ  involvements  included  in  the  1982  
revised criteria for the diagnosis of  SLE and those related to vasculitis  are shown 
in Table  1. There were no statistically significant differences in the frequencies of 
occurrence  of  symptoms  between  the  ANCA-positive  and  ANCA-negative  
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patients,  hi  another  approach,  we  compared  the  cANCA  and  pANCA-positive  
groups with regard to clinical  organ involvements  throughout the  entire  course of  
the disease (i.e.  before or after the time of blood sampling).  This  comparison did 
not  reveal  any  subgroup  of  patients  with  an  increased  prevalence  of  ANCA  
positivity either. 
The  SLEDAI  was  12.8  in  ANCA-positive  and  10.2  in  ANCA-negative  
patients with  SLE;  similarly,  no  significant  difference was  revealed  between the 
ANCA-positive  and ANCA-negative  patients with respect to sex  or to the age  at  
the time of diagnosis. 
The results of the other autoantibody examinations (anti-dsDNA,  anti-SSA,  
anti-SSB,  anti-Sm,  anti-Ul-RNP  and  aCL antibodies  and LAC  are presented  in  
Tables 2a  and 2b.  We  did not find any significant correlation of these  examined  
autoantibody positivities with ANCA positivity. 
Discussion 
The  presence  of  the  ANCAs  in  the  systemic  vasculitides  has  been  
intensively  investigated.  While  cANCA  occur  most  commonly  in  Wegener  
granulomatosis  and pANCA in microscopic polyangiitis, these antibodies can also 
be  detected  in  other types  of  systemic  vasculitides  [6,7].  In  our  control  patients  
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with  vasculitis,  anti-PR3  antibodies  were  present  in  nearly  half  and  anti-MPO  
antibodies in a third of the cases examined.  The concentrations of both antibodies 
were highly elevated in about 40% of these patients. 
In this  study, we  determined the prevalence of ANCA in  SLE patients and 
examined whether there is a correlation between ANCA positivity  and the clinical 
picture  of  the  disease,  because  the  published  reports  concerning  the  diagnostic  
value of cANCA in  SLE patients  are controversial.  Wong et  al.  found high anti-
PR3  titers  in  4  of  23  examined  children  with  active  SLE  [8].  Bygrem  et  al.  
detected positivity  against  PR3 in  6  of  44  SLE patients  [9].  In  contrast,  several  
authors have reported the complete absence of cANCA in SLE [10-12].  Schnabel  
et al. did not detect anti-MPO antibodies in patients with SLE [13]. Another study 
reports the occurrence of a low percentage (1.4%) of anti-MPO antibodies in SLE 
patients  [14], while higher frequencies (up to 21%) have also been detected  [10].  
The variety of the reported prevalences may be due to the different purities of the 
antigen used in the ELISA technique or to the different patient populations.  In the 
present study, we detected low positive levels of cANCA in 3 cases (7.3%) and of 
pANCA in 10 (24.4%) of 41  SLE patients.  The prevalence of the latter antibody is 
the highest  published to  date.  Although the prevalence  of pANCA was  higher in 
the  SLE patients  (24.4%) than in the normal controls  (8.3%),  the  difference was 
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not statistically significant (p=0.42). 
Our  examinations  are  consistent  with  previous  studies  [15,16]  in  that  the  
concentrations  of  ANCAs  are  quite  similar in  the  SLE patients  and the  normal  
control  group  (mean  cANCA  concentration:  1.0  U/l  vs  0.7  U/l;  mean  pANCA 
concentration: 5.1 U/l vs 3.7 U/l).  In the vasculitis  control group, the mean levels 
of cANCA (10.5 U/l)  and pANCA (15.5 U/l) were essentially higher than those in 
the  SLE patients  and the  healthy  controls  (vasculitis/SLE:  cANCA:  10.5  U/l  vs  
1.0  U/l,  p=0.035;  pANCA:  15.5  U/l  vs  5.1  U/l,  p=0.035;  vasculitis/normal  
controls:  cANCA:  10.5  U/l  vs  0.7  U  /l,  p=0.07;  pANCA:  15.5  U/l  vs  3.7  U/l,  
p=0.044). 
Several  authors  have  reported  the  detection  of  ANCA  in  normal  control  
persons.  Both  cANCA  and  the  PR3  molecule  itself  have  been  detected  in  low  
level  in normal individuals  and in  SLE patients  [17-19].  Our study also  revealed  
ANCA positivity in less than 10% of the healthy controls (Fig.  1).  
Accordingly,  it  seems  likely  that  high  titers  of  anti-PR3  or  anti-MPO  
antibodies  may  be  found  in  patients  with  various  types  of  systemic  vasculitis,  
while a low titer of antibody positivity may be a rather nonspecific finding, and its 
clinical significance appears limited. 
Controversial  data  are to be  found on the  connection between ANCA  and  
other  autoantibodies.  Spronk  et  al.  demonstrated  that  the  levels  of  anti-dsDNA  
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were  similar  in  patients  with  or  without  ANCA  positivity  [20].  Lawton  et  al.  
detected  anti-dsDNA in  16 of  18  SLE patients  (89%),  who  also  proved positive 
for  the  anti-lactoferrin  antibody,  this  prevalence  being  higher  than  that  for  the  
whole  SLE group  [21]. It is  thought  that through inducing the release  of reactive 
oxygen species in the vascular wall, ANCA may induce the release  of DNA and 
thus play a role both in anti-dsDNA production and in the inflammatory response. 
We investigated the joint  occurrence of ANCA with other autoantibodies,  but we 
were  unable to  detect  a  significant  association between the  presence  of  ANCAs 
and  anti-DNA,  anti-SSA,  anti-SSB,  anti-Sm,  anti-Ul-RNP,  and  aCL  
autoantibodies  or LAC. 
Since the  clinical picture of  SLE varies,  there is  an important  clinical need 
to answer the question of whether the presence of ANCA may identify a particular 
subgroup  of  SLE  patients.  Various  data  are  available  as  concerns  the  organ  
involvements in ANCA-positive  SLE patients,  but the findings are not completely 
concordant.  Some  authors have observed a more frequent occurrence  of  serositis  
in  ANCA-positive  patients,  while  in  other  studies  arthritis  or  neurological  
involvement  was  found  to  be  more  common  in  these  cases  [20-23].  ANCA  
positivity can also be present in primary Sjögren syndrome, usually in association 
with vascular manifestations of the disease  [24].  It  seemed reasonable,  therefore  
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for us  to  compare  the  prevalence  of  ANCA  in  SLE  patients  with  and  without  
vasculitis;  however,  we  were  not  able  to  detect  a  close  correlation  between  
ANCA positivity and the vascular manifestations other organ involvements. 
To  summarize,  some  conclusions  may be  drawn.  On the  basis  of  ANCA  
positivity,  no  specific  SLE  subgoups  could  be  identified.  ANCA  (especially  
pANCA)  can  be  detected  in  higher frequency in  SLE  patients  than  in  healthy  
controls,  but  there  is  no  difference  in  the  levels  of  autoantibodies.  In  our  
experience,  the routine  examination of ANCA in SLE patients is  unnecessary,  as  
the  results  do  not  furnish  any  additional  data  concerning  the  diagnosis  and  
prognosis. 
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Legends 
Fig.  la,b  
cANCA and pANCA levels in patients with  SLE,  in patients with vasculitis  and  in the  control  
group. cANCA: <2 U/l: normal, 2-6 U/l mildly elevated, >6 U/l highly elevated  levels.  
pANCA: <7 U/l normal, 7-25 U/l mildly elevated, >25 U/l highly elevated levels.  
Table  1  
A  comparison  of organ  involvements  in patients with  systemic lupus  erythematosus  in  relation  
to the presence of ANCAs. 
One patient was  positive for both  cANCA  and pANCA.  The numbers  of  affected patients  are  
included  in  the  Table.  DLE:  discoid  lupus  erythematosus.  No  significant  difference  was  
revealed between the  frequencies  in the ANCA-negative  and ANCA-positive  groups.  
Table 2a 
Associated  autoantibody  positivities  in  ANCA-positive  patients  with  systemic  lupus  
erythematosus. 
Table 2b 
Associated  autoantibody  positivities  in  cANCA-  and  pANCA-positive  and  in  ANCA-negative  
patients  with  systemic  lupus  erythematosus.  One  patient  was  positive  for  both  cANCA  and  
pANCA. 
Table  2a  
A comparison  of organ  involvements  in  patients  with  systemic  lupus erythematosus  (SLE)  in  relation to  the  
presence of  ANCAs  
Symptoms 
SLE 
(n=41) 
CANCA+ 
(n=3) 
pANCA+ 
(n=10) 
ANCA-
(n=29) 
Butterfly  erythema  3 0 0 3 
Photosensitivity 7  1  0  2 5 
Discoid  lupus  
erythematosus 
2 0  1  0  
l 
2 
Oral  ulcer  1 
i 
0  j  0  1 
Anaemia/leukopenia 16/11 2/1 3/2 11/8 
Arthritis 23  1  4 18 
Nephritis 12  1  3  j  8  
Serositis 10  1  
i 
2  !  7  
I 
Cerebral  involvement  2  0  
• 
1  1  1  
Skin  vasculitis  9  0  !  0  I  9  
Table 2a 
Associated autoantibody positivities in ANCA-positive patients with systemic lupus erythematosus (SLE). 
Patients/ 
antibodies CANCA pANCA 
ANA anti-dsDN anti-SSA anti-SSB anti-Sm anti-RNP 
1 negative positive negative positive negative negative negative negative 
2 negative positive positive positive negative positive negative negative 
3 negative positive positive positive negative negative negative negative 
4 negative positive negative negative negative negative negative negative 
5 negative positive positive negative negative negative negative negative 
6 negative positive negative positive negative negative negative negative 
7 negative positive positive positive negative negative negative negative 
8 negative positive positive positive negative negative negative negative 
9 negative positive positive positive negative negative positive positive 
10 positive negative positive positive negative negative negative negative 
11 positive negative positive positive positive negative negative positive 
12 positive positive positive negative negative negative negative negative 
Table  2a 
Associated  autoantibody  positivities  in cANCA-  and  pANCA-positive  and  in ANCA-negative  patients  
with  systemic lupus erythematosus  (SLE).  
Autoantibody 
SLE 
(n=41) 
CANCA+ 
(n=3) 
pANCA+ 
(n=10) 
ANCA-
(n=29) 
a-DNA 25/40 2/3 7/10 16/28 
a-SSA 7/40 1/3 0/10 6/28 
a-SSB 7/40 0/3 1/10 6/28 
a-Sm 2/40 0/3 1/10 1/28 
a-Ul-RNP 7/40 1/3 1/10 5/28 
LAC 8/26 0/1 2/5 6/20 
aCL 16/34 2/2 4/6 10/26 
